EXCLUSIVE: WHO Deleted India’s Air Pollution Data from its New Air Quality Database – Why? 14/04/2022 Elaine Ruth Fletcher & Jyoti Pande Lavakare Young protesters in Delhi, India take to the streets to demand action against air pollution during a 2019 air pollution emergency. Nearly ten years of air pollution data for dozens of Indian cities – among the most polluted in the world – was deleted from the latest World Health Organization Air Quality database just before WHO published the report on 4 April 2022, Health Policy Watch has learned. The Indian air quality data, spanning the years 2010 to 2019, and including 1,139 data points in all, was collected largely from published government sources, including India’s Central Pollution Control Board, and the government’s SAFAR air quality research network, supplemented by the US State Departments AirNow network, which monitors air quality from missions and embassies around the world. The suppressed Indian data is reproduced in full here by Health Policy Watch from the embargoed version of the WHO release, alongside the data of other South-East Asian Region cities and communities. India is among eight other countries in WHO’s South-East Asia region whose data was originally included in the report. Others included neighbouring Bangladesh, Nepal, and Sri Lanka, as well as Bhutan, Indonesia, Maldives, Myanmar, and Thailand. Except for India, all of the other countries’ data from the region remained intact in the public excel version of the database that was put online by WHO at its 4 April launch. Why is this important? The omission is significant as the WHO database was for many years regarded as a gold-standard baseline for assessment and comparison of countries’ air quality challenges. While it has been superseded, somewhat, by a range of other open-access and research-based data collection efforts, WHO’s work remains a critical benchmark for national, regional and global analysis of air pollution challenges in different cities and regions. Alongside more cutting edge satellite data and other ‘modelled’ data sources, the ground station monitoring data collected by WHO also is a major input to the global bosy’s assessments of air pollution exposures, illness and premature deaths. An estimated 4.2 million people die every year from diseases attributable to ambient (outdoor) air pollution levels – with the largest burden in the South East Asia region, according to WHO. About 7 million people die from combined ambient and household air pollution exposures, with some overlap between the two risk factors. WHO estimates that in India alone, nearly 1.8 million people die from air pollution every year. WHO – No response to queries Dr Maria Neira, Director of WHO’s Department of Environment, Climate Change and Health, at a media briefing on the 2022 WHO Air Quality database update. Health Policy Watch repeatedly sent queries to WHO officials and spokespeople asking why the Indian data had been wiped clean from the 2022 version of the WHO database. WHO initially did not reply. However, following publication of this report Thursday, a WHO scientist told Health Policy Watch, “The data for India will be released soon. The data is still going through final checks to ensure accuracy.” The scientist rejected suggestions that the data had been pulled at the last minute as a result of political pressures – but rather out of an abundance of caution with the sensitive data set. The WHO trumpeted that its latest WHO Air Quality database was its largest collection of ground station monitoring data ever. And indeed it was. The publicly available excel sheet contains new data on average annual particulate concentrations from around 6,000 cities and settlements worldwide – but Indian data is nowhere to be found in the new collection of concentrations of PM10 and PM2.5 – the pollutants most directly linked with a range of cardiovascular, respiratory diseases and cancers, and related premature deaths. The 2022 database, the first WHO update since 2018, also included some more limited data on NO2 concentrations for the first time ever – a common pollutant from vehicle emissions that is a precursor to ozone, stunting food production exacerbating asthma and other chronic respiratory diseases. The embargoed version of the WHO database also reflected new reporting on Indian NO2 data, which also was deleted from the published version. WHO global Air Quality map, presented with its 2022 database update. The darkest green areas highlight parts of the world with the highest air pollution levels, but with little granularity to distinguish countries with high levels of pollution, from those with the most dangerous levels, e.g. 15×20 times WHO guideline levels or more. India’s data – controversial from the beginning of the WHO effort Pollution in Delhi peaks in late autumn when drifting emissions from crop burning exacerbate the usual urban household, traffic and industrial sources. India’s data has been a regular feature of the WHO Air Quality database for nearly a decade when the global health agency first started amassing data in order to build a more accurate model of disease and deaths from air pollution – a then poorly-recognized factor in cardiovascular and respiratory diseases as well as cancers. The collection of such data was a particularly bold move for the agency at the time. And it caused a big stir worldwide – particularly in India, which emerged as one of the world’s most polluted countries – overtaking China which had begun making strenuous efforts to clean up its skies. Both in private and publicly, Indian air quality officials repudiated WHO’s findings, which placed Indian cities at the top of the global air pollution charts, saying that the WHO assessment provided a distorted view of the state of the country’s air. The Indian officials complained that WHO was overestimating air pollution levels in Delhi, despite the fact that the city faces an air pollution emergency almost every winter as crop waste burning in rural areas to the north drive smoke to the city, combining with Delhi’s already dirty urban sources, transforming the city into a pollution nightmare. The government’s objections were often linked to highly technical issues such as: a) the reliance upon one air pollution monitoring station in many Indian cities; b) alleged bias toward data from pollution hot spots where stations are placed; c) bias from stations that don’t operate continuously and; d) a lack of reference to the fact that some of India’s urban pollution is due to dust, rather than human sources. Over time, those protests have increasingly sounded hollow as more air quality research was published with similar findings. Meanwhile, India’s own air quality monitoring data was constantly improving revealing a similarly dire picture. Any shortcomings that still exist in Indian data, or reporting about it, can be overcome by careful analysis, experts say. Real-time air pollution data broadcast in Delhi, during a 2019 air pollution emergency; showing data of government monitoring networks, CPCB, DPCC and SAFAR. The Indian data included in the 2018 WHO database released four years ago was received in just that light by Indian air quality junkies who combed it for both strengths and gaps. That reflects exactly the kind of transparent debate that is missing from the 2022 release – along with the Indian data itself, of course. So if the Indian government had asked WHO to pull the data, it would be particularly hard to understand why now since other reputable global air quality research is now producing similar order-of-magnitude results, year after year. While precise estimates of air pollution levels and peoples’ exposures in different Indian regions and cities might vary across diverse analyses, they tend to reflect the same unhealthy air pollution concentrations across large swathes of northern India, until the present day. Other global databases carefully tracking Indian trends One such example is the State of Global Air, a report by the Boston-based Health Effects Institute (HEI). HEI also funds air quality research involving Washington University, St. Louis, the University of British Columbia and the University of Washington. Together, those institutions regularly scrape and analyze publicly available Indian monitoring data from official sites. In combination with NASA satellite data and other data, they, too, produce estimates of average annual PM2.5 concentrations and from those inputs, model the levels of “population exposure” to air pollution in India, and worldwide. According to some of those recent findings, further distilled by an Indian analysis, and portrayed graphically here, nearly a quarter of India’s population was exposed to annual average PM2.5 concentrations ranging from 80 micrograms/meter3 (µg/m3) or more in 2020 . This is 16 or more times higher than the WHO guideline level of 5 µg/m3 for PM2.5. That guideline limit was tightened by WHO in 2021 in the face of mounting evidence about the health impacts of particulate air pollution, even at comparatively low concentrations. Indian analysis of the proportion of a) people exposed and b) land area covered by air pollution at various levels in 2020, based on data extracted from a global database distributed by Washington University, St. Louis USA. (Source: urbanemissions.info) Air pollution worsened over the past two decades India air quality analysis (year 2000), based on data extracted from a global database by Washington University in St. Louis, USA. (source urbanemissions.info) Looking back further, however, India’s air pollution has worsened significantly over the past two decades. A comparison of the same mapping from 2000 and 2020 highlights that trend, showing a much wider belt of northern India etched in the dark browns and orange of excessive pollution levels, as compared to the green shades of two decades ago. Annual average air pollution exposures appeared to peak in 2014 then had a slight, gradual decline, stagnating at a high level of around 80 µg/m3 for PM2.5, suggests data from the State of Global Air report series. Population-weighted exposure to polluted air in India over time. (State of Global Air, Health Effects Institute) WHO data on Delhi – from the embargoed WHO data set never released – reflects similar trends and fluctuations – even if it is urban, not national, data – and framed somewhat differently in technical terms. According to the WHO data compilation, Delhi’s PM2.5 levels peaked as well around 2014, and then declined somewhat, levelling off recently to concentrations of about 105 µg/m3 – still some 21 times higher than recommended WHO guideline levels of 5 µg/m3. But a deeper analysis by WHO would be needed to be performed to further gauge trends nationally or regionally over time. Needless to say, with the most recent India data missing altogether, that kind of trend analysis hasn’t been done in WHO’s latest Status Report. Delhi air pollution data (PM2.5) from 2010-2019, which was deleted from the WHO’s final, published version of its 2022 Air Quality database. It shows a sharp rise in average annual levels in 2014, which then declined and steadied at concentrations still 26 times above new WHO guideline levels. CPCB officials say data is freely available on website, no reply from SAFAR Health Policy Watch reached out to several Indian government air quality officials for explanations as to why India’s data had disappeared from the final version of the 2020 WHO air quality database. Calls to Dr Prashant Gargava, Member Secretary of the Central Pollution Control Board (CPCB), India’s statutory body, went unanswered. But two other senior CPCB officials said in separate phone interviews that updated CPCB data is freely available on their website for the general public – and denied there had been any effort to censor WHO’s report. “As far as I know, the WHO has not asked us for any data. They are welcome to take it from the website – anyone can do that,” one official told our India correspondent. “We have data from our manual as well as our CAQM (continuous air quality monitoring) stations on our website – anyone can take that data – they just have to mention the data source and acknowledge it,” the official who directly supervises this data said. An independent Indian air pollution expert interviewed by Health Policy Watch, also confirmed that since the Indian air quality data is publicly available from the official, Central Pollution Control Board, database, the statutory Air Quality monitoring body in India – WHO certainly shouldn’t censor itself over use. “Technically CPCB is posting the data online and it is supposed to be public by default for anyone to use, with due credit,” the data scientist told Health Policy Watch, “Then why not just use it, and not ask for another permission to use it.” Other major Indian data sources: SAFAR and the US State Department’s ‘AirNow’ SAFAR India, a government air quality research and monitoring network with an extensive monitoring system in Delhi WHO’s suppressed Indian data set also drew upon data from SAFAR-India, a parallel research network operated by the Indian Ministry of Earth Sciences. SAFAR, the “System of Air Quality and Weather Forecasting And Research” is an internationally recognized network that collects data from 11 monitoring stations in Delhi, as well as individual stations in 11 other Indian cities. It’s network includes academic, and meteorological research institutions, as well as some municipal authorities. SAFAR also provides real-time air quality forecasting and alerts, based on an Air Quality Index, important for air pollution emergencies. Its reporting is particularly important for Delhi, which suffers some of the worst pollution peaks in the country almost every winter, and along with that, the need to make decisions about drastic public health measures, from mask distribution, to work stoppages and school closures. A leading air pollution official at SAFAR contacted by Health Policy Watch about the removal of the Indian data from the 2022 WHO database, also did not respond to emailed requests for clarifications, as of the time of this publication. Even so, insofar as authoritative Indian data is plentiful, current and public, there should be no problem with WHO using it freely. The Indian data scientist interviewed by Health Policy Watch stated: “I think WHO should scrape it [the data], or use a group scraping the data, to make their own current averages and publish. This is public information, though it is a little difficult to access data in bulk from the CPCB site, some groups have already put in their time to make it useful. “My personal opinion (and that of some others) is that when we get stuck in this circle of permissions to even publish what is already public, it makes policy dialogue very difficult, leading to second-guessing to do the right thing, even as simple a task as public awareness of health impacts of air pollution.” WHO – a scientific or member state body? A World Health Assembly committee meeting, 2018. WHO’s findings and recommendations are supposed to be science-based, but member states constantly lobby for influence, particularly to shape the outcomes of unflattering or unfavourable reports and recommendations. But the pressures WHO faces as a science body, under the constant scrutiny of its member states, tends to complicate its research. In fact, whenever potentially unflattering data lurks, the WHO tends to walk tiptoe around the sensitivities of member states. This has been highlighted during the COVID-19 pandemic in WHO’s public statements and relation to member states from China to Italy. In the case of the latter, WHO withdrew from a 2020 report on Italy’s pandemic response, An unprecedented challenge, just a few hours after it was published. Although the official narrative was that the account was deleted was due to “errors”, the report’s chief coordinator, who has since left the WHO, attributed the report’s withdrawal to intense political pressure from the government of Italy and a leading WHO official affiliated with the government, who had found certain findings unflattering. A pattern of much-delayed reports in WHO’s Disease Outbreak News about new outbreak threats can also likely be traced to excessive concerns with member states’ sensitivities. There was a three-month delay in WHO’s publication about the recent wild polio outbreak in Malawi, which occurred in November 2021, but only was reported by WHO in late February 2022, shortly before it launched a five-nation vaccination campaign. A July 2021 Zika outbreak in India’s Kerala and Maharashtra states was only reported by WHO in October 2021, a full three months after the outbreak came to light – with considerable local media coverage. In the case of the WHO air quality database, traditionally, data had to be reviewed by countries prior to WHO’s publication. More recently, an online template for government authorities to enter their own data manually is now available on the WHO website. That, WHO says, has become one of the “primary sources of data” potentially also simplifying the official approval process. “The primary sources of data were official reports of countries sent to WHO upon request, official national and subnational reports and national and subnational websites that contain measurements of PM10 or PM2.5 and ground measurements compiled in the framework of the Global Burden of Disease project,” state WHO acknowledgements. “Measurements reported by the following regional networks were also used: Clean Air for Asia, the Air quality e-reporting database of the European Environment Agency for Europe and the AirNow Programme from the United States embassies and consulates. If such official data were not available, values from peer-reviewed journals were used.” Missing Indian data went unnoticed in media reports Despite the widespread attention that the WHO Air Quality database updates typically receives, major media reporting of the 2022 Air Quality database update, entirely missed the fact that the Indian data had been suppressed from the update, both in India and media reports published abroad. Health Policy Watch also reported on the 4 April WHO database launch, with reference to various Indian cities as global pollution hotspots. In our report, we explicitly referred to Indian urban data contained in the embargoed database – which we had downloaded from the embargoed report ahead of publication without realizing that the same data had been deleted from the actual, published database that went online that day. South-East Asia, Africa and Middle East are World’s Air Pollution Hot Spots in WHO’s Largest-Ever Data Release Only a few days later, did it become apparent in an interview with a global air quality expert, that all of the Indian data contained in the embargoed version of the report had been removed from the final report. Indian data removed just days before launch Insofar as the embargoed version of the WHO database is dated 31 March 2022, it’s clear that the Indian data was removed at the very last minute. For those who look diligently, however, historical Indian data from previous years can still, however, be found online in previous versions of the Air Quality database, at least for now. For instance, at the time of this publication, the following historical data for India could be found in WHO’s: 2011 database, the first version of WHO’s public collection efforts, has data for 31 Indian cities, dating from 2008; 2014 database, which had data from 123 Indian cities, including multiple stations in some cities, dating from 2010-2012; 2016 database has average annual data from 131 Indian cities, including multiple stations in some cities, all dating from 2012; 2018 database update, in contrast, has annual averages from only 31 Indian cities, including multiple stations in many cities, dating from 2016; Heavy reliance on US State Department’s Air Now database for new data on major Indian cities Real-time data for Delhi, India as of 13 April, collected by the US State Department’s AirNow initiative. Along with data from CPCB and SAFAR, a third source for Indian data in the embargoed database version was the US State Department’s “AirNow” monitoring system. AirNow covers cities in the United States, as well as internationally, in sites where the US has a diplomatic presence. Over the past decade, air quality monitoring systems were established in embassy and mission buildings, as a measure to protect the health of diplomatic staff. As real-time continous data is published online, the system serves the secondary function of awareness-raising about air pollution in local communities. Among the 100 new data points cited from 2017-2019 in the embargoed report, analyzed by Health Policy Watch, values for most of India’s largest cities are attributed to AirNow. For instance, major cities with annual average PM10 data from 2019, attributed to AirNow, include: Haryana – 167 µg/m3 Ahmedabad -119 µg/m3 Bangalore – 81 µg/m3 Bengaluru – 71 µg/m3 Those concentrations are 5 to 11 times above the WHO guideline of 15 µg/m3 for PM10. For cities with PM2.5 data, AirNow is also cited as the main source. It includes Delhi’s PM2.5 annual average of 105 µg/m3 (2019) which ranked it as the most polluted city in India for that year – 25 times above the WHO guidelines of 5 µg/m3. Other cities with data sourced from AirNow, reported concentrations 8-12 times above the WHO guideline levels for PM2.5, including: Kolkata, 68 µg/m3 Mumbai, 43 µg/m3 Chennai, 39 µg/m3 Outside of large cities, however, the 2017-2019 data for other Indian cities was attributed to CPCB or SAFAR. Passive data collection – versus ‘data scraping’ One noteworthy feature of recent WHO air quality reporting is the fact that the expanding Air Quality database is soliciting and receiving more active contributions by the countries themselves via the online template. “The WHO global ambient air quality database is continuously being updated. If you are an official air quality data provider at either the country or city level, please use this template to submit the data to WHO,” states WHO on its air quality theme pages. While certainly that helps engage countries more actively in the air pollution data collection process, the question is what happens when officials are reluctant to share their data at all? It’s possible that in the absence of an active contribution from the Indian government, WHO scraped data available from AirNow and the CPCB for key Indian locations – and then discarded it at the last minute after India objected. But without clear answers from WHO, that remains speculation. Other countries’ air quality data is also outdated or missing Israel maintains a sophisticated air pollution monitoring system, with public reporting of real-time data and annual averages from dozens of points within its recognized pre-1967 borders. But the latest Israeli data points in the WHO database are seven years old. Those are not the only questions about the database, however, that remain unanswered. While this year’s WHO Global Air Quality database update can indeed boast the largest number data points ever, coverage by region remains highly inconsistent, as WHO’s own maps reveal. In some key regions, broad data networks such as the European Environment Agency and Clean Air Asia, also capture lots of data for WHO from countries uninterested or unable to report for themselves. But such networks do not extend everywhere. And so, whether as a result of barriers of language, technical incompetence, or pure indifference, cities and even whole countries with data can fall entirely through the cracks. Israel, a high-income country considered to be part of WHO’s European Region, has had no new data entries recorded in the WHO database since 2015. That is despite the fact that Israel has a sophisticated air quality network, publishing real time air quality data and annual average PM2.5 values for dozens of cities and locations within its pre-1967 borders. However, that database is in Hebrew and WHO’s data searches are limited to English, French, Spanish and Portuguese, as described in its Status Report on the 2020 update. A spot check by Health Policy Watch also found cities in the United States had outdated data. For example, Columbus, Ohio, a major industrial city in the midwest, has not reported an updated value for average annual PM2.5 concentrations since 2011. New African data – laudable but still loaded with flaws Accra, Ghana, is one of Africa’s few cities monitoring air pollution – but its last publicly reported measurement dates from 2015. The newest version of the WHO database also is noteworthy for its growing list entries of data from the WHO African Region. This year’s update includes nearly 50 data points across more than 10 major African countries, including Kenya, Ghana, Nigeria, Cameroon, Uganda, Senegal – as well as South Africa, which has the largest and most well-established network including some 140 monitoring stations. However, even the African data represented here often appears dated and patchy, yet many countries have rapidly growing cities that desperately need more consistent and transparent reporting on air quality. Accra in Ghana is one such example. Home of one of the largest e-waste facilities in the world, it suffers from considerable air pollution from the incineration of plastics and other hazardous materials. In 2015, the city publicly reported its air pollution data for the first time ever – revealing an annual average PM2.5 value of 55 µg/m3 – 11 times more than the WHO Guideline levels. That measurement is now seven years old. Nothing has been reported since. And that is despite intensive efforts to strengthen the city’s air quality monitoring efforts through a WHO-led Urban Health Initiative, co-sponsored by UNEP and a joint US-World Bank initiative, which saw the installation of new air quality monitoring equipment in Accra in October 2021. Nairobi’s single data point in the WHO database is a value of 5.91µg/m3 of PM 2.5 for the year 2018. That value, provided by the US State Department’s AirNow monitoring, may be unrepresentative of the city as a whole if it is drawn from monitors at the US Embassy itself. The Embassy is located in a posh neighborhood on the northern edge of Nairobi just past the famed Karura Forest, which would act as a natural filter for air pollutants drifting from the center city. Other available real-time data, as well as peer-reviewed studies of Nairobi’s air quality also suggest much higher levels for the downtown area. But the WHO data doesn’t yet consider new, and increasingly robust methods of low-cost air quality monitoring being rolled out in low-income cities such as Nairobi. Data shortcomings: mix of politics and resource shortages Taken together, the gaps and shortcomings described here are a complex mix of objective circumstances (e.g. Africa’s air quality monitoring network was largely non-existent only a few years ago); human resource shortages, and long-ingrained institutional and political constraints. WHO insiders point to the fact that WHO’s core air quality database team is led by a single staff scientist. That effort is indeed supported by a wider circle of consultants and advisors, including known global experts such as Michael Brauer, at the University of British Columbia, and Gavin Shaddick, of the University of Exeter. But collaborations with busy professionals accountable to their own institutions can only go so far. So while other global air quality monitoring initiatives now boast flashy websites with interactive maps, charts and graphics, that ease public understanding and highlight trends, WHO’s database remains a single PDF file and flat excel sheet download. That alone makes the job of sorting and assessing values across cities, countries, regions, and over time onerous, to say the least. In its global database effort, WHO largely goes it alone. But acting alone, WHO also may be underpowered for the massive task that it tries to fulfil. Even so, until WHO and the Indian government reinstate the India data, as well as explaining more transparently why it went ‘missing-in-action’, dialogue about a way forward that is more robust, accessible, up-to-date, and inclusive, of all countries’ data would be difficult. Removal was unplanned and occurred at the last minute The gauge on the WHO-led BreatheLife campaign site reveals some of the recent India data deleted from the technical database. Here, results of a search for Delhi. But whatever the drivers, it’s clear is that the removal of the Indian data was unplanned and came only at the very last minute. For instance, at least some of the new Indian data points suppressed in the technical report can be called up on the interactive search tool of the BreatheLife campaign – a joint awareness-raising effort of WHO, the United Nations Environment Programme’s Climate and Clean Air Coalition (CCAC). A search for Delhi, Chennai, Kolkata and Mumbai showed the gauge arrow responding with the same 2019 value for PM2.5 (105µg/m3) that had been deleted from the technical data base. In addition, the online WHO Status Report, the technical report that accompanied the 4 April database launch, also displays the Indian data points for PM10 and PM2.5 in its global map of monitoring stations from which data was collected. That technical summary, still marked with the big bold words DRAFT on its cover and inside pages, even calls out the Indian data monitoring effort in a caption that states: “More ground measurements are generally found in high- and middle-income countries, in China, Europe, India and North America.” Ultimately, the removal of the India data was not only hasty but awkward for the entire WHO database effort; the end of the story can only be written by WHO and India’s official authorities. _________________________________________________________________________ Elaine Ruth Fletcher is the editor-in-chief of Health Policy Watch. From 2003- to 2018 she was a technical officer and editor at the World Health Organization, engaged mostly in WHO’s air pollution and urban health work – including co-founding the BreatheLife campaign dedicated to awareness raising of the health and climate impacts of air pollution. She is the co-author and/or editor of over two dozen WHO reports and peer reviewed journal articles on air pollution, urban health and other environmental health themes. Jyoti Pande Lavakare is a core contributor to Health Policy Watch from Delhi. She is the author of the recently published grief memoir on the human cost of air pollution titled “Breathing Here is Injurious to Your Health”, and a long time contributor to Indian and global media on air pollution themes. She is also co-founder of the Indian NGO, Care for Air. -Updated at 18:50 CEST 14. April 2022 with initial reply from the World Health Organization. Image Credits: DYFI Delhi Twitter, Flickr, www.aqicn.org, urbanemissions.info, urbanemissions.info, State of Global Air/Health Effects Institute, Embargoed version of the WHO air quality data base, WHO/A. Kari, WHO Ambient Air Quality Update 2022 Status Report . With COVID Vaccine Supply Outstripping Vaccination Rates, Pharma Giants Question Pursuit of IP Waiver 13/04/2022 Kerry Cullinan IFPMA Director General Thomas Cueni (foreground) with moderator Claire Doole and Albert Bourla, David Ricks and Bill Anderson on screen. Pharmaceutical giants have questioned why a waiver on intellectual property (IP) rights for COVID-19 vaccines is still on the table when they are battling to find markets for their vaccines amid order cancellations – including from the Africa Centre for Disease Control. “I’m stunned that the proposed IP waiver is still being debated while supplies of vaccines are far outstripping demand and some factories have been put to a halt because of missing orders,” Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) told a media briefing on Wednesday. With almost a billion vaccines now being produced every month, countries’ lack of capacity to vaccinate is now the main barrier to stopping COVID-19, added Cueni. In the first quarter of the year 13.7 billion vaccine doses were delivered and 11 billion doses administered, said Cueni. “Now orders are slowing down. Countries as well as organisations such as Africa CDC, are not only asking for orders to be delayed but are cancelling them,” added Cueni. “Leading voices are still calling out vaccine scarcity. I do understand the concern. Vaccines are not reaching all those who need them. But the cause is no longer the lack of supplies. It’s scarcity of vaccination, which is due to the lack of country readiness, absorption capacity and the lack of resources needed to get the vaccines into arms.” Countries’ lack of capacity Pfizer CEO Dr Albert Bourla also weighed in on country capacity, saying that the US government was offering 200 million free doses to the poorest countries of the world but they lacked the capacity to administer the vaccines. “The problem is not if there is availability or access to pricing. The problem is that the infrastructure of these countries is very poor, so they cannot absorb them. They cannot run a vaccination campaign,” said Bourla. Bourla added that one of the pandemic’s key lessons was that more attention should have been paid to preparing countries to vaccinate people. He also described any move to remove IP on vaccines as “insane”, while Roche CEO Bill Anderson described it as “unproductive”. Eli Lilly CEO David Ricks warned that pharmaceutical companies and investors would “never have invested” in trying to develop COVID-19 vaccines “if there was not the promise of IP”. “The next investments on the unknown technology which we can repurpose for the next pandemic won’t be made if investors believe that IP will be undermined,” warned Ricks. “What is a patent? It’s a promise to disclose our inventions in return for a period of exclusivity,” added Ricks. “You’ll get much less disclosure about inventions actually as a result of an IP waiver. There’ll be a strong incentive to retain know-how, retain the recipes for what we do, much like you see in some other industries.” Collaboration successes Bourla said one of the best aspects of the pandemic had been the collaborations between different the industry partners, where competitors worked together, as we as public-private collaboration, particularly with regulators. He commended particularly the US Food and Drug Administration, the European Medicines Agency and the Canadian, Israeli and Japanese regulators for their speedy reviews of industry data. “What did not help was the politicisation – if you take a vaccine or not, or wear a mask or not. Tthat created tremendous damage to the global health,” said Bourla. At the IFPMA briefing (clockwise): Pfizer CEO Albert Bourla, IFPMA Director General Thomas Cueni and moderator Claire Doole, Roche CEO Bill Anderson and Eli Lilly CEO David Ricks Future COVID vaccines The IFPMA noted that there was “increasing acceptance that society will have to live with COVID-19”, and that continued innovation remains essential to expand on the 10 vaccines that have so far received WHO Emergency Use Listing approval and the 18 different treatments that have been approved in the UK, USA, and EU. Bourla said that Pfizer and Moderna were working on “multivariant” vaccines but this was “very challenging”, as was developing a COVID-19 vaccine that offered robust protection for at least a year. He hoped this would be ready for testing in the third quarter of the year. COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar A COVID-19 vaccination being administered in Senegal. COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros Adhanom Ghebreyesus, the Director-General of WHO, at a press briefing on Wednesday in Geneva. “This virus has over time become more transmissible and it remains deadly, especially for the unprotected and unvaccinated that don’t have access to health care and antivirals. The best way to protect yourself is to get vaccinated and boosted when recommended,” he said. The briefing comes at the end of a meeting of the WHO Emergency Committee convened under the International Health Regulations (IHR). The committee discussed the capacities of states to respond to the pandemic, the problem of vaccine inequity, reduced testing and monitoring, and raised concerns about the inappropriate use of antivirals that may give impetus to drug-resistant variants. Ukraine and Ethiopia In the past 50 days since theRussia invasion of Ukraine, 4.6 million refugees have fled the country, and thousands of civilians, including children, have died, and there have been 119 verified attacks on health care workers. Dr Tedros said that there is a need for humanitarian corridors to enable the delivery of medical supplies, food and water and the evacuation of civilians. He added that to date, the WHO had only received about half of the funding needed to support Ukraine for the first three months. Dr Michael Ryan, WHO’s Executive Director of Health Emergencies, said that there was a high risk of chemical contamination and exposure due to attacks, as well as compromised infrastructure associated with the chemical production, nuclear weapons and energy production. Dr Michael Ryan at the WHO Press Briefing. “We’ve been doing training and other support to the authorities in Ukraine in preparation for such an event. This is very different from the intentional use of chemicals as a weapon in war, which is against international Law and is a war crime,” said Ryan. This comes on the back of reports of the use of chemical weapons in Mariupol. With respect to Ethiopia, Tedors said that the siege by the Ethiopian and Eritrean forces continues to avert the humanitarian calamity and thousands of people from dying. Tedros, who is an Ethiopian and a former Minister of Foreign Affairs, said that the Tigray crisis is one of the most alarming humanitarian crises of our times. “But the world is not treating the human race the same way. Some are more equal than others,” he said referring to the negligible attention received by Afghanistan, Ethiopia, Yemen, and Libya versus the attention that is meted to Ukraine currently. Newer variants According to Dr Maria Van Kerkhove, WHO’s Technical lead on COVID-19, the new sub-variants of the Omicron variant– BA.4 and BA.5– have been reported from a number of countries, including South Africa, in Europe. She said that more sequencing and concerted global efforts to track and share the data on the virus are needed to understand the characteristics of the variants. Responding to the concerns about the reduced testing and tracking of COVID-19 cases, Ryan said that it was important to track the virus as it went “underground”. “It will be very, very, very short-sighted at this time to assume that lower numbers of cases mean an absolute lower risk,” he said. “This virus has surprised us before… We need to do our jobs and track this virus as best we can while people get back to living as normal a life as possible. We in the scientific and public health community need to continue to track this virus closely in every single country.” Dr Maria Van Kerkhove,WHO’s Technical lead for COVID-19, Van Kerkhove added that the committee which met today outlined three main scenarios in the modified Strategic Preparedness, Readiness, and Response Plan (SPRRP) publication: a best case, a worst case, and a base case in terms of outlining what virus evolution and changes and how our countermeasures will react or react to those. There is also a fourth scenario, called ‘reset’ where there is so much change in the virus there will be a population that is susceptible again, and “it resets us.” Vaccinate, vaccinate, vaccinate The updated SPRRP report highlights the need to achieve national COVID-19 vaccination targets in line with global WHO recommendations of at least 70% of all countries’ populations vaccinated by the start of July 2022. “Countries really must start looking at their data breakdown by age and sex,” said Dr Soumya Swaminathan, WHO’s Chief Scientist, while highlighting the importance of boosting the population over the age of 60. Swaminathan added that a majority of countries plan to meet the 70% target, but a handful of countries have set their goal at less than 40%. “ Many of these countries have competing health priorities and so we need to make sure that as COVID vaccine uptake is expanded, scaled up, strengthened, and routine immunization services are also strengthened,” said Swaminathan. Swaminathan mentioned that COVAX has the capability to cater to the vaccination needs of the vulnerable population, but there needs to be more focus on making sure the older, more vulnerable population is catered to and not left out despite the inequitable vaccine situation currently. “The inequity is not just in the overall distribution of vaccines, it is also occurring within countries in terms of not reaching those most likely to benefit from the vaccine and that’s particularly acute,” said Ryan. He added that while 85% of the population over 60 years of age in Europe is fully vaccinated, the number for the same metric stands at 25% in Africa. “If we fail to vaccinate everyone, if we fail to continue diagnosing, if we fail to find the people who can benefit from treatment, then we will fail in the future, and in the next pandemic. So our success now will determine a successful future,” Ryan said. Image Credits: Flickr – Trinity Care Foundation, Georges Yameogo.. Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman Global Health Matters podcast host Dr. Garry Aslanyan, TDR After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – and can inspire others as well. The Global Health Matters podcast hosted by Aslanyan, a public health professional with TDR, the Special Programme for Research and Training in Tropical Diseases, co-sponsored by UNICEF, UNDP, the World Bank and WHO, is now entering its second season of broadcasts. It features a diverse mix of themes and line-up of speakers – has picked up an audience of followers in places as diverse as Yemeni villages and Ulaanbaatar, Mongolia. The first episode of Season 2 was launched on Tuesday, April 12. It focuses on “Championing Health Equity in South Africa.” “The podcast gives people a unique peek into the experiences of people who are just like them,” Aslanyan told Health Policy Watch. “Listeners can relate to the guests and their experiences and compare what they themselves are living through – they can think, ‘can I do this?’ or ‘how does that work?’ or ‘what can this mean for me in my own setting or country?’” The podcast began at the height of the COVID-19 pandemic, when new, virtual information tools became all the more important to people confined for days and weeks at home. The podcast series has already covered a broad range of innovative and inspiring research topics – from climate change and health to science communication and the challenge of ‘decolonizing global health.’ With a focus on sharing perspectives and voices from low- and middle-income countries, the series has already been downloaded more than 11,000 times by listeners in more than 130 countries, Aslanyan said. “The hope is to inspire listeners to do something in their day job with the information they heard,” Aslanyan said. South Africa at the nexus of the global health equity debate This week’s episode on “Championing health equity in South Africa” takes a long look at the country’s COVID vaccine campaign, whose successes and setbacks were a weathervane for the rest of Africa, as well as its precedent-setting examples in advocating for HIV medicines access, in light of the recent pandemic. “As of early March, 74% of those in high-income countries have been fully vaccinated against COVID-19, compared with just 11% of people in low-income countries. As the world commits to global access to medicines and vaccines, is this just on paper or a reality?” the podcast teaser states. “Can South Africa’s experience with tackling HIV/AIDS and COVID-19 point to future solutions for other low- and middle-income countries? How has intellectual property rights affected development of vaccines across Africa?” Appearing on the podcast are three guests: human rights lawyer and activist Fatima Hassan; UNDP policy specialist Judit Rius Sanjuan; and Petro Terblanche, Managing Director of Afrigen Biologics, host of the new mRNA hub in South Africa. Season 2 of Global Health Matters launched this week: Championing Health Equity in South Africa. The goal: To inspire Aslanyan said he started the series after becoming an active listener of podcasts himself. He fell for the audio genre because it runs against the current of 30-second social media soundbytes, providing more thoughtful and detailed coverage of issues in a digestible format – that listeners can tune into while they are travelling or doing something else. But when he searched for something that “really covers global health, I did not find much” – especially not one that featured voices from low- and middle- income countries. So, he and his team decided to start their own series. “The ability to get a more insightful, in-depth understanding of a topic is why this medium is appealing. And for us at TDR, most importantly, this allows people from around the globe to learn from the experiences of others and apply them to their own reality,” said Aslanyan. Although WHO’s Regional Office for Europe offers a ‘Health in Europe’ podcast, and WHO headquarters features a popular Science in Five video series, Global Health Matters is the only broad-based and regular global health podcast featured by WHO, where TDR is based. Aslanyan has postgraduate training in public health and health policy and systems. While not a trained media professional, he was driven by a clear public health mission: to inspire his colleagues in the field. “You may not immediately think somebody trained in public health to host a podcast, but I have done all kinds of work for organizations focused on global health,” Aslanyan explained. “I also have experience in innovation and advocacy and have worked in government departments in Canada before moving to Geneva where I really pushed the boundaries of national health.” He said public health professionals need to be knowledgeable but also able to present things in a way that galvanizes the public around different causes. He had not thought of himself as that person before starting Global Health Matters, but since launch last year he hears from listeners that this is exactly the role he and his guests are fulfilling. “What makes me think that the podcast medium is amazing is the way that we reach cities, towns and villages in the most remote parts of the world, which is VERY satisfying – we know that from our stats,” Aslanyan says. What were some of the most popular episodes last year? “COVID-19 in Africa: the role of research” helped debunk some of the myths around why there was less virus on the continent. Global Health Matters Episode 3. An episode on “Climate change’s impact on health” looked at the impact of climate change on rural areas whose communities’ health and livelihood depends on the environment. A particular focus was on Maasai communities in northern Tanzania, where persistent droughts have made the people vulnerable to sleeping sickness, a disease spread by the tsetse fly. There was also a piece on Communicating science, not fiction featured Natalia Pasternak, founder of Brazilian-based Instituto Questão de Ciência, which combats pseudoscience and advocates for evidence-based treatments. Natalia spoke of her own personal experience as a member of WhatsApp groups for mothers that took a sudden turn into vaccine skepticism. And thousands of kilometers away, in the Western Pacific, Navigating digital health waves featuring Dr Alvin Marcelo, Executive Director of the Asia eHealth Information Network, explained how the Philippine government allowed open access to data from COVID-19 tests, creating a big opportunity for health researchers and services, for instance better matching of COVID-19 test results from particular locations with availability of hospital bed spaces. Natalia Pasternak, founder of Brazilian-based Instituto Questão de Ciência Dr Alvin Marcelo, Executive Director of the Asia eHealth Information Network. “Of course, we get feedback on every episode,” Aslanyan said. “It seems all of them have touched, inspired or at least piqued the interest of our listeners.” He said that he and his team at TDR stepped into podcasting with no experience but they have already learned a lot. Season 2 builds on last year’s, bringing in additional topics such as science diplomacy, corruption in health, migration and health and diversity in global health. Aslanyan said he also hopes to add an even greater variety of personalities to the podcasts, including, potentially, some guests who are public health service recipients rather than providers. He added that two universities in the global North and South are using some podcast episodes to assist students in understanding complex public health subjects – a testimony to the information and clarity being provided by the show. “We think it gives learners the ability to relate to the topics they are studying,” Aslanyan said. In terms of the spread and reach of his audience- it’s both surprising and satisfying, Aslanyan adds. “Sometimes I look at the analytics data showing the people listening to the podcast, and I think, my gosh, who are these eight people in that small city in Yemen who listened to me? I have no idea who they are, but they are there, in a place I don’t know, and I imagine they are probably working in public health.” The first episode of Season 2 launched on Tuesday April 12. Find it here. Link here to all Season 1 episodes of Global Health Matters. Find it on YouTube Championing Health Equity in South Africa Follow @TDRnews on Twitter, TDR on LinkedIn and @ghm_podcast on Instagram for updates about upcoming shows. Image Credits: WHO, GHM Show , GHM. Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, is this just on paper or a reality? In the case of COVID-19, as of early April 2022, 74% of people in high-income countries had been fully vaccinated, compared with just 15% in Africa and 11% of people in low-income countries worldwide. With 30% of people fully vaccinated, South Africa, has one of the highest COVID vaccination rates in sub-Saharan Africa. And it has been an African leader in the manufacture of COVID vaccines, as well as a leader in the global campaign to waive intellectual property rights on COVID vaccines, tests and treatment – not to mention the historic role it played a generation ago in the legal battles that paved the way for the widespread manufacture of low-cost, generic antivirals for HIV treatment. Can South Africa’s experience with tackling HIV/AIDS and COVID-19 point to future solutions for other low- and middle-income countries? And how has the state of play regarding intellectual property rights for COVID health products affected development of vaccines across Africa? Global Health Matters podcast host Garry Aslanyan fields these and other questions to three leading South Africans scientists, policymakers and health activists, including Fatima Hassan (founder of the Health Justice Initiative), Petro Terblanche (Managing Director of Afrigen Biologics), and Judit Rius Sanjuan (Policy Specialist at UNDP). Click here to catch this episode, the first of the second season of TDR’s Global Health Matters podcast. Find it on YouTube: Championing Health Equity in South Africa Link here for all Season 1 episodes of Global Health Matters. NCDs Finally Get Attention at Presidential Level 12/04/2022 Kerry Cullinan Diabetes protest in South Africa After years of being the neglected stepchild of global health, non-communicable diseases (NCDs) might finally be getting the urgent attention they need with Tuesday’s launch of an international NCD compact and presidential group. The measures were announced at the International Strategic Dialogue on NCDs and Sustainable Development Goals (SDGs) co-hosted by the governments of Ghana and Norway and the World Health Organization (WHO). Mike Bloomberg, the WHO Global NCD Ambassador, told the Accra meeting via video that global investment in NCDs was a “pitiful 1-2% of global health funding”. Very few countries are on track to achieve the United Nations Sustainable Development Goal (SDGs) 3.4, which commits member states to “reduce by one-third premature mortality from NCDs through prevention and treatment, and promote mental health and wellbeing by 2030”. But the NCD Alliance says that the compact and Presidential Council on NCDs (NCD Presidential Group) “could be a turning point in the fight against chronic diseases, which is responsible for 74 % of deaths annually”, finally demonstrating the political will needed to address the world’s biggest killer. Co-organized by the Governments of Ghana🇬🇭 and Norway🇳🇴, and the @WHO, the International Dialogue on #NCDs and the #SDGs taking place in #Accra, is a demonstration of our collective effort, at the leadership level, to forge ahead a common agenda to tackle the challenges of #NCDs. pic.twitter.com/wXP9JHfnP3 — UNinGhana (@UNinGhana) April 12, 2022 WHO member states and leaders will be encouraged to sign up to both the compact and the presidential group and “align strategies and operations with universal commitments made to accelerate and scale up the global collective efforts to prevent and control NCDs and achieve universal health coverage”, according to an outcome document from Tuesday’s meeting. “The NCD Compact is a living document and will be updated on a yearly basis by its current and future signatories among Heads of State and Governments to navigate in preparation of the next UN High-level meeting on NCDs in 2025 and going forward towards 2030,” the document states. “Two years into the global COVID-19 pandemic, there can no longer be any doubt about the case for investing in NCDs,” said Katie Dain, CEO of the NCD Alliance. “COVID-19 has upended health systems, drained economies and disproportionately affected people living with NCDs. This pandemic must be a wake-up call for governments and political leaders to value, prioritise and invest in healthy societies, NCD prevention and strong According to the NCD Alliance, 39 million lives could be saved before 2030 if an additional $18 billion is annually on implementing packages of cost-effective NCD interventions, tailored to local disease burden and risk factors. “This would also generate an average net economic benefit of $2.7 trillion, or $390 per capita, equal to a 19 to one return on investment,” said the alliance, referring to recent research published in The Lancet. The Accra meeting was addressed by a variety of high-profile leaders, particularly from Africa and the Caribbean, including a number of First Ladies who have an active international forum aimed at preventing NCDs. Co-host Norweigan Prime Minister Jonas Gahr Støre said that most of the premature deaths from NCDs can be avoided, and governments “must intensify our efforts to prevent and control them”. 🇳🇴Prime Minister of Norway @jonasgahrstore "Only 14 countries are on track to meet #SDG 3.4 today, we are launching the international NCD compact – a consolidated global effort to prevent people from dying. NCDs are a global problem but I am convinced it is achievable"@NorwayMFA pic.twitter.com/Nk1P7qlbVz — NCD Alliance (@ncdalliance) April 12, 2022 Barbados Prime Minister Mia Mottley lamented that only 14 countries were on track to achieving SGD 3.4, 11 years after the first UN high-level meeting on non-communicable diseases and seven years after the adoption of the SDGs. September meeting The President of Ghana will chair the first meeting of the Presidential Council on NCDs, which will take place in September during the 77th session of the UN General Assembly in New York. Meanwhile, the International NCD Compact 2022-2030 contains strategic priorities to accelerate action and encourage countries to reach SDG targets on NCDs by 2030. According to the NCD Alliance, 41 million people die every year due to an NCD and annual deaths from NCDs are projected to escalate to 52 million by 2030. “To put these figures into perspective, in 2020 annual deaths from tuberculosis, malaria and HIV/AIDS reached 1.5 million, 627,000, and 680,000 respectively. Meanwhile, deaths attributed to the COVID-19 pandemic, from its beginning in 2019 to April 2022, are nearing six million, and 60-90% of these deaths are in people living with one or more NCD. Image Credits: Kerry Cullinan. Historic Public Hearings on WHO Pandemic Instrument; Some Unhappiness with Process 12/04/2022 Kerry Cullinan The last Ebola patient leaves a treatment centre in the Democratic Republic of Congo at the end of March 2021, marking the countdown to declaring the end of that pandemic. The World Health Organization (WHO) convened public hearings for only the second time in its history on Tuesday, asking interested parties what substantive issues should be contained in its proposed international instrument on pandemic preparedness and response. The first and only other WHO hearings were held 22 years ago in the run-up to the adoption of the Framework Convention on Tobacco Control, according to WHO principal legal officer Steven Solomon. Welcoming the public hearing, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that informed opinion and active public cooperation are of the utmost importance to improve health, and it was important to learn from the COVID-19 pandemic to ensure the world is “better prepared” for the next pandemic. Tedros had been mandated by last year’s World Health Assembly Special Session to convene public hearings to inform the work of the Intergovernmental Negotiating Body (INB) which is in charge of negotiating the pandemic instrument or treaty. INB co-chair, South Africa’s Dr Precious Matsoso, described the hearings as “remarkable” and “historic”. Dr Precious Matsoso, INB co-chair Narrow responsibility However, the Civil Society Alliance for Human Rights in the Pandemic Treaty warned that the consultative process risks being “inadequate”. “While this week’s public hearings reflect the INB’s stated objective to consult the public to some extent, it has interpreted its responsibility to do so very narrowly,” according to the alliance. “The INB has allocated minimal time to engaging with the wide range of stakeholders who could inform the process and improve both the legitimacy and quality of the Treaty that emerges.” Dr Meg Davis, from the Global Health Centre at the Graduate Institute in Geneva, also said that participants had been given no indication of whether or how their submissions would be included in the negotiations and recommended policymaking models to ensure meaningful civil society engagement. A number of organisations gave two-minute speeches focusing on a wide range of issues including ‘One Health’, research and development (R&D) and intellectual property rights at the hearings, which continue on Wednesday and then reconvene in mid-June. Equity means sharing Research and Development Professor Suerie Moon, co-director of the Global Health Centre at the Graduate Institute in Geneva. All member states have committed to equity at the heart of any pandemic instrument, but Professor Suerie Moon, co-director of the Geneva Graduate Institute’s Global Health Centre, told the hearings that “equity requires collective research and development of vaccines, drugs and diagnostics”. Pointing out that COVID-19 has led to the development of technology transfer hubs in South Africa and the Republic of Korea, Moon warned that “there’s a risk that new factories will sit idle in the next emergency unless the new international instrument forges agreement on obligations to share knowledge, data and intellectual property before and during future emergencies”. “It’s unlikely, however, that countries or companies will do so out of the goodness of their hearts,” added Moon. “To make such sharing feasible, we have to tie it to commitments to jointly finance research and development to share pathogen samples and genomic sequencing data. In other words, the key idea is collective research and development for collective benefit.” Acknowledging that intellectual property was a difficult issue, Moon nonetheless said that if equitable access was to become a reality “the new instrument must include the nuts-and-bolts provisions to make sharing technology for pandemics the new normal”. To address IP, Knowledge Ecology International (KEI) recommended that governments should “agree to collectively use exceptions to intellectual property rights that are permitted in existing trade agreements and treaties”. “A model for this is the WIPO Marrakesh Treaty for the Blind, which mandates its members to use exceptions in copyrights to enhance global access to works made accessible to persons who are blind or have other disabilities,” according to KEI’s James Love. KEI also proposed “a robust chapter on transparency”, adding that “the lack of transparency in many areas for the current pandemic is an appalling and unnecessary policy failure, and one that both makes it more difficult to manage a pandemic response, and undermines the public’s trust in institutions”. Rachael Crockett from the Drugs for Neglected Diseases initiative (DNDi) stressed the need to co-ordinate R&D as a substantive element of the new instrument. DNDi wants R&D priority setting, and “globally agreed norms and binding rules that govern the R&D process, including transparency and open sharing of research, data, knowledge, technology, and equitable allocation of health tools”. Sharing pathogens IFPMA’s Grega Kumer Grega Kumer from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) said “any system should be built on what worked well during the COVID pandemic, in particular, immediate sharing of pathogens and a robust response from the IP based private sector”. The IFPMA presented eight core principles, including that the negotiation process should be “inclusive and transparent, involving the private sector and all critical contributors to pandemic preparedness efforts”. “Any system should allow for immediate access of pathogens and genetic sequence data and correct the negative effects of access and benefit-sharing legislation,” said Kumer. The IFPMA also supports more equitable access to tests, treatments and vaccines “based on medical need, thus enhancing solidarity and facilitating emergency financing to institutions procuring for developing countries”, and the protection of supply chains ”from arbitrary export restrictions and other trade barriers”. “While the public sector might play a larger role in pandemic setting, the system should build on the private sector strengths for R&D, manufacturing and distribution,” he concluded. One Health is key The need for any pandemic instrument to adopt a One Health approach also emerged as a key theme. Dame Sally Davies, speaking for the UN Global Leaders Group on Antimicrobial Resistance (AMR), said that they wanted AMR to be integrated alongside a primary focus on pandemics. “The next pandemic could be drug-resistant, or could depend on antimicrobials to mitigate it,” said Davies, saying that one health surveillance needed to be at the heart of any pandemic treaty to enable “rapid, transparent and responsive protection”. Governance principles The Panel for a Global Health Convention believes the instrument must be governed by four non-negotiable principles, according to Dame Barbara Stocking. “Solidarity, because we’re all in this together, and solidarity is in our own self-interest,” explained Stocking. “Equity: there must be equal access to vaccines and treatments, but also an equal voice in decision-making. Transparency in reporting data and samples. Accountability, as the lack of accountability of countries is the fundamental reason that we are in disarray.” The hearings continue at 8am CET on Wednesday and can be followed live. Image Credits: WHO African Region. Single Dose of HPV Vaccine is Enough to Protect Against Cervical Cancer 11/04/2022 Kerry Cullinan WHO’s Dr Kate O’Brien and SAGE chairperson Dr Alejandro Cravioto The Human Papillomavirus (HPV), which is the cause of most cervical cancer cases, can be treated with a single vaccine dose instead of the two doses currently being given, according to the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE). SAGE chairperson Dr Alejandro Cravioto told a media briefing on Monday that, after reviewing all available evidence, the group concluded that a single vaccine was effective against HPV in girls and women aged nine to 20, but that women aged 21 and over needed two doses given six months apart. As HPV is generally sexually transmitted, vaccination is also recommended for boys and men who can carry the virus and infect women – and SAGE now also recommends a single dose for younger boys and men too. Only 13% of HPV target group is vaccinated The WHO described the new recommendation as a “game-changer” for the prevention of the disease as it would enable more doses of the vaccine to reach more girls. “The HPV vaccine is highly effective for the prevention of HPV serotypes 16 and 18, which cause 70% of cervical cancer,” said Cravioto. “SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes.” Meanwhile, the WHO described cervical cancer as being “almost entirely preventable” and “a disease of inequity of access”, adding that it was concerned by the slow introduction of the HPV vaccine into immunization programs and low coverage, especially in poorer countries. In 2020, only 13% of the global target population had received two doses, with WHO citing barriers as challenges of supply, cost and delivering a two-dose regimen to older girls who are not part of childhood vaccination programs. Dr Nono Simelela, WHO Assistant Director-General for Strategic Programmatic Priorities: Cervical Cancer Elimination. WHO Assistant Director-General Dr Nono Simelela said that single-dose recommendation “has the potential to take us faster to our goal of having 90 per cent of girls vaccinated by the age of 15 by 2030”. “We need political commitment complemented with equitable pathways for the accessibility of the HPV vaccine. Failure to do so is an injustice to the generation of girls and young women who may be at risk of cervical cancer,” added Simelela. SAGE also recommended that hepatitis A could also be treated with a single vaccine. China’s CanSino Bio vaccine expected to get WHO approval SAGE also evaluated the data on the Chinese CanSino Bio (Ad5-nCOV-S) vaccine, but will only release the outcome of this discussion if the WHO grants the vaccine emergency use listing (EUL) – “hopefully in the next few weeks”, according to Cravioto. An mRNA based COVID-19 vaccine also developed by the Chinese company was cleared for clinical trials last week. Currently, there are no mRNA vaccines available in China. WHO’s Director of Immunization, Dr Kate O’Brien, expressed concern that only around 65% of healthworkers globally were vaccinated against COVID-19, and a similar number of people over the age of 60. In addition, 21 countries had vaccinated less than 10% of citizens, said O’Brien – 14 countries in the African region, four in the eastern Mediterranean region, and then one each in the Americas, the Western Pacific and the Southeast Asian region. “These are countries that are working really hard to advance their programmes now that supply is no longer the issue,” said O’Brien. SAGE admitted that there was a lack of data about the efficacy of non-mRNA vaccines’ efficacy against Omicron. As far as the spread of Omicron in Hong Kong was concerned, Cravioto said the high mortality rate in older people was related to that age group’s reluctance to be infected rather than an indictment on Chinese-produced vaccines. However, he said Nineteen More Attacks on Ukraine’s Health Facilities Since Friday: WHO 11/04/2022 Kerry Cullinan Ukraine operating theatre destroyed The World Health Organization (WHO) has verified 108 attacks on health care in Ukraine as of Monday in which 73 people have died and 51 have been injured. That is 19 more attacks on health facilities than the already deadly toll of 91 attacks that had been verified by WHO as of early Friday afternoon, and as reported at a press conference by WHO’s Regional Director Hans Kluge in Lviv. .@WHO has verified 5 additional reports of attacks on health care in #Ukraine. As of 11 April, 108 attacks on health care in Ukraine have been verified, causing 73 deaths and 51 injuries. We are outraged that attacks on health care are continuing. pic.twitter.com/8GNUQZFiK9 — WHO Ukraine (@WHOUkraine) April 11, 2022 Meanwhile, the Office of the UN High Commissioner for Human Rights (OHCHR) has recorded 1,793 civilian deaths and 2,439 injuries since the start of the Russian invasion on 24 February and Sunday. Most of the civilian casualties have been caused by “explosive weapons with a wide impact area”, including shelling from heavy artillery and rocket, missile and air strikes. https://data.humdata.org/visualization/ukraine-humanitarian-operations/ “OHCHR believes that the actual figures are considerably higher, as the receipt of information from some locations where intense hostilities have been going on has been delayed and many reports are still pending corroboration,” according to a statement from the office. “This concerns, for example, Mariupol (Donetsk region), Izium (Kharkiv region), Popasna (Luhansk region), and Borodianka (Kyiv region), where there are allegations of numerous civilian casualties. These figures are being further corroborated and are not included in the above statistics.” According to the Prosecutor General’s Office of Ukraine, 176 children had been killed and at least 336 injured as of Sunday. Image Credits: WHO. Non-Communicable Diseases: Is the ‘New Normal’ Too Much Like The Old One? 11/04/2022 Katie Dain & David Watkins The vast majority of people who died of COVID-19 had a non-communicable disease – yet investment in NCD prevention is pitiful. More than two years after the novel coronavirus erupted into a global pandemic, the world is beginning to settle into a new normal. COVID-19 changed how we live and work in ways that will continue long after the pandemic subsides. Digital and automation technologies are here to stay, work is done remotely, and shopping and entertainment have gone online. But the COVID-19 pandemic also laid bare an indisputable truth: the destructive path carved by the infectious SARS-CoV2 virus was only the tip of the iceberg. Studies have estimated that 60-90% of COVID-19 deaths have been of people living with one or more chronic conditions, like obesity, heart or kidney disease, or cardiovascular diseases. And people living with non-communicable diseases (NCDs) are still experiencing the collateral damage of the pandemic, due to severe disruptions to essential health services. The lack of investment in NCD prevention and care over the years has vastly amplified the toll of the COVID-19 pandemic. The bigger, long-term pandemic that we face Responsible for 74% of all deaths globally, NCDs are the even bigger, long-term pandemic that we face. Governments and global institutions have been learning many harsh lessons about the need to build back better, with more resilient health systems and more equitable access to quality, affordable treatment. But too often this has been a slogan without much substance behind it. We now need to see real changes taking hold. Beyond COVID, there is a strong and urgent imperative for investment in NCDs, which now cause 15 million premature deaths of people between the ages of 30 and 70 each year, 85% of them in low- and middle-income countries. This makes action and investment in NCDs a prerequisite for resilience, pandemic preparedness and health security, not to mention for meeting the most critical health challenges of the next decade in countries at all stages of development. Yet financing for NCDs has stagnated at a pitiful 1-2% of development assistance for health for two decades. If we look at development assistance that has gone towards health system strengthening which also helps people living with NCDs we can add a further 5%, but that is simply inconsequential when compared to government handouts for fossils fuels and agriculture, which climb to $1.8 trillion annually – and more importantly, when compared to the magnitude of disease and economic burden of NCDs. Still hope to see healthier populations by 2030 In 2015, all UN member countries committed to the Sustainable Development Goals (SDGs) to achieve a better and more sustainable future for all, including SDG target 3.4 to reduce NCD premature mortality by one-third by 2030. This and other NCD commitments should not lose priority because of the COVID-19 pandemic. They should actually gain priority. Although the vast majority of countries are well off-track to meet SDG 3.4, a March 2022 paper published in The Lancet shows that there is still hope. All countries – and especially low- and middle-income countries (LMICs) – can achieve or nearly achieve SDG 3.4 to reduce premature NCD mortality by one-third by 2030 by introducing a cost-effective package of NCD prevention and treatment interventions. Investment in the mitigation of NCDs boosts productivity by cutting the number of wasted lives. The paper presents an NCD investment framework that aims to support LMICs in getting back on track towards achieving SDG target 3.4 in the wake of the COVID-19 pandemic. It is centred around a package of 21 cost-effective interventions; essentially, a feasible and pragmatic roadmap to healthier populations and more resilient health systems. There are 15 clinical interventions, like screening and early detection for diabetes and cervical cancer, and cardiovascular disease prevention programmes. Many of these can be implemented at primary health care level. There are also six policy interventions, focused on taxing and regulating tobacco and alcohol, and measures to reduce intake of sodium and transfats. All of the interventions are aligned with WHO recommendations for NCD programmes, helping ensure a more coordinated NCD and pandemic response. The paper provides guidance on the types of interventions that can best accelerate progress on NCDs in 123 LMICs, and the resources required to implement these interventions. While the clinical interventions are meant to be selected according to national needs and contexts, the policy interventions are crucial for all countries, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. These actions could also generate significant revenue, which can then be reinvested in health. The bottom line for NCD investment As the paper demonstrates, implementing the most efficient package of interventions in each world region would require $140 billion in new spending over 2023–30, equivalent to $18 billion per year. This investment could avert 39 million deaths and generate an average net economic benefit of US$2.7 trillion, or US$390 per capita. This means that benefits outweigh costs by 19 to one. LMIC ministries of health would need to contribute around 20% of their budgets to the priority NCD interventions. Many countries would also need external support (bilateral, multilateral, philanthropy, private sector), particularly in light of the economic impacts of COVID-19. For the first time, we have a price tag for tackling NCDs in LMICs – and it’s peanuts alongside current NCD treatment costs and economic losses due to premature death and disability. For instance, in 2021, health expenditure for diabetes reached $966 billion; the annual cost of obesity is projected to top $1.2 trillion globally by 2025; the total economic loss due to cardiovascular disease in LMICs was estimated at $3.7 trillion between 2011 and 2015. The paper provides further evidence that underscores the urgent need to invest now in proven strategies to save lives and prevent and treat NCDs. Investments in NCDs are not only cost-effective, but they can also save money even within a short timeframe. The bottom line is that governments can reap substantial economic rewards, in both the short- and long-run, by taking bold action on NCDs and thus ensuring the security and fiscal sustainability of their health systems. This requires a view of health as an investment not a cost, and one that requires long-term thinking. Trailblazing the road to recovery Leaders must shift their priorities to achieving healthier populations, with impactful action for NCD prevention and care. Some countries are taking bold steps. India’s budget for 2021 more than doubled national healthcare and wellbeing spending from previous levels. The Philippines increased the taxation of tobacco products during the COVID-19 pandemic, with a share being earmarked to bolster capacity for universal health coverage to reach the poorest communities. Meanwhile, Latin America has made big gains for healthy diets. Recognising a high number of COVID-19 cases among overweight children and adults, the Mexican states of Oaxaca and Tabasco banned the sale of junk food and sugary drinks to people under 18 in 2020, with more states planning to follow suit. Front of package labels in Mexico A Mexican nationwide front-of-packaging warning labelling law also entered into effect in 2020, requiring black stop signs on packages of foods high in added sugar, fats, calories and sodium. Various Caribbean nations have implemented taxes on sugary beverages and made advances to control marketing of junk food in and near schools. These are just a sample of the actions being taken around the world, and are reason for optimism that real progress can be made. What we need now to accelerate this progress is strong leadership that is committed to putting health and health security first. NCD action and investment must no longer be seen as an afterthought to infectious diseases and neglected within health services, but as fundamental to resilience, security, equity, and economic stability. As Heads of State and Governments meet this week in Ghana for the International Strategic Dialogue on NCDs and the SDGs, we call on leaders to take the bold action so urgently needed. Whether NCDs and their prevention are addressed by future policy action will make or break the effectiveness of the pandemic response. Katie Dain is the Chief Executive Officer of the NCD Alliance. David Watkins, University of Washington, is the lead author of a recent Lancet NCD 2030 Countdown series article on pathways and investments to accelerate NCDs progress. Interactive map reproduced with permission from Politico Studio, based on data from WHO’s 2020 NCDs Progress Monitor. Image Credits: WHO/A. Loke, World Health Organization , World Heart Federation / WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
With COVID Vaccine Supply Outstripping Vaccination Rates, Pharma Giants Question Pursuit of IP Waiver 13/04/2022 Kerry Cullinan IFPMA Director General Thomas Cueni (foreground) with moderator Claire Doole and Albert Bourla, David Ricks and Bill Anderson on screen. Pharmaceutical giants have questioned why a waiver on intellectual property (IP) rights for COVID-19 vaccines is still on the table when they are battling to find markets for their vaccines amid order cancellations – including from the Africa Centre for Disease Control. “I’m stunned that the proposed IP waiver is still being debated while supplies of vaccines are far outstripping demand and some factories have been put to a halt because of missing orders,” Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) told a media briefing on Wednesday. With almost a billion vaccines now being produced every month, countries’ lack of capacity to vaccinate is now the main barrier to stopping COVID-19, added Cueni. In the first quarter of the year 13.7 billion vaccine doses were delivered and 11 billion doses administered, said Cueni. “Now orders are slowing down. Countries as well as organisations such as Africa CDC, are not only asking for orders to be delayed but are cancelling them,” added Cueni. “Leading voices are still calling out vaccine scarcity. I do understand the concern. Vaccines are not reaching all those who need them. But the cause is no longer the lack of supplies. It’s scarcity of vaccination, which is due to the lack of country readiness, absorption capacity and the lack of resources needed to get the vaccines into arms.” Countries’ lack of capacity Pfizer CEO Dr Albert Bourla also weighed in on country capacity, saying that the US government was offering 200 million free doses to the poorest countries of the world but they lacked the capacity to administer the vaccines. “The problem is not if there is availability or access to pricing. The problem is that the infrastructure of these countries is very poor, so they cannot absorb them. They cannot run a vaccination campaign,” said Bourla. Bourla added that one of the pandemic’s key lessons was that more attention should have been paid to preparing countries to vaccinate people. He also described any move to remove IP on vaccines as “insane”, while Roche CEO Bill Anderson described it as “unproductive”. Eli Lilly CEO David Ricks warned that pharmaceutical companies and investors would “never have invested” in trying to develop COVID-19 vaccines “if there was not the promise of IP”. “The next investments on the unknown technology which we can repurpose for the next pandemic won’t be made if investors believe that IP will be undermined,” warned Ricks. “What is a patent? It’s a promise to disclose our inventions in return for a period of exclusivity,” added Ricks. “You’ll get much less disclosure about inventions actually as a result of an IP waiver. There’ll be a strong incentive to retain know-how, retain the recipes for what we do, much like you see in some other industries.” Collaboration successes Bourla said one of the best aspects of the pandemic had been the collaborations between different the industry partners, where competitors worked together, as we as public-private collaboration, particularly with regulators. He commended particularly the US Food and Drug Administration, the European Medicines Agency and the Canadian, Israeli and Japanese regulators for their speedy reviews of industry data. “What did not help was the politicisation – if you take a vaccine or not, or wear a mask or not. Tthat created tremendous damage to the global health,” said Bourla. At the IFPMA briefing (clockwise): Pfizer CEO Albert Bourla, IFPMA Director General Thomas Cueni and moderator Claire Doole, Roche CEO Bill Anderson and Eli Lilly CEO David Ricks Future COVID vaccines The IFPMA noted that there was “increasing acceptance that society will have to live with COVID-19”, and that continued innovation remains essential to expand on the 10 vaccines that have so far received WHO Emergency Use Listing approval and the 18 different treatments that have been approved in the UK, USA, and EU. Bourla said that Pfizer and Moderna were working on “multivariant” vaccines but this was “very challenging”, as was developing a COVID-19 vaccine that offered robust protection for at least a year. He hoped this would be ready for testing in the third quarter of the year. COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar A COVID-19 vaccination being administered in Senegal. COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros Adhanom Ghebreyesus, the Director-General of WHO, at a press briefing on Wednesday in Geneva. “This virus has over time become more transmissible and it remains deadly, especially for the unprotected and unvaccinated that don’t have access to health care and antivirals. The best way to protect yourself is to get vaccinated and boosted when recommended,” he said. The briefing comes at the end of a meeting of the WHO Emergency Committee convened under the International Health Regulations (IHR). The committee discussed the capacities of states to respond to the pandemic, the problem of vaccine inequity, reduced testing and monitoring, and raised concerns about the inappropriate use of antivirals that may give impetus to drug-resistant variants. Ukraine and Ethiopia In the past 50 days since theRussia invasion of Ukraine, 4.6 million refugees have fled the country, and thousands of civilians, including children, have died, and there have been 119 verified attacks on health care workers. Dr Tedros said that there is a need for humanitarian corridors to enable the delivery of medical supplies, food and water and the evacuation of civilians. He added that to date, the WHO had only received about half of the funding needed to support Ukraine for the first three months. Dr Michael Ryan, WHO’s Executive Director of Health Emergencies, said that there was a high risk of chemical contamination and exposure due to attacks, as well as compromised infrastructure associated with the chemical production, nuclear weapons and energy production. Dr Michael Ryan at the WHO Press Briefing. “We’ve been doing training and other support to the authorities in Ukraine in preparation for such an event. This is very different from the intentional use of chemicals as a weapon in war, which is against international Law and is a war crime,” said Ryan. This comes on the back of reports of the use of chemical weapons in Mariupol. With respect to Ethiopia, Tedors said that the siege by the Ethiopian and Eritrean forces continues to avert the humanitarian calamity and thousands of people from dying. Tedros, who is an Ethiopian and a former Minister of Foreign Affairs, said that the Tigray crisis is one of the most alarming humanitarian crises of our times. “But the world is not treating the human race the same way. Some are more equal than others,” he said referring to the negligible attention received by Afghanistan, Ethiopia, Yemen, and Libya versus the attention that is meted to Ukraine currently. Newer variants According to Dr Maria Van Kerkhove, WHO’s Technical lead on COVID-19, the new sub-variants of the Omicron variant– BA.4 and BA.5– have been reported from a number of countries, including South Africa, in Europe. She said that more sequencing and concerted global efforts to track and share the data on the virus are needed to understand the characteristics of the variants. Responding to the concerns about the reduced testing and tracking of COVID-19 cases, Ryan said that it was important to track the virus as it went “underground”. “It will be very, very, very short-sighted at this time to assume that lower numbers of cases mean an absolute lower risk,” he said. “This virus has surprised us before… We need to do our jobs and track this virus as best we can while people get back to living as normal a life as possible. We in the scientific and public health community need to continue to track this virus closely in every single country.” Dr Maria Van Kerkhove,WHO’s Technical lead for COVID-19, Van Kerkhove added that the committee which met today outlined three main scenarios in the modified Strategic Preparedness, Readiness, and Response Plan (SPRRP) publication: a best case, a worst case, and a base case in terms of outlining what virus evolution and changes and how our countermeasures will react or react to those. There is also a fourth scenario, called ‘reset’ where there is so much change in the virus there will be a population that is susceptible again, and “it resets us.” Vaccinate, vaccinate, vaccinate The updated SPRRP report highlights the need to achieve national COVID-19 vaccination targets in line with global WHO recommendations of at least 70% of all countries’ populations vaccinated by the start of July 2022. “Countries really must start looking at their data breakdown by age and sex,” said Dr Soumya Swaminathan, WHO’s Chief Scientist, while highlighting the importance of boosting the population over the age of 60. Swaminathan added that a majority of countries plan to meet the 70% target, but a handful of countries have set their goal at less than 40%. “ Many of these countries have competing health priorities and so we need to make sure that as COVID vaccine uptake is expanded, scaled up, strengthened, and routine immunization services are also strengthened,” said Swaminathan. Swaminathan mentioned that COVAX has the capability to cater to the vaccination needs of the vulnerable population, but there needs to be more focus on making sure the older, more vulnerable population is catered to and not left out despite the inequitable vaccine situation currently. “The inequity is not just in the overall distribution of vaccines, it is also occurring within countries in terms of not reaching those most likely to benefit from the vaccine and that’s particularly acute,” said Ryan. He added that while 85% of the population over 60 years of age in Europe is fully vaccinated, the number for the same metric stands at 25% in Africa. “If we fail to vaccinate everyone, if we fail to continue diagnosing, if we fail to find the people who can benefit from treatment, then we will fail in the future, and in the next pandemic. So our success now will determine a successful future,” Ryan said. Image Credits: Flickr – Trinity Care Foundation, Georges Yameogo.. Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman Global Health Matters podcast host Dr. Garry Aslanyan, TDR After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – and can inspire others as well. The Global Health Matters podcast hosted by Aslanyan, a public health professional with TDR, the Special Programme for Research and Training in Tropical Diseases, co-sponsored by UNICEF, UNDP, the World Bank and WHO, is now entering its second season of broadcasts. It features a diverse mix of themes and line-up of speakers – has picked up an audience of followers in places as diverse as Yemeni villages and Ulaanbaatar, Mongolia. The first episode of Season 2 was launched on Tuesday, April 12. It focuses on “Championing Health Equity in South Africa.” “The podcast gives people a unique peek into the experiences of people who are just like them,” Aslanyan told Health Policy Watch. “Listeners can relate to the guests and their experiences and compare what they themselves are living through – they can think, ‘can I do this?’ or ‘how does that work?’ or ‘what can this mean for me in my own setting or country?’” The podcast began at the height of the COVID-19 pandemic, when new, virtual information tools became all the more important to people confined for days and weeks at home. The podcast series has already covered a broad range of innovative and inspiring research topics – from climate change and health to science communication and the challenge of ‘decolonizing global health.’ With a focus on sharing perspectives and voices from low- and middle-income countries, the series has already been downloaded more than 11,000 times by listeners in more than 130 countries, Aslanyan said. “The hope is to inspire listeners to do something in their day job with the information they heard,” Aslanyan said. South Africa at the nexus of the global health equity debate This week’s episode on “Championing health equity in South Africa” takes a long look at the country’s COVID vaccine campaign, whose successes and setbacks were a weathervane for the rest of Africa, as well as its precedent-setting examples in advocating for HIV medicines access, in light of the recent pandemic. “As of early March, 74% of those in high-income countries have been fully vaccinated against COVID-19, compared with just 11% of people in low-income countries. As the world commits to global access to medicines and vaccines, is this just on paper or a reality?” the podcast teaser states. “Can South Africa’s experience with tackling HIV/AIDS and COVID-19 point to future solutions for other low- and middle-income countries? How has intellectual property rights affected development of vaccines across Africa?” Appearing on the podcast are three guests: human rights lawyer and activist Fatima Hassan; UNDP policy specialist Judit Rius Sanjuan; and Petro Terblanche, Managing Director of Afrigen Biologics, host of the new mRNA hub in South Africa. Season 2 of Global Health Matters launched this week: Championing Health Equity in South Africa. The goal: To inspire Aslanyan said he started the series after becoming an active listener of podcasts himself. He fell for the audio genre because it runs against the current of 30-second social media soundbytes, providing more thoughtful and detailed coverage of issues in a digestible format – that listeners can tune into while they are travelling or doing something else. But when he searched for something that “really covers global health, I did not find much” – especially not one that featured voices from low- and middle- income countries. So, he and his team decided to start their own series. “The ability to get a more insightful, in-depth understanding of a topic is why this medium is appealing. And for us at TDR, most importantly, this allows people from around the globe to learn from the experiences of others and apply them to their own reality,” said Aslanyan. Although WHO’s Regional Office for Europe offers a ‘Health in Europe’ podcast, and WHO headquarters features a popular Science in Five video series, Global Health Matters is the only broad-based and regular global health podcast featured by WHO, where TDR is based. Aslanyan has postgraduate training in public health and health policy and systems. While not a trained media professional, he was driven by a clear public health mission: to inspire his colleagues in the field. “You may not immediately think somebody trained in public health to host a podcast, but I have done all kinds of work for organizations focused on global health,” Aslanyan explained. “I also have experience in innovation and advocacy and have worked in government departments in Canada before moving to Geneva where I really pushed the boundaries of national health.” He said public health professionals need to be knowledgeable but also able to present things in a way that galvanizes the public around different causes. He had not thought of himself as that person before starting Global Health Matters, but since launch last year he hears from listeners that this is exactly the role he and his guests are fulfilling. “What makes me think that the podcast medium is amazing is the way that we reach cities, towns and villages in the most remote parts of the world, which is VERY satisfying – we know that from our stats,” Aslanyan says. What were some of the most popular episodes last year? “COVID-19 in Africa: the role of research” helped debunk some of the myths around why there was less virus on the continent. Global Health Matters Episode 3. An episode on “Climate change’s impact on health” looked at the impact of climate change on rural areas whose communities’ health and livelihood depends on the environment. A particular focus was on Maasai communities in northern Tanzania, where persistent droughts have made the people vulnerable to sleeping sickness, a disease spread by the tsetse fly. There was also a piece on Communicating science, not fiction featured Natalia Pasternak, founder of Brazilian-based Instituto Questão de Ciência, which combats pseudoscience and advocates for evidence-based treatments. Natalia spoke of her own personal experience as a member of WhatsApp groups for mothers that took a sudden turn into vaccine skepticism. And thousands of kilometers away, in the Western Pacific, Navigating digital health waves featuring Dr Alvin Marcelo, Executive Director of the Asia eHealth Information Network, explained how the Philippine government allowed open access to data from COVID-19 tests, creating a big opportunity for health researchers and services, for instance better matching of COVID-19 test results from particular locations with availability of hospital bed spaces. Natalia Pasternak, founder of Brazilian-based Instituto Questão de Ciência Dr Alvin Marcelo, Executive Director of the Asia eHealth Information Network. “Of course, we get feedback on every episode,” Aslanyan said. “It seems all of them have touched, inspired or at least piqued the interest of our listeners.” He said that he and his team at TDR stepped into podcasting with no experience but they have already learned a lot. Season 2 builds on last year’s, bringing in additional topics such as science diplomacy, corruption in health, migration and health and diversity in global health. Aslanyan said he also hopes to add an even greater variety of personalities to the podcasts, including, potentially, some guests who are public health service recipients rather than providers. He added that two universities in the global North and South are using some podcast episodes to assist students in understanding complex public health subjects – a testimony to the information and clarity being provided by the show. “We think it gives learners the ability to relate to the topics they are studying,” Aslanyan said. In terms of the spread and reach of his audience- it’s both surprising and satisfying, Aslanyan adds. “Sometimes I look at the analytics data showing the people listening to the podcast, and I think, my gosh, who are these eight people in that small city in Yemen who listened to me? I have no idea who they are, but they are there, in a place I don’t know, and I imagine they are probably working in public health.” The first episode of Season 2 launched on Tuesday April 12. Find it here. Link here to all Season 1 episodes of Global Health Matters. Find it on YouTube Championing Health Equity in South Africa Follow @TDRnews on Twitter, TDR on LinkedIn and @ghm_podcast on Instagram for updates about upcoming shows. Image Credits: WHO, GHM Show , GHM. Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, is this just on paper or a reality? In the case of COVID-19, as of early April 2022, 74% of people in high-income countries had been fully vaccinated, compared with just 15% in Africa and 11% of people in low-income countries worldwide. With 30% of people fully vaccinated, South Africa, has one of the highest COVID vaccination rates in sub-Saharan Africa. And it has been an African leader in the manufacture of COVID vaccines, as well as a leader in the global campaign to waive intellectual property rights on COVID vaccines, tests and treatment – not to mention the historic role it played a generation ago in the legal battles that paved the way for the widespread manufacture of low-cost, generic antivirals for HIV treatment. Can South Africa’s experience with tackling HIV/AIDS and COVID-19 point to future solutions for other low- and middle-income countries? And how has the state of play regarding intellectual property rights for COVID health products affected development of vaccines across Africa? Global Health Matters podcast host Garry Aslanyan fields these and other questions to three leading South Africans scientists, policymakers and health activists, including Fatima Hassan (founder of the Health Justice Initiative), Petro Terblanche (Managing Director of Afrigen Biologics), and Judit Rius Sanjuan (Policy Specialist at UNDP). Click here to catch this episode, the first of the second season of TDR’s Global Health Matters podcast. Find it on YouTube: Championing Health Equity in South Africa Link here for all Season 1 episodes of Global Health Matters. NCDs Finally Get Attention at Presidential Level 12/04/2022 Kerry Cullinan Diabetes protest in South Africa After years of being the neglected stepchild of global health, non-communicable diseases (NCDs) might finally be getting the urgent attention they need with Tuesday’s launch of an international NCD compact and presidential group. The measures were announced at the International Strategic Dialogue on NCDs and Sustainable Development Goals (SDGs) co-hosted by the governments of Ghana and Norway and the World Health Organization (WHO). Mike Bloomberg, the WHO Global NCD Ambassador, told the Accra meeting via video that global investment in NCDs was a “pitiful 1-2% of global health funding”. Very few countries are on track to achieve the United Nations Sustainable Development Goal (SDGs) 3.4, which commits member states to “reduce by one-third premature mortality from NCDs through prevention and treatment, and promote mental health and wellbeing by 2030”. But the NCD Alliance says that the compact and Presidential Council on NCDs (NCD Presidential Group) “could be a turning point in the fight against chronic diseases, which is responsible for 74 % of deaths annually”, finally demonstrating the political will needed to address the world’s biggest killer. Co-organized by the Governments of Ghana🇬🇭 and Norway🇳🇴, and the @WHO, the International Dialogue on #NCDs and the #SDGs taking place in #Accra, is a demonstration of our collective effort, at the leadership level, to forge ahead a common agenda to tackle the challenges of #NCDs. pic.twitter.com/wXP9JHfnP3 — UNinGhana (@UNinGhana) April 12, 2022 WHO member states and leaders will be encouraged to sign up to both the compact and the presidential group and “align strategies and operations with universal commitments made to accelerate and scale up the global collective efforts to prevent and control NCDs and achieve universal health coverage”, according to an outcome document from Tuesday’s meeting. “The NCD Compact is a living document and will be updated on a yearly basis by its current and future signatories among Heads of State and Governments to navigate in preparation of the next UN High-level meeting on NCDs in 2025 and going forward towards 2030,” the document states. “Two years into the global COVID-19 pandemic, there can no longer be any doubt about the case for investing in NCDs,” said Katie Dain, CEO of the NCD Alliance. “COVID-19 has upended health systems, drained economies and disproportionately affected people living with NCDs. This pandemic must be a wake-up call for governments and political leaders to value, prioritise and invest in healthy societies, NCD prevention and strong According to the NCD Alliance, 39 million lives could be saved before 2030 if an additional $18 billion is annually on implementing packages of cost-effective NCD interventions, tailored to local disease burden and risk factors. “This would also generate an average net economic benefit of $2.7 trillion, or $390 per capita, equal to a 19 to one return on investment,” said the alliance, referring to recent research published in The Lancet. The Accra meeting was addressed by a variety of high-profile leaders, particularly from Africa and the Caribbean, including a number of First Ladies who have an active international forum aimed at preventing NCDs. Co-host Norweigan Prime Minister Jonas Gahr Støre said that most of the premature deaths from NCDs can be avoided, and governments “must intensify our efforts to prevent and control them”. 🇳🇴Prime Minister of Norway @jonasgahrstore "Only 14 countries are on track to meet #SDG 3.4 today, we are launching the international NCD compact – a consolidated global effort to prevent people from dying. NCDs are a global problem but I am convinced it is achievable"@NorwayMFA pic.twitter.com/Nk1P7qlbVz — NCD Alliance (@ncdalliance) April 12, 2022 Barbados Prime Minister Mia Mottley lamented that only 14 countries were on track to achieving SGD 3.4, 11 years after the first UN high-level meeting on non-communicable diseases and seven years after the adoption of the SDGs. September meeting The President of Ghana will chair the first meeting of the Presidential Council on NCDs, which will take place in September during the 77th session of the UN General Assembly in New York. Meanwhile, the International NCD Compact 2022-2030 contains strategic priorities to accelerate action and encourage countries to reach SDG targets on NCDs by 2030. According to the NCD Alliance, 41 million people die every year due to an NCD and annual deaths from NCDs are projected to escalate to 52 million by 2030. “To put these figures into perspective, in 2020 annual deaths from tuberculosis, malaria and HIV/AIDS reached 1.5 million, 627,000, and 680,000 respectively. Meanwhile, deaths attributed to the COVID-19 pandemic, from its beginning in 2019 to April 2022, are nearing six million, and 60-90% of these deaths are in people living with one or more NCD. Image Credits: Kerry Cullinan. Historic Public Hearings on WHO Pandemic Instrument; Some Unhappiness with Process 12/04/2022 Kerry Cullinan The last Ebola patient leaves a treatment centre in the Democratic Republic of Congo at the end of March 2021, marking the countdown to declaring the end of that pandemic. The World Health Organization (WHO) convened public hearings for only the second time in its history on Tuesday, asking interested parties what substantive issues should be contained in its proposed international instrument on pandemic preparedness and response. The first and only other WHO hearings were held 22 years ago in the run-up to the adoption of the Framework Convention on Tobacco Control, according to WHO principal legal officer Steven Solomon. Welcoming the public hearing, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that informed opinion and active public cooperation are of the utmost importance to improve health, and it was important to learn from the COVID-19 pandemic to ensure the world is “better prepared” for the next pandemic. Tedros had been mandated by last year’s World Health Assembly Special Session to convene public hearings to inform the work of the Intergovernmental Negotiating Body (INB) which is in charge of negotiating the pandemic instrument or treaty. INB co-chair, South Africa’s Dr Precious Matsoso, described the hearings as “remarkable” and “historic”. Dr Precious Matsoso, INB co-chair Narrow responsibility However, the Civil Society Alliance for Human Rights in the Pandemic Treaty warned that the consultative process risks being “inadequate”. “While this week’s public hearings reflect the INB’s stated objective to consult the public to some extent, it has interpreted its responsibility to do so very narrowly,” according to the alliance. “The INB has allocated minimal time to engaging with the wide range of stakeholders who could inform the process and improve both the legitimacy and quality of the Treaty that emerges.” Dr Meg Davis, from the Global Health Centre at the Graduate Institute in Geneva, also said that participants had been given no indication of whether or how their submissions would be included in the negotiations and recommended policymaking models to ensure meaningful civil society engagement. A number of organisations gave two-minute speeches focusing on a wide range of issues including ‘One Health’, research and development (R&D) and intellectual property rights at the hearings, which continue on Wednesday and then reconvene in mid-June. Equity means sharing Research and Development Professor Suerie Moon, co-director of the Global Health Centre at the Graduate Institute in Geneva. All member states have committed to equity at the heart of any pandemic instrument, but Professor Suerie Moon, co-director of the Geneva Graduate Institute’s Global Health Centre, told the hearings that “equity requires collective research and development of vaccines, drugs and diagnostics”. Pointing out that COVID-19 has led to the development of technology transfer hubs in South Africa and the Republic of Korea, Moon warned that “there’s a risk that new factories will sit idle in the next emergency unless the new international instrument forges agreement on obligations to share knowledge, data and intellectual property before and during future emergencies”. “It’s unlikely, however, that countries or companies will do so out of the goodness of their hearts,” added Moon. “To make such sharing feasible, we have to tie it to commitments to jointly finance research and development to share pathogen samples and genomic sequencing data. In other words, the key idea is collective research and development for collective benefit.” Acknowledging that intellectual property was a difficult issue, Moon nonetheless said that if equitable access was to become a reality “the new instrument must include the nuts-and-bolts provisions to make sharing technology for pandemics the new normal”. To address IP, Knowledge Ecology International (KEI) recommended that governments should “agree to collectively use exceptions to intellectual property rights that are permitted in existing trade agreements and treaties”. “A model for this is the WIPO Marrakesh Treaty for the Blind, which mandates its members to use exceptions in copyrights to enhance global access to works made accessible to persons who are blind or have other disabilities,” according to KEI’s James Love. KEI also proposed “a robust chapter on transparency”, adding that “the lack of transparency in many areas for the current pandemic is an appalling and unnecessary policy failure, and one that both makes it more difficult to manage a pandemic response, and undermines the public’s trust in institutions”. Rachael Crockett from the Drugs for Neglected Diseases initiative (DNDi) stressed the need to co-ordinate R&D as a substantive element of the new instrument. DNDi wants R&D priority setting, and “globally agreed norms and binding rules that govern the R&D process, including transparency and open sharing of research, data, knowledge, technology, and equitable allocation of health tools”. Sharing pathogens IFPMA’s Grega Kumer Grega Kumer from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) said “any system should be built on what worked well during the COVID pandemic, in particular, immediate sharing of pathogens and a robust response from the IP based private sector”. The IFPMA presented eight core principles, including that the negotiation process should be “inclusive and transparent, involving the private sector and all critical contributors to pandemic preparedness efforts”. “Any system should allow for immediate access of pathogens and genetic sequence data and correct the negative effects of access and benefit-sharing legislation,” said Kumer. The IFPMA also supports more equitable access to tests, treatments and vaccines “based on medical need, thus enhancing solidarity and facilitating emergency financing to institutions procuring for developing countries”, and the protection of supply chains ”from arbitrary export restrictions and other trade barriers”. “While the public sector might play a larger role in pandemic setting, the system should build on the private sector strengths for R&D, manufacturing and distribution,” he concluded. One Health is key The need for any pandemic instrument to adopt a One Health approach also emerged as a key theme. Dame Sally Davies, speaking for the UN Global Leaders Group on Antimicrobial Resistance (AMR), said that they wanted AMR to be integrated alongside a primary focus on pandemics. “The next pandemic could be drug-resistant, or could depend on antimicrobials to mitigate it,” said Davies, saying that one health surveillance needed to be at the heart of any pandemic treaty to enable “rapid, transparent and responsive protection”. Governance principles The Panel for a Global Health Convention believes the instrument must be governed by four non-negotiable principles, according to Dame Barbara Stocking. “Solidarity, because we’re all in this together, and solidarity is in our own self-interest,” explained Stocking. “Equity: there must be equal access to vaccines and treatments, but also an equal voice in decision-making. Transparency in reporting data and samples. Accountability, as the lack of accountability of countries is the fundamental reason that we are in disarray.” The hearings continue at 8am CET on Wednesday and can be followed live. Image Credits: WHO African Region. Single Dose of HPV Vaccine is Enough to Protect Against Cervical Cancer 11/04/2022 Kerry Cullinan WHO’s Dr Kate O’Brien and SAGE chairperson Dr Alejandro Cravioto The Human Papillomavirus (HPV), which is the cause of most cervical cancer cases, can be treated with a single vaccine dose instead of the two doses currently being given, according to the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE). SAGE chairperson Dr Alejandro Cravioto told a media briefing on Monday that, after reviewing all available evidence, the group concluded that a single vaccine was effective against HPV in girls and women aged nine to 20, but that women aged 21 and over needed two doses given six months apart. As HPV is generally sexually transmitted, vaccination is also recommended for boys and men who can carry the virus and infect women – and SAGE now also recommends a single dose for younger boys and men too. Only 13% of HPV target group is vaccinated The WHO described the new recommendation as a “game-changer” for the prevention of the disease as it would enable more doses of the vaccine to reach more girls. “The HPV vaccine is highly effective for the prevention of HPV serotypes 16 and 18, which cause 70% of cervical cancer,” said Cravioto. “SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes.” Meanwhile, the WHO described cervical cancer as being “almost entirely preventable” and “a disease of inequity of access”, adding that it was concerned by the slow introduction of the HPV vaccine into immunization programs and low coverage, especially in poorer countries. In 2020, only 13% of the global target population had received two doses, with WHO citing barriers as challenges of supply, cost and delivering a two-dose regimen to older girls who are not part of childhood vaccination programs. Dr Nono Simelela, WHO Assistant Director-General for Strategic Programmatic Priorities: Cervical Cancer Elimination. WHO Assistant Director-General Dr Nono Simelela said that single-dose recommendation “has the potential to take us faster to our goal of having 90 per cent of girls vaccinated by the age of 15 by 2030”. “We need political commitment complemented with equitable pathways for the accessibility of the HPV vaccine. Failure to do so is an injustice to the generation of girls and young women who may be at risk of cervical cancer,” added Simelela. SAGE also recommended that hepatitis A could also be treated with a single vaccine. China’s CanSino Bio vaccine expected to get WHO approval SAGE also evaluated the data on the Chinese CanSino Bio (Ad5-nCOV-S) vaccine, but will only release the outcome of this discussion if the WHO grants the vaccine emergency use listing (EUL) – “hopefully in the next few weeks”, according to Cravioto. An mRNA based COVID-19 vaccine also developed by the Chinese company was cleared for clinical trials last week. Currently, there are no mRNA vaccines available in China. WHO’s Director of Immunization, Dr Kate O’Brien, expressed concern that only around 65% of healthworkers globally were vaccinated against COVID-19, and a similar number of people over the age of 60. In addition, 21 countries had vaccinated less than 10% of citizens, said O’Brien – 14 countries in the African region, four in the eastern Mediterranean region, and then one each in the Americas, the Western Pacific and the Southeast Asian region. “These are countries that are working really hard to advance their programmes now that supply is no longer the issue,” said O’Brien. SAGE admitted that there was a lack of data about the efficacy of non-mRNA vaccines’ efficacy against Omicron. As far as the spread of Omicron in Hong Kong was concerned, Cravioto said the high mortality rate in older people was related to that age group’s reluctance to be infected rather than an indictment on Chinese-produced vaccines. However, he said Nineteen More Attacks on Ukraine’s Health Facilities Since Friday: WHO 11/04/2022 Kerry Cullinan Ukraine operating theatre destroyed The World Health Organization (WHO) has verified 108 attacks on health care in Ukraine as of Monday in which 73 people have died and 51 have been injured. That is 19 more attacks on health facilities than the already deadly toll of 91 attacks that had been verified by WHO as of early Friday afternoon, and as reported at a press conference by WHO’s Regional Director Hans Kluge in Lviv. .@WHO has verified 5 additional reports of attacks on health care in #Ukraine. As of 11 April, 108 attacks on health care in Ukraine have been verified, causing 73 deaths and 51 injuries. We are outraged that attacks on health care are continuing. pic.twitter.com/8GNUQZFiK9 — WHO Ukraine (@WHOUkraine) April 11, 2022 Meanwhile, the Office of the UN High Commissioner for Human Rights (OHCHR) has recorded 1,793 civilian deaths and 2,439 injuries since the start of the Russian invasion on 24 February and Sunday. Most of the civilian casualties have been caused by “explosive weapons with a wide impact area”, including shelling from heavy artillery and rocket, missile and air strikes. https://data.humdata.org/visualization/ukraine-humanitarian-operations/ “OHCHR believes that the actual figures are considerably higher, as the receipt of information from some locations where intense hostilities have been going on has been delayed and many reports are still pending corroboration,” according to a statement from the office. “This concerns, for example, Mariupol (Donetsk region), Izium (Kharkiv region), Popasna (Luhansk region), and Borodianka (Kyiv region), where there are allegations of numerous civilian casualties. These figures are being further corroborated and are not included in the above statistics.” According to the Prosecutor General’s Office of Ukraine, 176 children had been killed and at least 336 injured as of Sunday. Image Credits: WHO. Non-Communicable Diseases: Is the ‘New Normal’ Too Much Like The Old One? 11/04/2022 Katie Dain & David Watkins The vast majority of people who died of COVID-19 had a non-communicable disease – yet investment in NCD prevention is pitiful. More than two years after the novel coronavirus erupted into a global pandemic, the world is beginning to settle into a new normal. COVID-19 changed how we live and work in ways that will continue long after the pandemic subsides. Digital and automation technologies are here to stay, work is done remotely, and shopping and entertainment have gone online. But the COVID-19 pandemic also laid bare an indisputable truth: the destructive path carved by the infectious SARS-CoV2 virus was only the tip of the iceberg. Studies have estimated that 60-90% of COVID-19 deaths have been of people living with one or more chronic conditions, like obesity, heart or kidney disease, or cardiovascular diseases. And people living with non-communicable diseases (NCDs) are still experiencing the collateral damage of the pandemic, due to severe disruptions to essential health services. The lack of investment in NCD prevention and care over the years has vastly amplified the toll of the COVID-19 pandemic. The bigger, long-term pandemic that we face Responsible for 74% of all deaths globally, NCDs are the even bigger, long-term pandemic that we face. Governments and global institutions have been learning many harsh lessons about the need to build back better, with more resilient health systems and more equitable access to quality, affordable treatment. But too often this has been a slogan without much substance behind it. We now need to see real changes taking hold. Beyond COVID, there is a strong and urgent imperative for investment in NCDs, which now cause 15 million premature deaths of people between the ages of 30 and 70 each year, 85% of them in low- and middle-income countries. This makes action and investment in NCDs a prerequisite for resilience, pandemic preparedness and health security, not to mention for meeting the most critical health challenges of the next decade in countries at all stages of development. Yet financing for NCDs has stagnated at a pitiful 1-2% of development assistance for health for two decades. If we look at development assistance that has gone towards health system strengthening which also helps people living with NCDs we can add a further 5%, but that is simply inconsequential when compared to government handouts for fossils fuels and agriculture, which climb to $1.8 trillion annually – and more importantly, when compared to the magnitude of disease and economic burden of NCDs. Still hope to see healthier populations by 2030 In 2015, all UN member countries committed to the Sustainable Development Goals (SDGs) to achieve a better and more sustainable future for all, including SDG target 3.4 to reduce NCD premature mortality by one-third by 2030. This and other NCD commitments should not lose priority because of the COVID-19 pandemic. They should actually gain priority. Although the vast majority of countries are well off-track to meet SDG 3.4, a March 2022 paper published in The Lancet shows that there is still hope. All countries – and especially low- and middle-income countries (LMICs) – can achieve or nearly achieve SDG 3.4 to reduce premature NCD mortality by one-third by 2030 by introducing a cost-effective package of NCD prevention and treatment interventions. Investment in the mitigation of NCDs boosts productivity by cutting the number of wasted lives. The paper presents an NCD investment framework that aims to support LMICs in getting back on track towards achieving SDG target 3.4 in the wake of the COVID-19 pandemic. It is centred around a package of 21 cost-effective interventions; essentially, a feasible and pragmatic roadmap to healthier populations and more resilient health systems. There are 15 clinical interventions, like screening and early detection for diabetes and cervical cancer, and cardiovascular disease prevention programmes. Many of these can be implemented at primary health care level. There are also six policy interventions, focused on taxing and regulating tobacco and alcohol, and measures to reduce intake of sodium and transfats. All of the interventions are aligned with WHO recommendations for NCD programmes, helping ensure a more coordinated NCD and pandemic response. The paper provides guidance on the types of interventions that can best accelerate progress on NCDs in 123 LMICs, and the resources required to implement these interventions. While the clinical interventions are meant to be selected according to national needs and contexts, the policy interventions are crucial for all countries, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. These actions could also generate significant revenue, which can then be reinvested in health. The bottom line for NCD investment As the paper demonstrates, implementing the most efficient package of interventions in each world region would require $140 billion in new spending over 2023–30, equivalent to $18 billion per year. This investment could avert 39 million deaths and generate an average net economic benefit of US$2.7 trillion, or US$390 per capita. This means that benefits outweigh costs by 19 to one. LMIC ministries of health would need to contribute around 20% of their budgets to the priority NCD interventions. Many countries would also need external support (bilateral, multilateral, philanthropy, private sector), particularly in light of the economic impacts of COVID-19. For the first time, we have a price tag for tackling NCDs in LMICs – and it’s peanuts alongside current NCD treatment costs and economic losses due to premature death and disability. For instance, in 2021, health expenditure for diabetes reached $966 billion; the annual cost of obesity is projected to top $1.2 trillion globally by 2025; the total economic loss due to cardiovascular disease in LMICs was estimated at $3.7 trillion between 2011 and 2015. The paper provides further evidence that underscores the urgent need to invest now in proven strategies to save lives and prevent and treat NCDs. Investments in NCDs are not only cost-effective, but they can also save money even within a short timeframe. The bottom line is that governments can reap substantial economic rewards, in both the short- and long-run, by taking bold action on NCDs and thus ensuring the security and fiscal sustainability of their health systems. This requires a view of health as an investment not a cost, and one that requires long-term thinking. Trailblazing the road to recovery Leaders must shift their priorities to achieving healthier populations, with impactful action for NCD prevention and care. Some countries are taking bold steps. India’s budget for 2021 more than doubled national healthcare and wellbeing spending from previous levels. The Philippines increased the taxation of tobacco products during the COVID-19 pandemic, with a share being earmarked to bolster capacity for universal health coverage to reach the poorest communities. Meanwhile, Latin America has made big gains for healthy diets. Recognising a high number of COVID-19 cases among overweight children and adults, the Mexican states of Oaxaca and Tabasco banned the sale of junk food and sugary drinks to people under 18 in 2020, with more states planning to follow suit. Front of package labels in Mexico A Mexican nationwide front-of-packaging warning labelling law also entered into effect in 2020, requiring black stop signs on packages of foods high in added sugar, fats, calories and sodium. Various Caribbean nations have implemented taxes on sugary beverages and made advances to control marketing of junk food in and near schools. These are just a sample of the actions being taken around the world, and are reason for optimism that real progress can be made. What we need now to accelerate this progress is strong leadership that is committed to putting health and health security first. NCD action and investment must no longer be seen as an afterthought to infectious diseases and neglected within health services, but as fundamental to resilience, security, equity, and economic stability. As Heads of State and Governments meet this week in Ghana for the International Strategic Dialogue on NCDs and the SDGs, we call on leaders to take the bold action so urgently needed. Whether NCDs and their prevention are addressed by future policy action will make or break the effectiveness of the pandemic response. Katie Dain is the Chief Executive Officer of the NCD Alliance. David Watkins, University of Washington, is the lead author of a recent Lancet NCD 2030 Countdown series article on pathways and investments to accelerate NCDs progress. Interactive map reproduced with permission from Politico Studio, based on data from WHO’s 2020 NCDs Progress Monitor. Image Credits: WHO/A. Loke, World Health Organization , World Heart Federation / WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar A COVID-19 vaccination being administered in Senegal. COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros Adhanom Ghebreyesus, the Director-General of WHO, at a press briefing on Wednesday in Geneva. “This virus has over time become more transmissible and it remains deadly, especially for the unprotected and unvaccinated that don’t have access to health care and antivirals. The best way to protect yourself is to get vaccinated and boosted when recommended,” he said. The briefing comes at the end of a meeting of the WHO Emergency Committee convened under the International Health Regulations (IHR). The committee discussed the capacities of states to respond to the pandemic, the problem of vaccine inequity, reduced testing and monitoring, and raised concerns about the inappropriate use of antivirals that may give impetus to drug-resistant variants. Ukraine and Ethiopia In the past 50 days since theRussia invasion of Ukraine, 4.6 million refugees have fled the country, and thousands of civilians, including children, have died, and there have been 119 verified attacks on health care workers. Dr Tedros said that there is a need for humanitarian corridors to enable the delivery of medical supplies, food and water and the evacuation of civilians. He added that to date, the WHO had only received about half of the funding needed to support Ukraine for the first three months. Dr Michael Ryan, WHO’s Executive Director of Health Emergencies, said that there was a high risk of chemical contamination and exposure due to attacks, as well as compromised infrastructure associated with the chemical production, nuclear weapons and energy production. Dr Michael Ryan at the WHO Press Briefing. “We’ve been doing training and other support to the authorities in Ukraine in preparation for such an event. This is very different from the intentional use of chemicals as a weapon in war, which is against international Law and is a war crime,” said Ryan. This comes on the back of reports of the use of chemical weapons in Mariupol. With respect to Ethiopia, Tedors said that the siege by the Ethiopian and Eritrean forces continues to avert the humanitarian calamity and thousands of people from dying. Tedros, who is an Ethiopian and a former Minister of Foreign Affairs, said that the Tigray crisis is one of the most alarming humanitarian crises of our times. “But the world is not treating the human race the same way. Some are more equal than others,” he said referring to the negligible attention received by Afghanistan, Ethiopia, Yemen, and Libya versus the attention that is meted to Ukraine currently. Newer variants According to Dr Maria Van Kerkhove, WHO’s Technical lead on COVID-19, the new sub-variants of the Omicron variant– BA.4 and BA.5– have been reported from a number of countries, including South Africa, in Europe. She said that more sequencing and concerted global efforts to track and share the data on the virus are needed to understand the characteristics of the variants. Responding to the concerns about the reduced testing and tracking of COVID-19 cases, Ryan said that it was important to track the virus as it went “underground”. “It will be very, very, very short-sighted at this time to assume that lower numbers of cases mean an absolute lower risk,” he said. “This virus has surprised us before… We need to do our jobs and track this virus as best we can while people get back to living as normal a life as possible. We in the scientific and public health community need to continue to track this virus closely in every single country.” Dr Maria Van Kerkhove,WHO’s Technical lead for COVID-19, Van Kerkhove added that the committee which met today outlined three main scenarios in the modified Strategic Preparedness, Readiness, and Response Plan (SPRRP) publication: a best case, a worst case, and a base case in terms of outlining what virus evolution and changes and how our countermeasures will react or react to those. There is also a fourth scenario, called ‘reset’ where there is so much change in the virus there will be a population that is susceptible again, and “it resets us.” Vaccinate, vaccinate, vaccinate The updated SPRRP report highlights the need to achieve national COVID-19 vaccination targets in line with global WHO recommendations of at least 70% of all countries’ populations vaccinated by the start of July 2022. “Countries really must start looking at their data breakdown by age and sex,” said Dr Soumya Swaminathan, WHO’s Chief Scientist, while highlighting the importance of boosting the population over the age of 60. Swaminathan added that a majority of countries plan to meet the 70% target, but a handful of countries have set their goal at less than 40%. “ Many of these countries have competing health priorities and so we need to make sure that as COVID vaccine uptake is expanded, scaled up, strengthened, and routine immunization services are also strengthened,” said Swaminathan. Swaminathan mentioned that COVAX has the capability to cater to the vaccination needs of the vulnerable population, but there needs to be more focus on making sure the older, more vulnerable population is catered to and not left out despite the inequitable vaccine situation currently. “The inequity is not just in the overall distribution of vaccines, it is also occurring within countries in terms of not reaching those most likely to benefit from the vaccine and that’s particularly acute,” said Ryan. He added that while 85% of the population over 60 years of age in Europe is fully vaccinated, the number for the same metric stands at 25% in Africa. “If we fail to vaccinate everyone, if we fail to continue diagnosing, if we fail to find the people who can benefit from treatment, then we will fail in the future, and in the next pandemic. So our success now will determine a successful future,” Ryan said. Image Credits: Flickr – Trinity Care Foundation, Georges Yameogo.. Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman Global Health Matters podcast host Dr. Garry Aslanyan, TDR After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – and can inspire others as well. The Global Health Matters podcast hosted by Aslanyan, a public health professional with TDR, the Special Programme for Research and Training in Tropical Diseases, co-sponsored by UNICEF, UNDP, the World Bank and WHO, is now entering its second season of broadcasts. It features a diverse mix of themes and line-up of speakers – has picked up an audience of followers in places as diverse as Yemeni villages and Ulaanbaatar, Mongolia. The first episode of Season 2 was launched on Tuesday, April 12. It focuses on “Championing Health Equity in South Africa.” “The podcast gives people a unique peek into the experiences of people who are just like them,” Aslanyan told Health Policy Watch. “Listeners can relate to the guests and their experiences and compare what they themselves are living through – they can think, ‘can I do this?’ or ‘how does that work?’ or ‘what can this mean for me in my own setting or country?’” The podcast began at the height of the COVID-19 pandemic, when new, virtual information tools became all the more important to people confined for days and weeks at home. The podcast series has already covered a broad range of innovative and inspiring research topics – from climate change and health to science communication and the challenge of ‘decolonizing global health.’ With a focus on sharing perspectives and voices from low- and middle-income countries, the series has already been downloaded more than 11,000 times by listeners in more than 130 countries, Aslanyan said. “The hope is to inspire listeners to do something in their day job with the information they heard,” Aslanyan said. South Africa at the nexus of the global health equity debate This week’s episode on “Championing health equity in South Africa” takes a long look at the country’s COVID vaccine campaign, whose successes and setbacks were a weathervane for the rest of Africa, as well as its precedent-setting examples in advocating for HIV medicines access, in light of the recent pandemic. “As of early March, 74% of those in high-income countries have been fully vaccinated against COVID-19, compared with just 11% of people in low-income countries. As the world commits to global access to medicines and vaccines, is this just on paper or a reality?” the podcast teaser states. “Can South Africa’s experience with tackling HIV/AIDS and COVID-19 point to future solutions for other low- and middle-income countries? How has intellectual property rights affected development of vaccines across Africa?” Appearing on the podcast are three guests: human rights lawyer and activist Fatima Hassan; UNDP policy specialist Judit Rius Sanjuan; and Petro Terblanche, Managing Director of Afrigen Biologics, host of the new mRNA hub in South Africa. Season 2 of Global Health Matters launched this week: Championing Health Equity in South Africa. The goal: To inspire Aslanyan said he started the series after becoming an active listener of podcasts himself. He fell for the audio genre because it runs against the current of 30-second social media soundbytes, providing more thoughtful and detailed coverage of issues in a digestible format – that listeners can tune into while they are travelling or doing something else. But when he searched for something that “really covers global health, I did not find much” – especially not one that featured voices from low- and middle- income countries. So, he and his team decided to start their own series. “The ability to get a more insightful, in-depth understanding of a topic is why this medium is appealing. And for us at TDR, most importantly, this allows people from around the globe to learn from the experiences of others and apply them to their own reality,” said Aslanyan. Although WHO’s Regional Office for Europe offers a ‘Health in Europe’ podcast, and WHO headquarters features a popular Science in Five video series, Global Health Matters is the only broad-based and regular global health podcast featured by WHO, where TDR is based. Aslanyan has postgraduate training in public health and health policy and systems. While not a trained media professional, he was driven by a clear public health mission: to inspire his colleagues in the field. “You may not immediately think somebody trained in public health to host a podcast, but I have done all kinds of work for organizations focused on global health,” Aslanyan explained. “I also have experience in innovation and advocacy and have worked in government departments in Canada before moving to Geneva where I really pushed the boundaries of national health.” He said public health professionals need to be knowledgeable but also able to present things in a way that galvanizes the public around different causes. He had not thought of himself as that person before starting Global Health Matters, but since launch last year he hears from listeners that this is exactly the role he and his guests are fulfilling. “What makes me think that the podcast medium is amazing is the way that we reach cities, towns and villages in the most remote parts of the world, which is VERY satisfying – we know that from our stats,” Aslanyan says. What were some of the most popular episodes last year? “COVID-19 in Africa: the role of research” helped debunk some of the myths around why there was less virus on the continent. Global Health Matters Episode 3. An episode on “Climate change’s impact on health” looked at the impact of climate change on rural areas whose communities’ health and livelihood depends on the environment. A particular focus was on Maasai communities in northern Tanzania, where persistent droughts have made the people vulnerable to sleeping sickness, a disease spread by the tsetse fly. There was also a piece on Communicating science, not fiction featured Natalia Pasternak, founder of Brazilian-based Instituto Questão de Ciência, which combats pseudoscience and advocates for evidence-based treatments. Natalia spoke of her own personal experience as a member of WhatsApp groups for mothers that took a sudden turn into vaccine skepticism. And thousands of kilometers away, in the Western Pacific, Navigating digital health waves featuring Dr Alvin Marcelo, Executive Director of the Asia eHealth Information Network, explained how the Philippine government allowed open access to data from COVID-19 tests, creating a big opportunity for health researchers and services, for instance better matching of COVID-19 test results from particular locations with availability of hospital bed spaces. Natalia Pasternak, founder of Brazilian-based Instituto Questão de Ciência Dr Alvin Marcelo, Executive Director of the Asia eHealth Information Network. “Of course, we get feedback on every episode,” Aslanyan said. “It seems all of them have touched, inspired or at least piqued the interest of our listeners.” He said that he and his team at TDR stepped into podcasting with no experience but they have already learned a lot. Season 2 builds on last year’s, bringing in additional topics such as science diplomacy, corruption in health, migration and health and diversity in global health. Aslanyan said he also hopes to add an even greater variety of personalities to the podcasts, including, potentially, some guests who are public health service recipients rather than providers. He added that two universities in the global North and South are using some podcast episodes to assist students in understanding complex public health subjects – a testimony to the information and clarity being provided by the show. “We think it gives learners the ability to relate to the topics they are studying,” Aslanyan said. In terms of the spread and reach of his audience- it’s both surprising and satisfying, Aslanyan adds. “Sometimes I look at the analytics data showing the people listening to the podcast, and I think, my gosh, who are these eight people in that small city in Yemen who listened to me? I have no idea who they are, but they are there, in a place I don’t know, and I imagine they are probably working in public health.” The first episode of Season 2 launched on Tuesday April 12. Find it here. Link here to all Season 1 episodes of Global Health Matters. Find it on YouTube Championing Health Equity in South Africa Follow @TDRnews on Twitter, TDR on LinkedIn and @ghm_podcast on Instagram for updates about upcoming shows. Image Credits: WHO, GHM Show , GHM. Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, is this just on paper or a reality? In the case of COVID-19, as of early April 2022, 74% of people in high-income countries had been fully vaccinated, compared with just 15% in Africa and 11% of people in low-income countries worldwide. With 30% of people fully vaccinated, South Africa, has one of the highest COVID vaccination rates in sub-Saharan Africa. And it has been an African leader in the manufacture of COVID vaccines, as well as a leader in the global campaign to waive intellectual property rights on COVID vaccines, tests and treatment – not to mention the historic role it played a generation ago in the legal battles that paved the way for the widespread manufacture of low-cost, generic antivirals for HIV treatment. Can South Africa’s experience with tackling HIV/AIDS and COVID-19 point to future solutions for other low- and middle-income countries? And how has the state of play regarding intellectual property rights for COVID health products affected development of vaccines across Africa? Global Health Matters podcast host Garry Aslanyan fields these and other questions to three leading South Africans scientists, policymakers and health activists, including Fatima Hassan (founder of the Health Justice Initiative), Petro Terblanche (Managing Director of Afrigen Biologics), and Judit Rius Sanjuan (Policy Specialist at UNDP). Click here to catch this episode, the first of the second season of TDR’s Global Health Matters podcast. Find it on YouTube: Championing Health Equity in South Africa Link here for all Season 1 episodes of Global Health Matters. NCDs Finally Get Attention at Presidential Level 12/04/2022 Kerry Cullinan Diabetes protest in South Africa After years of being the neglected stepchild of global health, non-communicable diseases (NCDs) might finally be getting the urgent attention they need with Tuesday’s launch of an international NCD compact and presidential group. The measures were announced at the International Strategic Dialogue on NCDs and Sustainable Development Goals (SDGs) co-hosted by the governments of Ghana and Norway and the World Health Organization (WHO). Mike Bloomberg, the WHO Global NCD Ambassador, told the Accra meeting via video that global investment in NCDs was a “pitiful 1-2% of global health funding”. Very few countries are on track to achieve the United Nations Sustainable Development Goal (SDGs) 3.4, which commits member states to “reduce by one-third premature mortality from NCDs through prevention and treatment, and promote mental health and wellbeing by 2030”. But the NCD Alliance says that the compact and Presidential Council on NCDs (NCD Presidential Group) “could be a turning point in the fight against chronic diseases, which is responsible for 74 % of deaths annually”, finally demonstrating the political will needed to address the world’s biggest killer. Co-organized by the Governments of Ghana🇬🇭 and Norway🇳🇴, and the @WHO, the International Dialogue on #NCDs and the #SDGs taking place in #Accra, is a demonstration of our collective effort, at the leadership level, to forge ahead a common agenda to tackle the challenges of #NCDs. pic.twitter.com/wXP9JHfnP3 — UNinGhana (@UNinGhana) April 12, 2022 WHO member states and leaders will be encouraged to sign up to both the compact and the presidential group and “align strategies and operations with universal commitments made to accelerate and scale up the global collective efforts to prevent and control NCDs and achieve universal health coverage”, according to an outcome document from Tuesday’s meeting. “The NCD Compact is a living document and will be updated on a yearly basis by its current and future signatories among Heads of State and Governments to navigate in preparation of the next UN High-level meeting on NCDs in 2025 and going forward towards 2030,” the document states. “Two years into the global COVID-19 pandemic, there can no longer be any doubt about the case for investing in NCDs,” said Katie Dain, CEO of the NCD Alliance. “COVID-19 has upended health systems, drained economies and disproportionately affected people living with NCDs. This pandemic must be a wake-up call for governments and political leaders to value, prioritise and invest in healthy societies, NCD prevention and strong According to the NCD Alliance, 39 million lives could be saved before 2030 if an additional $18 billion is annually on implementing packages of cost-effective NCD interventions, tailored to local disease burden and risk factors. “This would also generate an average net economic benefit of $2.7 trillion, or $390 per capita, equal to a 19 to one return on investment,” said the alliance, referring to recent research published in The Lancet. The Accra meeting was addressed by a variety of high-profile leaders, particularly from Africa and the Caribbean, including a number of First Ladies who have an active international forum aimed at preventing NCDs. Co-host Norweigan Prime Minister Jonas Gahr Støre said that most of the premature deaths from NCDs can be avoided, and governments “must intensify our efforts to prevent and control them”. 🇳🇴Prime Minister of Norway @jonasgahrstore "Only 14 countries are on track to meet #SDG 3.4 today, we are launching the international NCD compact – a consolidated global effort to prevent people from dying. NCDs are a global problem but I am convinced it is achievable"@NorwayMFA pic.twitter.com/Nk1P7qlbVz — NCD Alliance (@ncdalliance) April 12, 2022 Barbados Prime Minister Mia Mottley lamented that only 14 countries were on track to achieving SGD 3.4, 11 years after the first UN high-level meeting on non-communicable diseases and seven years after the adoption of the SDGs. September meeting The President of Ghana will chair the first meeting of the Presidential Council on NCDs, which will take place in September during the 77th session of the UN General Assembly in New York. Meanwhile, the International NCD Compact 2022-2030 contains strategic priorities to accelerate action and encourage countries to reach SDG targets on NCDs by 2030. According to the NCD Alliance, 41 million people die every year due to an NCD and annual deaths from NCDs are projected to escalate to 52 million by 2030. “To put these figures into perspective, in 2020 annual deaths from tuberculosis, malaria and HIV/AIDS reached 1.5 million, 627,000, and 680,000 respectively. Meanwhile, deaths attributed to the COVID-19 pandemic, from its beginning in 2019 to April 2022, are nearing six million, and 60-90% of these deaths are in people living with one or more NCD. Image Credits: Kerry Cullinan. Historic Public Hearings on WHO Pandemic Instrument; Some Unhappiness with Process 12/04/2022 Kerry Cullinan The last Ebola patient leaves a treatment centre in the Democratic Republic of Congo at the end of March 2021, marking the countdown to declaring the end of that pandemic. The World Health Organization (WHO) convened public hearings for only the second time in its history on Tuesday, asking interested parties what substantive issues should be contained in its proposed international instrument on pandemic preparedness and response. The first and only other WHO hearings were held 22 years ago in the run-up to the adoption of the Framework Convention on Tobacco Control, according to WHO principal legal officer Steven Solomon. Welcoming the public hearing, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that informed opinion and active public cooperation are of the utmost importance to improve health, and it was important to learn from the COVID-19 pandemic to ensure the world is “better prepared” for the next pandemic. Tedros had been mandated by last year’s World Health Assembly Special Session to convene public hearings to inform the work of the Intergovernmental Negotiating Body (INB) which is in charge of negotiating the pandemic instrument or treaty. INB co-chair, South Africa’s Dr Precious Matsoso, described the hearings as “remarkable” and “historic”. Dr Precious Matsoso, INB co-chair Narrow responsibility However, the Civil Society Alliance for Human Rights in the Pandemic Treaty warned that the consultative process risks being “inadequate”. “While this week’s public hearings reflect the INB’s stated objective to consult the public to some extent, it has interpreted its responsibility to do so very narrowly,” according to the alliance. “The INB has allocated minimal time to engaging with the wide range of stakeholders who could inform the process and improve both the legitimacy and quality of the Treaty that emerges.” Dr Meg Davis, from the Global Health Centre at the Graduate Institute in Geneva, also said that participants had been given no indication of whether or how their submissions would be included in the negotiations and recommended policymaking models to ensure meaningful civil society engagement. A number of organisations gave two-minute speeches focusing on a wide range of issues including ‘One Health’, research and development (R&D) and intellectual property rights at the hearings, which continue on Wednesday and then reconvene in mid-June. Equity means sharing Research and Development Professor Suerie Moon, co-director of the Global Health Centre at the Graduate Institute in Geneva. All member states have committed to equity at the heart of any pandemic instrument, but Professor Suerie Moon, co-director of the Geneva Graduate Institute’s Global Health Centre, told the hearings that “equity requires collective research and development of vaccines, drugs and diagnostics”. Pointing out that COVID-19 has led to the development of technology transfer hubs in South Africa and the Republic of Korea, Moon warned that “there’s a risk that new factories will sit idle in the next emergency unless the new international instrument forges agreement on obligations to share knowledge, data and intellectual property before and during future emergencies”. “It’s unlikely, however, that countries or companies will do so out of the goodness of their hearts,” added Moon. “To make such sharing feasible, we have to tie it to commitments to jointly finance research and development to share pathogen samples and genomic sequencing data. In other words, the key idea is collective research and development for collective benefit.” Acknowledging that intellectual property was a difficult issue, Moon nonetheless said that if equitable access was to become a reality “the new instrument must include the nuts-and-bolts provisions to make sharing technology for pandemics the new normal”. To address IP, Knowledge Ecology International (KEI) recommended that governments should “agree to collectively use exceptions to intellectual property rights that are permitted in existing trade agreements and treaties”. “A model for this is the WIPO Marrakesh Treaty for the Blind, which mandates its members to use exceptions in copyrights to enhance global access to works made accessible to persons who are blind or have other disabilities,” according to KEI’s James Love. KEI also proposed “a robust chapter on transparency”, adding that “the lack of transparency in many areas for the current pandemic is an appalling and unnecessary policy failure, and one that both makes it more difficult to manage a pandemic response, and undermines the public’s trust in institutions”. Rachael Crockett from the Drugs for Neglected Diseases initiative (DNDi) stressed the need to co-ordinate R&D as a substantive element of the new instrument. DNDi wants R&D priority setting, and “globally agreed norms and binding rules that govern the R&D process, including transparency and open sharing of research, data, knowledge, technology, and equitable allocation of health tools”. Sharing pathogens IFPMA’s Grega Kumer Grega Kumer from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) said “any system should be built on what worked well during the COVID pandemic, in particular, immediate sharing of pathogens and a robust response from the IP based private sector”. The IFPMA presented eight core principles, including that the negotiation process should be “inclusive and transparent, involving the private sector and all critical contributors to pandemic preparedness efforts”. “Any system should allow for immediate access of pathogens and genetic sequence data and correct the negative effects of access and benefit-sharing legislation,” said Kumer. The IFPMA also supports more equitable access to tests, treatments and vaccines “based on medical need, thus enhancing solidarity and facilitating emergency financing to institutions procuring for developing countries”, and the protection of supply chains ”from arbitrary export restrictions and other trade barriers”. “While the public sector might play a larger role in pandemic setting, the system should build on the private sector strengths for R&D, manufacturing and distribution,” he concluded. One Health is key The need for any pandemic instrument to adopt a One Health approach also emerged as a key theme. Dame Sally Davies, speaking for the UN Global Leaders Group on Antimicrobial Resistance (AMR), said that they wanted AMR to be integrated alongside a primary focus on pandemics. “The next pandemic could be drug-resistant, or could depend on antimicrobials to mitigate it,” said Davies, saying that one health surveillance needed to be at the heart of any pandemic treaty to enable “rapid, transparent and responsive protection”. Governance principles The Panel for a Global Health Convention believes the instrument must be governed by four non-negotiable principles, according to Dame Barbara Stocking. “Solidarity, because we’re all in this together, and solidarity is in our own self-interest,” explained Stocking. “Equity: there must be equal access to vaccines and treatments, but also an equal voice in decision-making. Transparency in reporting data and samples. Accountability, as the lack of accountability of countries is the fundamental reason that we are in disarray.” The hearings continue at 8am CET on Wednesday and can be followed live. Image Credits: WHO African Region. Single Dose of HPV Vaccine is Enough to Protect Against Cervical Cancer 11/04/2022 Kerry Cullinan WHO’s Dr Kate O’Brien and SAGE chairperson Dr Alejandro Cravioto The Human Papillomavirus (HPV), which is the cause of most cervical cancer cases, can be treated with a single vaccine dose instead of the two doses currently being given, according to the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE). SAGE chairperson Dr Alejandro Cravioto told a media briefing on Monday that, after reviewing all available evidence, the group concluded that a single vaccine was effective against HPV in girls and women aged nine to 20, but that women aged 21 and over needed two doses given six months apart. As HPV is generally sexually transmitted, vaccination is also recommended for boys and men who can carry the virus and infect women – and SAGE now also recommends a single dose for younger boys and men too. Only 13% of HPV target group is vaccinated The WHO described the new recommendation as a “game-changer” for the prevention of the disease as it would enable more doses of the vaccine to reach more girls. “The HPV vaccine is highly effective for the prevention of HPV serotypes 16 and 18, which cause 70% of cervical cancer,” said Cravioto. “SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes.” Meanwhile, the WHO described cervical cancer as being “almost entirely preventable” and “a disease of inequity of access”, adding that it was concerned by the slow introduction of the HPV vaccine into immunization programs and low coverage, especially in poorer countries. In 2020, only 13% of the global target population had received two doses, with WHO citing barriers as challenges of supply, cost and delivering a two-dose regimen to older girls who are not part of childhood vaccination programs. Dr Nono Simelela, WHO Assistant Director-General for Strategic Programmatic Priorities: Cervical Cancer Elimination. WHO Assistant Director-General Dr Nono Simelela said that single-dose recommendation “has the potential to take us faster to our goal of having 90 per cent of girls vaccinated by the age of 15 by 2030”. “We need political commitment complemented with equitable pathways for the accessibility of the HPV vaccine. Failure to do so is an injustice to the generation of girls and young women who may be at risk of cervical cancer,” added Simelela. SAGE also recommended that hepatitis A could also be treated with a single vaccine. China’s CanSino Bio vaccine expected to get WHO approval SAGE also evaluated the data on the Chinese CanSino Bio (Ad5-nCOV-S) vaccine, but will only release the outcome of this discussion if the WHO grants the vaccine emergency use listing (EUL) – “hopefully in the next few weeks”, according to Cravioto. An mRNA based COVID-19 vaccine also developed by the Chinese company was cleared for clinical trials last week. Currently, there are no mRNA vaccines available in China. WHO’s Director of Immunization, Dr Kate O’Brien, expressed concern that only around 65% of healthworkers globally were vaccinated against COVID-19, and a similar number of people over the age of 60. In addition, 21 countries had vaccinated less than 10% of citizens, said O’Brien – 14 countries in the African region, four in the eastern Mediterranean region, and then one each in the Americas, the Western Pacific and the Southeast Asian region. “These are countries that are working really hard to advance their programmes now that supply is no longer the issue,” said O’Brien. SAGE admitted that there was a lack of data about the efficacy of non-mRNA vaccines’ efficacy against Omicron. As far as the spread of Omicron in Hong Kong was concerned, Cravioto said the high mortality rate in older people was related to that age group’s reluctance to be infected rather than an indictment on Chinese-produced vaccines. However, he said Nineteen More Attacks on Ukraine’s Health Facilities Since Friday: WHO 11/04/2022 Kerry Cullinan Ukraine operating theatre destroyed The World Health Organization (WHO) has verified 108 attacks on health care in Ukraine as of Monday in which 73 people have died and 51 have been injured. That is 19 more attacks on health facilities than the already deadly toll of 91 attacks that had been verified by WHO as of early Friday afternoon, and as reported at a press conference by WHO’s Regional Director Hans Kluge in Lviv. .@WHO has verified 5 additional reports of attacks on health care in #Ukraine. As of 11 April, 108 attacks on health care in Ukraine have been verified, causing 73 deaths and 51 injuries. We are outraged that attacks on health care are continuing. pic.twitter.com/8GNUQZFiK9 — WHO Ukraine (@WHOUkraine) April 11, 2022 Meanwhile, the Office of the UN High Commissioner for Human Rights (OHCHR) has recorded 1,793 civilian deaths and 2,439 injuries since the start of the Russian invasion on 24 February and Sunday. Most of the civilian casualties have been caused by “explosive weapons with a wide impact area”, including shelling from heavy artillery and rocket, missile and air strikes. https://data.humdata.org/visualization/ukraine-humanitarian-operations/ “OHCHR believes that the actual figures are considerably higher, as the receipt of information from some locations where intense hostilities have been going on has been delayed and many reports are still pending corroboration,” according to a statement from the office. “This concerns, for example, Mariupol (Donetsk region), Izium (Kharkiv region), Popasna (Luhansk region), and Borodianka (Kyiv region), where there are allegations of numerous civilian casualties. These figures are being further corroborated and are not included in the above statistics.” According to the Prosecutor General’s Office of Ukraine, 176 children had been killed and at least 336 injured as of Sunday. Image Credits: WHO. Non-Communicable Diseases: Is the ‘New Normal’ Too Much Like The Old One? 11/04/2022 Katie Dain & David Watkins The vast majority of people who died of COVID-19 had a non-communicable disease – yet investment in NCD prevention is pitiful. More than two years after the novel coronavirus erupted into a global pandemic, the world is beginning to settle into a new normal. COVID-19 changed how we live and work in ways that will continue long after the pandemic subsides. Digital and automation technologies are here to stay, work is done remotely, and shopping and entertainment have gone online. But the COVID-19 pandemic also laid bare an indisputable truth: the destructive path carved by the infectious SARS-CoV2 virus was only the tip of the iceberg. Studies have estimated that 60-90% of COVID-19 deaths have been of people living with one or more chronic conditions, like obesity, heart or kidney disease, or cardiovascular diseases. And people living with non-communicable diseases (NCDs) are still experiencing the collateral damage of the pandemic, due to severe disruptions to essential health services. The lack of investment in NCD prevention and care over the years has vastly amplified the toll of the COVID-19 pandemic. The bigger, long-term pandemic that we face Responsible for 74% of all deaths globally, NCDs are the even bigger, long-term pandemic that we face. Governments and global institutions have been learning many harsh lessons about the need to build back better, with more resilient health systems and more equitable access to quality, affordable treatment. But too often this has been a slogan without much substance behind it. We now need to see real changes taking hold. Beyond COVID, there is a strong and urgent imperative for investment in NCDs, which now cause 15 million premature deaths of people between the ages of 30 and 70 each year, 85% of them in low- and middle-income countries. This makes action and investment in NCDs a prerequisite for resilience, pandemic preparedness and health security, not to mention for meeting the most critical health challenges of the next decade in countries at all stages of development. Yet financing for NCDs has stagnated at a pitiful 1-2% of development assistance for health for two decades. If we look at development assistance that has gone towards health system strengthening which also helps people living with NCDs we can add a further 5%, but that is simply inconsequential when compared to government handouts for fossils fuels and agriculture, which climb to $1.8 trillion annually – and more importantly, when compared to the magnitude of disease and economic burden of NCDs. Still hope to see healthier populations by 2030 In 2015, all UN member countries committed to the Sustainable Development Goals (SDGs) to achieve a better and more sustainable future for all, including SDG target 3.4 to reduce NCD premature mortality by one-third by 2030. This and other NCD commitments should not lose priority because of the COVID-19 pandemic. They should actually gain priority. Although the vast majority of countries are well off-track to meet SDG 3.4, a March 2022 paper published in The Lancet shows that there is still hope. All countries – and especially low- and middle-income countries (LMICs) – can achieve or nearly achieve SDG 3.4 to reduce premature NCD mortality by one-third by 2030 by introducing a cost-effective package of NCD prevention and treatment interventions. Investment in the mitigation of NCDs boosts productivity by cutting the number of wasted lives. The paper presents an NCD investment framework that aims to support LMICs in getting back on track towards achieving SDG target 3.4 in the wake of the COVID-19 pandemic. It is centred around a package of 21 cost-effective interventions; essentially, a feasible and pragmatic roadmap to healthier populations and more resilient health systems. There are 15 clinical interventions, like screening and early detection for diabetes and cervical cancer, and cardiovascular disease prevention programmes. Many of these can be implemented at primary health care level. There are also six policy interventions, focused on taxing and regulating tobacco and alcohol, and measures to reduce intake of sodium and transfats. All of the interventions are aligned with WHO recommendations for NCD programmes, helping ensure a more coordinated NCD and pandemic response. The paper provides guidance on the types of interventions that can best accelerate progress on NCDs in 123 LMICs, and the resources required to implement these interventions. While the clinical interventions are meant to be selected according to national needs and contexts, the policy interventions are crucial for all countries, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. These actions could also generate significant revenue, which can then be reinvested in health. The bottom line for NCD investment As the paper demonstrates, implementing the most efficient package of interventions in each world region would require $140 billion in new spending over 2023–30, equivalent to $18 billion per year. This investment could avert 39 million deaths and generate an average net economic benefit of US$2.7 trillion, or US$390 per capita. This means that benefits outweigh costs by 19 to one. LMIC ministries of health would need to contribute around 20% of their budgets to the priority NCD interventions. Many countries would also need external support (bilateral, multilateral, philanthropy, private sector), particularly in light of the economic impacts of COVID-19. For the first time, we have a price tag for tackling NCDs in LMICs – and it’s peanuts alongside current NCD treatment costs and economic losses due to premature death and disability. For instance, in 2021, health expenditure for diabetes reached $966 billion; the annual cost of obesity is projected to top $1.2 trillion globally by 2025; the total economic loss due to cardiovascular disease in LMICs was estimated at $3.7 trillion between 2011 and 2015. The paper provides further evidence that underscores the urgent need to invest now in proven strategies to save lives and prevent and treat NCDs. Investments in NCDs are not only cost-effective, but they can also save money even within a short timeframe. The bottom line is that governments can reap substantial economic rewards, in both the short- and long-run, by taking bold action on NCDs and thus ensuring the security and fiscal sustainability of their health systems. This requires a view of health as an investment not a cost, and one that requires long-term thinking. Trailblazing the road to recovery Leaders must shift their priorities to achieving healthier populations, with impactful action for NCD prevention and care. Some countries are taking bold steps. India’s budget for 2021 more than doubled national healthcare and wellbeing spending from previous levels. The Philippines increased the taxation of tobacco products during the COVID-19 pandemic, with a share being earmarked to bolster capacity for universal health coverage to reach the poorest communities. Meanwhile, Latin America has made big gains for healthy diets. Recognising a high number of COVID-19 cases among overweight children and adults, the Mexican states of Oaxaca and Tabasco banned the sale of junk food and sugary drinks to people under 18 in 2020, with more states planning to follow suit. Front of package labels in Mexico A Mexican nationwide front-of-packaging warning labelling law also entered into effect in 2020, requiring black stop signs on packages of foods high in added sugar, fats, calories and sodium. Various Caribbean nations have implemented taxes on sugary beverages and made advances to control marketing of junk food in and near schools. These are just a sample of the actions being taken around the world, and are reason for optimism that real progress can be made. What we need now to accelerate this progress is strong leadership that is committed to putting health and health security first. NCD action and investment must no longer be seen as an afterthought to infectious diseases and neglected within health services, but as fundamental to resilience, security, equity, and economic stability. As Heads of State and Governments meet this week in Ghana for the International Strategic Dialogue on NCDs and the SDGs, we call on leaders to take the bold action so urgently needed. Whether NCDs and their prevention are addressed by future policy action will make or break the effectiveness of the pandemic response. Katie Dain is the Chief Executive Officer of the NCD Alliance. David Watkins, University of Washington, is the lead author of a recent Lancet NCD 2030 Countdown series article on pathways and investments to accelerate NCDs progress. Interactive map reproduced with permission from Politico Studio, based on data from WHO’s 2020 NCDs Progress Monitor. Image Credits: WHO/A. Loke, World Health Organization , World Heart Federation / WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman Global Health Matters podcast host Dr. Garry Aslanyan, TDR After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – and can inspire others as well. The Global Health Matters podcast hosted by Aslanyan, a public health professional with TDR, the Special Programme for Research and Training in Tropical Diseases, co-sponsored by UNICEF, UNDP, the World Bank and WHO, is now entering its second season of broadcasts. It features a diverse mix of themes and line-up of speakers – has picked up an audience of followers in places as diverse as Yemeni villages and Ulaanbaatar, Mongolia. The first episode of Season 2 was launched on Tuesday, April 12. It focuses on “Championing Health Equity in South Africa.” “The podcast gives people a unique peek into the experiences of people who are just like them,” Aslanyan told Health Policy Watch. “Listeners can relate to the guests and their experiences and compare what they themselves are living through – they can think, ‘can I do this?’ or ‘how does that work?’ or ‘what can this mean for me in my own setting or country?’” The podcast began at the height of the COVID-19 pandemic, when new, virtual information tools became all the more important to people confined for days and weeks at home. The podcast series has already covered a broad range of innovative and inspiring research topics – from climate change and health to science communication and the challenge of ‘decolonizing global health.’ With a focus on sharing perspectives and voices from low- and middle-income countries, the series has already been downloaded more than 11,000 times by listeners in more than 130 countries, Aslanyan said. “The hope is to inspire listeners to do something in their day job with the information they heard,” Aslanyan said. South Africa at the nexus of the global health equity debate This week’s episode on “Championing health equity in South Africa” takes a long look at the country’s COVID vaccine campaign, whose successes and setbacks were a weathervane for the rest of Africa, as well as its precedent-setting examples in advocating for HIV medicines access, in light of the recent pandemic. “As of early March, 74% of those in high-income countries have been fully vaccinated against COVID-19, compared with just 11% of people in low-income countries. As the world commits to global access to medicines and vaccines, is this just on paper or a reality?” the podcast teaser states. “Can South Africa’s experience with tackling HIV/AIDS and COVID-19 point to future solutions for other low- and middle-income countries? How has intellectual property rights affected development of vaccines across Africa?” Appearing on the podcast are three guests: human rights lawyer and activist Fatima Hassan; UNDP policy specialist Judit Rius Sanjuan; and Petro Terblanche, Managing Director of Afrigen Biologics, host of the new mRNA hub in South Africa. Season 2 of Global Health Matters launched this week: Championing Health Equity in South Africa. The goal: To inspire Aslanyan said he started the series after becoming an active listener of podcasts himself. He fell for the audio genre because it runs against the current of 30-second social media soundbytes, providing more thoughtful and detailed coverage of issues in a digestible format – that listeners can tune into while they are travelling or doing something else. But when he searched for something that “really covers global health, I did not find much” – especially not one that featured voices from low- and middle- income countries. So, he and his team decided to start their own series. “The ability to get a more insightful, in-depth understanding of a topic is why this medium is appealing. And for us at TDR, most importantly, this allows people from around the globe to learn from the experiences of others and apply them to their own reality,” said Aslanyan. Although WHO’s Regional Office for Europe offers a ‘Health in Europe’ podcast, and WHO headquarters features a popular Science in Five video series, Global Health Matters is the only broad-based and regular global health podcast featured by WHO, where TDR is based. Aslanyan has postgraduate training in public health and health policy and systems. While not a trained media professional, he was driven by a clear public health mission: to inspire his colleagues in the field. “You may not immediately think somebody trained in public health to host a podcast, but I have done all kinds of work for organizations focused on global health,” Aslanyan explained. “I also have experience in innovation and advocacy and have worked in government departments in Canada before moving to Geneva where I really pushed the boundaries of national health.” He said public health professionals need to be knowledgeable but also able to present things in a way that galvanizes the public around different causes. He had not thought of himself as that person before starting Global Health Matters, but since launch last year he hears from listeners that this is exactly the role he and his guests are fulfilling. “What makes me think that the podcast medium is amazing is the way that we reach cities, towns and villages in the most remote parts of the world, which is VERY satisfying – we know that from our stats,” Aslanyan says. What were some of the most popular episodes last year? “COVID-19 in Africa: the role of research” helped debunk some of the myths around why there was less virus on the continent. Global Health Matters Episode 3. An episode on “Climate change’s impact on health” looked at the impact of climate change on rural areas whose communities’ health and livelihood depends on the environment. A particular focus was on Maasai communities in northern Tanzania, where persistent droughts have made the people vulnerable to sleeping sickness, a disease spread by the tsetse fly. There was also a piece on Communicating science, not fiction featured Natalia Pasternak, founder of Brazilian-based Instituto Questão de Ciência, which combats pseudoscience and advocates for evidence-based treatments. Natalia spoke of her own personal experience as a member of WhatsApp groups for mothers that took a sudden turn into vaccine skepticism. And thousands of kilometers away, in the Western Pacific, Navigating digital health waves featuring Dr Alvin Marcelo, Executive Director of the Asia eHealth Information Network, explained how the Philippine government allowed open access to data from COVID-19 tests, creating a big opportunity for health researchers and services, for instance better matching of COVID-19 test results from particular locations with availability of hospital bed spaces. Natalia Pasternak, founder of Brazilian-based Instituto Questão de Ciência Dr Alvin Marcelo, Executive Director of the Asia eHealth Information Network. “Of course, we get feedback on every episode,” Aslanyan said. “It seems all of them have touched, inspired or at least piqued the interest of our listeners.” He said that he and his team at TDR stepped into podcasting with no experience but they have already learned a lot. Season 2 builds on last year’s, bringing in additional topics such as science diplomacy, corruption in health, migration and health and diversity in global health. Aslanyan said he also hopes to add an even greater variety of personalities to the podcasts, including, potentially, some guests who are public health service recipients rather than providers. He added that two universities in the global North and South are using some podcast episodes to assist students in understanding complex public health subjects – a testimony to the information and clarity being provided by the show. “We think it gives learners the ability to relate to the topics they are studying,” Aslanyan said. In terms of the spread and reach of his audience- it’s both surprising and satisfying, Aslanyan adds. “Sometimes I look at the analytics data showing the people listening to the podcast, and I think, my gosh, who are these eight people in that small city in Yemen who listened to me? I have no idea who they are, but they are there, in a place I don’t know, and I imagine they are probably working in public health.” The first episode of Season 2 launched on Tuesday April 12. Find it here. Link here to all Season 1 episodes of Global Health Matters. Find it on YouTube Championing Health Equity in South Africa Follow @TDRnews on Twitter, TDR on LinkedIn and @ghm_podcast on Instagram for updates about upcoming shows. Image Credits: WHO, GHM Show , GHM. Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, is this just on paper or a reality? In the case of COVID-19, as of early April 2022, 74% of people in high-income countries had been fully vaccinated, compared with just 15% in Africa and 11% of people in low-income countries worldwide. With 30% of people fully vaccinated, South Africa, has one of the highest COVID vaccination rates in sub-Saharan Africa. And it has been an African leader in the manufacture of COVID vaccines, as well as a leader in the global campaign to waive intellectual property rights on COVID vaccines, tests and treatment – not to mention the historic role it played a generation ago in the legal battles that paved the way for the widespread manufacture of low-cost, generic antivirals for HIV treatment. Can South Africa’s experience with tackling HIV/AIDS and COVID-19 point to future solutions for other low- and middle-income countries? And how has the state of play regarding intellectual property rights for COVID health products affected development of vaccines across Africa? Global Health Matters podcast host Garry Aslanyan fields these and other questions to three leading South Africans scientists, policymakers and health activists, including Fatima Hassan (founder of the Health Justice Initiative), Petro Terblanche (Managing Director of Afrigen Biologics), and Judit Rius Sanjuan (Policy Specialist at UNDP). Click here to catch this episode, the first of the second season of TDR’s Global Health Matters podcast. Find it on YouTube: Championing Health Equity in South Africa Link here for all Season 1 episodes of Global Health Matters. NCDs Finally Get Attention at Presidential Level 12/04/2022 Kerry Cullinan Diabetes protest in South Africa After years of being the neglected stepchild of global health, non-communicable diseases (NCDs) might finally be getting the urgent attention they need with Tuesday’s launch of an international NCD compact and presidential group. The measures were announced at the International Strategic Dialogue on NCDs and Sustainable Development Goals (SDGs) co-hosted by the governments of Ghana and Norway and the World Health Organization (WHO). Mike Bloomberg, the WHO Global NCD Ambassador, told the Accra meeting via video that global investment in NCDs was a “pitiful 1-2% of global health funding”. Very few countries are on track to achieve the United Nations Sustainable Development Goal (SDGs) 3.4, which commits member states to “reduce by one-third premature mortality from NCDs through prevention and treatment, and promote mental health and wellbeing by 2030”. But the NCD Alliance says that the compact and Presidential Council on NCDs (NCD Presidential Group) “could be a turning point in the fight against chronic diseases, which is responsible for 74 % of deaths annually”, finally demonstrating the political will needed to address the world’s biggest killer. Co-organized by the Governments of Ghana🇬🇭 and Norway🇳🇴, and the @WHO, the International Dialogue on #NCDs and the #SDGs taking place in #Accra, is a demonstration of our collective effort, at the leadership level, to forge ahead a common agenda to tackle the challenges of #NCDs. pic.twitter.com/wXP9JHfnP3 — UNinGhana (@UNinGhana) April 12, 2022 WHO member states and leaders will be encouraged to sign up to both the compact and the presidential group and “align strategies and operations with universal commitments made to accelerate and scale up the global collective efforts to prevent and control NCDs and achieve universal health coverage”, according to an outcome document from Tuesday’s meeting. “The NCD Compact is a living document and will be updated on a yearly basis by its current and future signatories among Heads of State and Governments to navigate in preparation of the next UN High-level meeting on NCDs in 2025 and going forward towards 2030,” the document states. “Two years into the global COVID-19 pandemic, there can no longer be any doubt about the case for investing in NCDs,” said Katie Dain, CEO of the NCD Alliance. “COVID-19 has upended health systems, drained economies and disproportionately affected people living with NCDs. This pandemic must be a wake-up call for governments and political leaders to value, prioritise and invest in healthy societies, NCD prevention and strong According to the NCD Alliance, 39 million lives could be saved before 2030 if an additional $18 billion is annually on implementing packages of cost-effective NCD interventions, tailored to local disease burden and risk factors. “This would also generate an average net economic benefit of $2.7 trillion, or $390 per capita, equal to a 19 to one return on investment,” said the alliance, referring to recent research published in The Lancet. The Accra meeting was addressed by a variety of high-profile leaders, particularly from Africa and the Caribbean, including a number of First Ladies who have an active international forum aimed at preventing NCDs. Co-host Norweigan Prime Minister Jonas Gahr Støre said that most of the premature deaths from NCDs can be avoided, and governments “must intensify our efforts to prevent and control them”. 🇳🇴Prime Minister of Norway @jonasgahrstore "Only 14 countries are on track to meet #SDG 3.4 today, we are launching the international NCD compact – a consolidated global effort to prevent people from dying. NCDs are a global problem but I am convinced it is achievable"@NorwayMFA pic.twitter.com/Nk1P7qlbVz — NCD Alliance (@ncdalliance) April 12, 2022 Barbados Prime Minister Mia Mottley lamented that only 14 countries were on track to achieving SGD 3.4, 11 years after the first UN high-level meeting on non-communicable diseases and seven years after the adoption of the SDGs. September meeting The President of Ghana will chair the first meeting of the Presidential Council on NCDs, which will take place in September during the 77th session of the UN General Assembly in New York. Meanwhile, the International NCD Compact 2022-2030 contains strategic priorities to accelerate action and encourage countries to reach SDG targets on NCDs by 2030. According to the NCD Alliance, 41 million people die every year due to an NCD and annual deaths from NCDs are projected to escalate to 52 million by 2030. “To put these figures into perspective, in 2020 annual deaths from tuberculosis, malaria and HIV/AIDS reached 1.5 million, 627,000, and 680,000 respectively. Meanwhile, deaths attributed to the COVID-19 pandemic, from its beginning in 2019 to April 2022, are nearing six million, and 60-90% of these deaths are in people living with one or more NCD. Image Credits: Kerry Cullinan. Historic Public Hearings on WHO Pandemic Instrument; Some Unhappiness with Process 12/04/2022 Kerry Cullinan The last Ebola patient leaves a treatment centre in the Democratic Republic of Congo at the end of March 2021, marking the countdown to declaring the end of that pandemic. The World Health Organization (WHO) convened public hearings for only the second time in its history on Tuesday, asking interested parties what substantive issues should be contained in its proposed international instrument on pandemic preparedness and response. The first and only other WHO hearings were held 22 years ago in the run-up to the adoption of the Framework Convention on Tobacco Control, according to WHO principal legal officer Steven Solomon. Welcoming the public hearing, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that informed opinion and active public cooperation are of the utmost importance to improve health, and it was important to learn from the COVID-19 pandemic to ensure the world is “better prepared” for the next pandemic. Tedros had been mandated by last year’s World Health Assembly Special Session to convene public hearings to inform the work of the Intergovernmental Negotiating Body (INB) which is in charge of negotiating the pandemic instrument or treaty. INB co-chair, South Africa’s Dr Precious Matsoso, described the hearings as “remarkable” and “historic”. Dr Precious Matsoso, INB co-chair Narrow responsibility However, the Civil Society Alliance for Human Rights in the Pandemic Treaty warned that the consultative process risks being “inadequate”. “While this week’s public hearings reflect the INB’s stated objective to consult the public to some extent, it has interpreted its responsibility to do so very narrowly,” according to the alliance. “The INB has allocated minimal time to engaging with the wide range of stakeholders who could inform the process and improve both the legitimacy and quality of the Treaty that emerges.” Dr Meg Davis, from the Global Health Centre at the Graduate Institute in Geneva, also said that participants had been given no indication of whether or how their submissions would be included in the negotiations and recommended policymaking models to ensure meaningful civil society engagement. A number of organisations gave two-minute speeches focusing on a wide range of issues including ‘One Health’, research and development (R&D) and intellectual property rights at the hearings, which continue on Wednesday and then reconvene in mid-June. Equity means sharing Research and Development Professor Suerie Moon, co-director of the Global Health Centre at the Graduate Institute in Geneva. All member states have committed to equity at the heart of any pandemic instrument, but Professor Suerie Moon, co-director of the Geneva Graduate Institute’s Global Health Centre, told the hearings that “equity requires collective research and development of vaccines, drugs and diagnostics”. Pointing out that COVID-19 has led to the development of technology transfer hubs in South Africa and the Republic of Korea, Moon warned that “there’s a risk that new factories will sit idle in the next emergency unless the new international instrument forges agreement on obligations to share knowledge, data and intellectual property before and during future emergencies”. “It’s unlikely, however, that countries or companies will do so out of the goodness of their hearts,” added Moon. “To make such sharing feasible, we have to tie it to commitments to jointly finance research and development to share pathogen samples and genomic sequencing data. In other words, the key idea is collective research and development for collective benefit.” Acknowledging that intellectual property was a difficult issue, Moon nonetheless said that if equitable access was to become a reality “the new instrument must include the nuts-and-bolts provisions to make sharing technology for pandemics the new normal”. To address IP, Knowledge Ecology International (KEI) recommended that governments should “agree to collectively use exceptions to intellectual property rights that are permitted in existing trade agreements and treaties”. “A model for this is the WIPO Marrakesh Treaty for the Blind, which mandates its members to use exceptions in copyrights to enhance global access to works made accessible to persons who are blind or have other disabilities,” according to KEI’s James Love. KEI also proposed “a robust chapter on transparency”, adding that “the lack of transparency in many areas for the current pandemic is an appalling and unnecessary policy failure, and one that both makes it more difficult to manage a pandemic response, and undermines the public’s trust in institutions”. Rachael Crockett from the Drugs for Neglected Diseases initiative (DNDi) stressed the need to co-ordinate R&D as a substantive element of the new instrument. DNDi wants R&D priority setting, and “globally agreed norms and binding rules that govern the R&D process, including transparency and open sharing of research, data, knowledge, technology, and equitable allocation of health tools”. Sharing pathogens IFPMA’s Grega Kumer Grega Kumer from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) said “any system should be built on what worked well during the COVID pandemic, in particular, immediate sharing of pathogens and a robust response from the IP based private sector”. The IFPMA presented eight core principles, including that the negotiation process should be “inclusive and transparent, involving the private sector and all critical contributors to pandemic preparedness efforts”. “Any system should allow for immediate access of pathogens and genetic sequence data and correct the negative effects of access and benefit-sharing legislation,” said Kumer. The IFPMA also supports more equitable access to tests, treatments and vaccines “based on medical need, thus enhancing solidarity and facilitating emergency financing to institutions procuring for developing countries”, and the protection of supply chains ”from arbitrary export restrictions and other trade barriers”. “While the public sector might play a larger role in pandemic setting, the system should build on the private sector strengths for R&D, manufacturing and distribution,” he concluded. One Health is key The need for any pandemic instrument to adopt a One Health approach also emerged as a key theme. Dame Sally Davies, speaking for the UN Global Leaders Group on Antimicrobial Resistance (AMR), said that they wanted AMR to be integrated alongside a primary focus on pandemics. “The next pandemic could be drug-resistant, or could depend on antimicrobials to mitigate it,” said Davies, saying that one health surveillance needed to be at the heart of any pandemic treaty to enable “rapid, transparent and responsive protection”. Governance principles The Panel for a Global Health Convention believes the instrument must be governed by four non-negotiable principles, according to Dame Barbara Stocking. “Solidarity, because we’re all in this together, and solidarity is in our own self-interest,” explained Stocking. “Equity: there must be equal access to vaccines and treatments, but also an equal voice in decision-making. Transparency in reporting data and samples. Accountability, as the lack of accountability of countries is the fundamental reason that we are in disarray.” The hearings continue at 8am CET on Wednesday and can be followed live. Image Credits: WHO African Region. Single Dose of HPV Vaccine is Enough to Protect Against Cervical Cancer 11/04/2022 Kerry Cullinan WHO’s Dr Kate O’Brien and SAGE chairperson Dr Alejandro Cravioto The Human Papillomavirus (HPV), which is the cause of most cervical cancer cases, can be treated with a single vaccine dose instead of the two doses currently being given, according to the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE). SAGE chairperson Dr Alejandro Cravioto told a media briefing on Monday that, after reviewing all available evidence, the group concluded that a single vaccine was effective against HPV in girls and women aged nine to 20, but that women aged 21 and over needed two doses given six months apart. As HPV is generally sexually transmitted, vaccination is also recommended for boys and men who can carry the virus and infect women – and SAGE now also recommends a single dose for younger boys and men too. Only 13% of HPV target group is vaccinated The WHO described the new recommendation as a “game-changer” for the prevention of the disease as it would enable more doses of the vaccine to reach more girls. “The HPV vaccine is highly effective for the prevention of HPV serotypes 16 and 18, which cause 70% of cervical cancer,” said Cravioto. “SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes.” Meanwhile, the WHO described cervical cancer as being “almost entirely preventable” and “a disease of inequity of access”, adding that it was concerned by the slow introduction of the HPV vaccine into immunization programs and low coverage, especially in poorer countries. In 2020, only 13% of the global target population had received two doses, with WHO citing barriers as challenges of supply, cost and delivering a two-dose regimen to older girls who are not part of childhood vaccination programs. Dr Nono Simelela, WHO Assistant Director-General for Strategic Programmatic Priorities: Cervical Cancer Elimination. WHO Assistant Director-General Dr Nono Simelela said that single-dose recommendation “has the potential to take us faster to our goal of having 90 per cent of girls vaccinated by the age of 15 by 2030”. “We need political commitment complemented with equitable pathways for the accessibility of the HPV vaccine. Failure to do so is an injustice to the generation of girls and young women who may be at risk of cervical cancer,” added Simelela. SAGE also recommended that hepatitis A could also be treated with a single vaccine. China’s CanSino Bio vaccine expected to get WHO approval SAGE also evaluated the data on the Chinese CanSino Bio (Ad5-nCOV-S) vaccine, but will only release the outcome of this discussion if the WHO grants the vaccine emergency use listing (EUL) – “hopefully in the next few weeks”, according to Cravioto. An mRNA based COVID-19 vaccine also developed by the Chinese company was cleared for clinical trials last week. Currently, there are no mRNA vaccines available in China. WHO’s Director of Immunization, Dr Kate O’Brien, expressed concern that only around 65% of healthworkers globally were vaccinated against COVID-19, and a similar number of people over the age of 60. In addition, 21 countries had vaccinated less than 10% of citizens, said O’Brien – 14 countries in the African region, four in the eastern Mediterranean region, and then one each in the Americas, the Western Pacific and the Southeast Asian region. “These are countries that are working really hard to advance their programmes now that supply is no longer the issue,” said O’Brien. SAGE admitted that there was a lack of data about the efficacy of non-mRNA vaccines’ efficacy against Omicron. As far as the spread of Omicron in Hong Kong was concerned, Cravioto said the high mortality rate in older people was related to that age group’s reluctance to be infected rather than an indictment on Chinese-produced vaccines. However, he said Nineteen More Attacks on Ukraine’s Health Facilities Since Friday: WHO 11/04/2022 Kerry Cullinan Ukraine operating theatre destroyed The World Health Organization (WHO) has verified 108 attacks on health care in Ukraine as of Monday in which 73 people have died and 51 have been injured. That is 19 more attacks on health facilities than the already deadly toll of 91 attacks that had been verified by WHO as of early Friday afternoon, and as reported at a press conference by WHO’s Regional Director Hans Kluge in Lviv. .@WHO has verified 5 additional reports of attacks on health care in #Ukraine. As of 11 April, 108 attacks on health care in Ukraine have been verified, causing 73 deaths and 51 injuries. We are outraged that attacks on health care are continuing. pic.twitter.com/8GNUQZFiK9 — WHO Ukraine (@WHOUkraine) April 11, 2022 Meanwhile, the Office of the UN High Commissioner for Human Rights (OHCHR) has recorded 1,793 civilian deaths and 2,439 injuries since the start of the Russian invasion on 24 February and Sunday. Most of the civilian casualties have been caused by “explosive weapons with a wide impact area”, including shelling from heavy artillery and rocket, missile and air strikes. https://data.humdata.org/visualization/ukraine-humanitarian-operations/ “OHCHR believes that the actual figures are considerably higher, as the receipt of information from some locations where intense hostilities have been going on has been delayed and many reports are still pending corroboration,” according to a statement from the office. “This concerns, for example, Mariupol (Donetsk region), Izium (Kharkiv region), Popasna (Luhansk region), and Borodianka (Kyiv region), where there are allegations of numerous civilian casualties. These figures are being further corroborated and are not included in the above statistics.” According to the Prosecutor General’s Office of Ukraine, 176 children had been killed and at least 336 injured as of Sunday. Image Credits: WHO. Non-Communicable Diseases: Is the ‘New Normal’ Too Much Like The Old One? 11/04/2022 Katie Dain & David Watkins The vast majority of people who died of COVID-19 had a non-communicable disease – yet investment in NCD prevention is pitiful. More than two years after the novel coronavirus erupted into a global pandemic, the world is beginning to settle into a new normal. COVID-19 changed how we live and work in ways that will continue long after the pandemic subsides. Digital and automation technologies are here to stay, work is done remotely, and shopping and entertainment have gone online. But the COVID-19 pandemic also laid bare an indisputable truth: the destructive path carved by the infectious SARS-CoV2 virus was only the tip of the iceberg. Studies have estimated that 60-90% of COVID-19 deaths have been of people living with one or more chronic conditions, like obesity, heart or kidney disease, or cardiovascular diseases. And people living with non-communicable diseases (NCDs) are still experiencing the collateral damage of the pandemic, due to severe disruptions to essential health services. The lack of investment in NCD prevention and care over the years has vastly amplified the toll of the COVID-19 pandemic. The bigger, long-term pandemic that we face Responsible for 74% of all deaths globally, NCDs are the even bigger, long-term pandemic that we face. Governments and global institutions have been learning many harsh lessons about the need to build back better, with more resilient health systems and more equitable access to quality, affordable treatment. But too often this has been a slogan without much substance behind it. We now need to see real changes taking hold. Beyond COVID, there is a strong and urgent imperative for investment in NCDs, which now cause 15 million premature deaths of people between the ages of 30 and 70 each year, 85% of them in low- and middle-income countries. This makes action and investment in NCDs a prerequisite for resilience, pandemic preparedness and health security, not to mention for meeting the most critical health challenges of the next decade in countries at all stages of development. Yet financing for NCDs has stagnated at a pitiful 1-2% of development assistance for health for two decades. If we look at development assistance that has gone towards health system strengthening which also helps people living with NCDs we can add a further 5%, but that is simply inconsequential when compared to government handouts for fossils fuels and agriculture, which climb to $1.8 trillion annually – and more importantly, when compared to the magnitude of disease and economic burden of NCDs. Still hope to see healthier populations by 2030 In 2015, all UN member countries committed to the Sustainable Development Goals (SDGs) to achieve a better and more sustainable future for all, including SDG target 3.4 to reduce NCD premature mortality by one-third by 2030. This and other NCD commitments should not lose priority because of the COVID-19 pandemic. They should actually gain priority. Although the vast majority of countries are well off-track to meet SDG 3.4, a March 2022 paper published in The Lancet shows that there is still hope. All countries – and especially low- and middle-income countries (LMICs) – can achieve or nearly achieve SDG 3.4 to reduce premature NCD mortality by one-third by 2030 by introducing a cost-effective package of NCD prevention and treatment interventions. Investment in the mitigation of NCDs boosts productivity by cutting the number of wasted lives. The paper presents an NCD investment framework that aims to support LMICs in getting back on track towards achieving SDG target 3.4 in the wake of the COVID-19 pandemic. It is centred around a package of 21 cost-effective interventions; essentially, a feasible and pragmatic roadmap to healthier populations and more resilient health systems. There are 15 clinical interventions, like screening and early detection for diabetes and cervical cancer, and cardiovascular disease prevention programmes. Many of these can be implemented at primary health care level. There are also six policy interventions, focused on taxing and regulating tobacco and alcohol, and measures to reduce intake of sodium and transfats. All of the interventions are aligned with WHO recommendations for NCD programmes, helping ensure a more coordinated NCD and pandemic response. The paper provides guidance on the types of interventions that can best accelerate progress on NCDs in 123 LMICs, and the resources required to implement these interventions. While the clinical interventions are meant to be selected according to national needs and contexts, the policy interventions are crucial for all countries, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. These actions could also generate significant revenue, which can then be reinvested in health. The bottom line for NCD investment As the paper demonstrates, implementing the most efficient package of interventions in each world region would require $140 billion in new spending over 2023–30, equivalent to $18 billion per year. This investment could avert 39 million deaths and generate an average net economic benefit of US$2.7 trillion, or US$390 per capita. This means that benefits outweigh costs by 19 to one. LMIC ministries of health would need to contribute around 20% of their budgets to the priority NCD interventions. Many countries would also need external support (bilateral, multilateral, philanthropy, private sector), particularly in light of the economic impacts of COVID-19. For the first time, we have a price tag for tackling NCDs in LMICs – and it’s peanuts alongside current NCD treatment costs and economic losses due to premature death and disability. For instance, in 2021, health expenditure for diabetes reached $966 billion; the annual cost of obesity is projected to top $1.2 trillion globally by 2025; the total economic loss due to cardiovascular disease in LMICs was estimated at $3.7 trillion between 2011 and 2015. The paper provides further evidence that underscores the urgent need to invest now in proven strategies to save lives and prevent and treat NCDs. Investments in NCDs are not only cost-effective, but they can also save money even within a short timeframe. The bottom line is that governments can reap substantial economic rewards, in both the short- and long-run, by taking bold action on NCDs and thus ensuring the security and fiscal sustainability of their health systems. This requires a view of health as an investment not a cost, and one that requires long-term thinking. Trailblazing the road to recovery Leaders must shift their priorities to achieving healthier populations, with impactful action for NCD prevention and care. Some countries are taking bold steps. India’s budget for 2021 more than doubled national healthcare and wellbeing spending from previous levels. The Philippines increased the taxation of tobacco products during the COVID-19 pandemic, with a share being earmarked to bolster capacity for universal health coverage to reach the poorest communities. Meanwhile, Latin America has made big gains for healthy diets. Recognising a high number of COVID-19 cases among overweight children and adults, the Mexican states of Oaxaca and Tabasco banned the sale of junk food and sugary drinks to people under 18 in 2020, with more states planning to follow suit. Front of package labels in Mexico A Mexican nationwide front-of-packaging warning labelling law also entered into effect in 2020, requiring black stop signs on packages of foods high in added sugar, fats, calories and sodium. Various Caribbean nations have implemented taxes on sugary beverages and made advances to control marketing of junk food in and near schools. These are just a sample of the actions being taken around the world, and are reason for optimism that real progress can be made. What we need now to accelerate this progress is strong leadership that is committed to putting health and health security first. NCD action and investment must no longer be seen as an afterthought to infectious diseases and neglected within health services, but as fundamental to resilience, security, equity, and economic stability. As Heads of State and Governments meet this week in Ghana for the International Strategic Dialogue on NCDs and the SDGs, we call on leaders to take the bold action so urgently needed. Whether NCDs and their prevention are addressed by future policy action will make or break the effectiveness of the pandemic response. Katie Dain is the Chief Executive Officer of the NCD Alliance. David Watkins, University of Washington, is the lead author of a recent Lancet NCD 2030 Countdown series article on pathways and investments to accelerate NCDs progress. Interactive map reproduced with permission from Politico Studio, based on data from WHO’s 2020 NCDs Progress Monitor. Image Credits: WHO/A. Loke, World Health Organization , World Heart Federation / WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, is this just on paper or a reality? In the case of COVID-19, as of early April 2022, 74% of people in high-income countries had been fully vaccinated, compared with just 15% in Africa and 11% of people in low-income countries worldwide. With 30% of people fully vaccinated, South Africa, has one of the highest COVID vaccination rates in sub-Saharan Africa. And it has been an African leader in the manufacture of COVID vaccines, as well as a leader in the global campaign to waive intellectual property rights on COVID vaccines, tests and treatment – not to mention the historic role it played a generation ago in the legal battles that paved the way for the widespread manufacture of low-cost, generic antivirals for HIV treatment. Can South Africa’s experience with tackling HIV/AIDS and COVID-19 point to future solutions for other low- and middle-income countries? And how has the state of play regarding intellectual property rights for COVID health products affected development of vaccines across Africa? Global Health Matters podcast host Garry Aslanyan fields these and other questions to three leading South Africans scientists, policymakers and health activists, including Fatima Hassan (founder of the Health Justice Initiative), Petro Terblanche (Managing Director of Afrigen Biologics), and Judit Rius Sanjuan (Policy Specialist at UNDP). Click here to catch this episode, the first of the second season of TDR’s Global Health Matters podcast. Find it on YouTube: Championing Health Equity in South Africa Link here for all Season 1 episodes of Global Health Matters. NCDs Finally Get Attention at Presidential Level 12/04/2022 Kerry Cullinan Diabetes protest in South Africa After years of being the neglected stepchild of global health, non-communicable diseases (NCDs) might finally be getting the urgent attention they need with Tuesday’s launch of an international NCD compact and presidential group. The measures were announced at the International Strategic Dialogue on NCDs and Sustainable Development Goals (SDGs) co-hosted by the governments of Ghana and Norway and the World Health Organization (WHO). Mike Bloomberg, the WHO Global NCD Ambassador, told the Accra meeting via video that global investment in NCDs was a “pitiful 1-2% of global health funding”. Very few countries are on track to achieve the United Nations Sustainable Development Goal (SDGs) 3.4, which commits member states to “reduce by one-third premature mortality from NCDs through prevention and treatment, and promote mental health and wellbeing by 2030”. But the NCD Alliance says that the compact and Presidential Council on NCDs (NCD Presidential Group) “could be a turning point in the fight against chronic diseases, which is responsible for 74 % of deaths annually”, finally demonstrating the political will needed to address the world’s biggest killer. Co-organized by the Governments of Ghana🇬🇭 and Norway🇳🇴, and the @WHO, the International Dialogue on #NCDs and the #SDGs taking place in #Accra, is a demonstration of our collective effort, at the leadership level, to forge ahead a common agenda to tackle the challenges of #NCDs. pic.twitter.com/wXP9JHfnP3 — UNinGhana (@UNinGhana) April 12, 2022 WHO member states and leaders will be encouraged to sign up to both the compact and the presidential group and “align strategies and operations with universal commitments made to accelerate and scale up the global collective efforts to prevent and control NCDs and achieve universal health coverage”, according to an outcome document from Tuesday’s meeting. “The NCD Compact is a living document and will be updated on a yearly basis by its current and future signatories among Heads of State and Governments to navigate in preparation of the next UN High-level meeting on NCDs in 2025 and going forward towards 2030,” the document states. “Two years into the global COVID-19 pandemic, there can no longer be any doubt about the case for investing in NCDs,” said Katie Dain, CEO of the NCD Alliance. “COVID-19 has upended health systems, drained economies and disproportionately affected people living with NCDs. This pandemic must be a wake-up call for governments and political leaders to value, prioritise and invest in healthy societies, NCD prevention and strong According to the NCD Alliance, 39 million lives could be saved before 2030 if an additional $18 billion is annually on implementing packages of cost-effective NCD interventions, tailored to local disease burden and risk factors. “This would also generate an average net economic benefit of $2.7 trillion, or $390 per capita, equal to a 19 to one return on investment,” said the alliance, referring to recent research published in The Lancet. The Accra meeting was addressed by a variety of high-profile leaders, particularly from Africa and the Caribbean, including a number of First Ladies who have an active international forum aimed at preventing NCDs. Co-host Norweigan Prime Minister Jonas Gahr Støre said that most of the premature deaths from NCDs can be avoided, and governments “must intensify our efforts to prevent and control them”. 🇳🇴Prime Minister of Norway @jonasgahrstore "Only 14 countries are on track to meet #SDG 3.4 today, we are launching the international NCD compact – a consolidated global effort to prevent people from dying. NCDs are a global problem but I am convinced it is achievable"@NorwayMFA pic.twitter.com/Nk1P7qlbVz — NCD Alliance (@ncdalliance) April 12, 2022 Barbados Prime Minister Mia Mottley lamented that only 14 countries were on track to achieving SGD 3.4, 11 years after the first UN high-level meeting on non-communicable diseases and seven years after the adoption of the SDGs. September meeting The President of Ghana will chair the first meeting of the Presidential Council on NCDs, which will take place in September during the 77th session of the UN General Assembly in New York. Meanwhile, the International NCD Compact 2022-2030 contains strategic priorities to accelerate action and encourage countries to reach SDG targets on NCDs by 2030. According to the NCD Alliance, 41 million people die every year due to an NCD and annual deaths from NCDs are projected to escalate to 52 million by 2030. “To put these figures into perspective, in 2020 annual deaths from tuberculosis, malaria and HIV/AIDS reached 1.5 million, 627,000, and 680,000 respectively. Meanwhile, deaths attributed to the COVID-19 pandemic, from its beginning in 2019 to April 2022, are nearing six million, and 60-90% of these deaths are in people living with one or more NCD. Image Credits: Kerry Cullinan. Historic Public Hearings on WHO Pandemic Instrument; Some Unhappiness with Process 12/04/2022 Kerry Cullinan The last Ebola patient leaves a treatment centre in the Democratic Republic of Congo at the end of March 2021, marking the countdown to declaring the end of that pandemic. The World Health Organization (WHO) convened public hearings for only the second time in its history on Tuesday, asking interested parties what substantive issues should be contained in its proposed international instrument on pandemic preparedness and response. The first and only other WHO hearings were held 22 years ago in the run-up to the adoption of the Framework Convention on Tobacco Control, according to WHO principal legal officer Steven Solomon. Welcoming the public hearing, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that informed opinion and active public cooperation are of the utmost importance to improve health, and it was important to learn from the COVID-19 pandemic to ensure the world is “better prepared” for the next pandemic. Tedros had been mandated by last year’s World Health Assembly Special Session to convene public hearings to inform the work of the Intergovernmental Negotiating Body (INB) which is in charge of negotiating the pandemic instrument or treaty. INB co-chair, South Africa’s Dr Precious Matsoso, described the hearings as “remarkable” and “historic”. Dr Precious Matsoso, INB co-chair Narrow responsibility However, the Civil Society Alliance for Human Rights in the Pandemic Treaty warned that the consultative process risks being “inadequate”. “While this week’s public hearings reflect the INB’s stated objective to consult the public to some extent, it has interpreted its responsibility to do so very narrowly,” according to the alliance. “The INB has allocated minimal time to engaging with the wide range of stakeholders who could inform the process and improve both the legitimacy and quality of the Treaty that emerges.” Dr Meg Davis, from the Global Health Centre at the Graduate Institute in Geneva, also said that participants had been given no indication of whether or how their submissions would be included in the negotiations and recommended policymaking models to ensure meaningful civil society engagement. A number of organisations gave two-minute speeches focusing on a wide range of issues including ‘One Health’, research and development (R&D) and intellectual property rights at the hearings, which continue on Wednesday and then reconvene in mid-June. Equity means sharing Research and Development Professor Suerie Moon, co-director of the Global Health Centre at the Graduate Institute in Geneva. All member states have committed to equity at the heart of any pandemic instrument, but Professor Suerie Moon, co-director of the Geneva Graduate Institute’s Global Health Centre, told the hearings that “equity requires collective research and development of vaccines, drugs and diagnostics”. Pointing out that COVID-19 has led to the development of technology transfer hubs in South Africa and the Republic of Korea, Moon warned that “there’s a risk that new factories will sit idle in the next emergency unless the new international instrument forges agreement on obligations to share knowledge, data and intellectual property before and during future emergencies”. “It’s unlikely, however, that countries or companies will do so out of the goodness of their hearts,” added Moon. “To make such sharing feasible, we have to tie it to commitments to jointly finance research and development to share pathogen samples and genomic sequencing data. In other words, the key idea is collective research and development for collective benefit.” Acknowledging that intellectual property was a difficult issue, Moon nonetheless said that if equitable access was to become a reality “the new instrument must include the nuts-and-bolts provisions to make sharing technology for pandemics the new normal”. To address IP, Knowledge Ecology International (KEI) recommended that governments should “agree to collectively use exceptions to intellectual property rights that are permitted in existing trade agreements and treaties”. “A model for this is the WIPO Marrakesh Treaty for the Blind, which mandates its members to use exceptions in copyrights to enhance global access to works made accessible to persons who are blind or have other disabilities,” according to KEI’s James Love. KEI also proposed “a robust chapter on transparency”, adding that “the lack of transparency in many areas for the current pandemic is an appalling and unnecessary policy failure, and one that both makes it more difficult to manage a pandemic response, and undermines the public’s trust in institutions”. Rachael Crockett from the Drugs for Neglected Diseases initiative (DNDi) stressed the need to co-ordinate R&D as a substantive element of the new instrument. DNDi wants R&D priority setting, and “globally agreed norms and binding rules that govern the R&D process, including transparency and open sharing of research, data, knowledge, technology, and equitable allocation of health tools”. Sharing pathogens IFPMA’s Grega Kumer Grega Kumer from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) said “any system should be built on what worked well during the COVID pandemic, in particular, immediate sharing of pathogens and a robust response from the IP based private sector”. The IFPMA presented eight core principles, including that the negotiation process should be “inclusive and transparent, involving the private sector and all critical contributors to pandemic preparedness efforts”. “Any system should allow for immediate access of pathogens and genetic sequence data and correct the negative effects of access and benefit-sharing legislation,” said Kumer. The IFPMA also supports more equitable access to tests, treatments and vaccines “based on medical need, thus enhancing solidarity and facilitating emergency financing to institutions procuring for developing countries”, and the protection of supply chains ”from arbitrary export restrictions and other trade barriers”. “While the public sector might play a larger role in pandemic setting, the system should build on the private sector strengths for R&D, manufacturing and distribution,” he concluded. One Health is key The need for any pandemic instrument to adopt a One Health approach also emerged as a key theme. Dame Sally Davies, speaking for the UN Global Leaders Group on Antimicrobial Resistance (AMR), said that they wanted AMR to be integrated alongside a primary focus on pandemics. “The next pandemic could be drug-resistant, or could depend on antimicrobials to mitigate it,” said Davies, saying that one health surveillance needed to be at the heart of any pandemic treaty to enable “rapid, transparent and responsive protection”. Governance principles The Panel for a Global Health Convention believes the instrument must be governed by four non-negotiable principles, according to Dame Barbara Stocking. “Solidarity, because we’re all in this together, and solidarity is in our own self-interest,” explained Stocking. “Equity: there must be equal access to vaccines and treatments, but also an equal voice in decision-making. Transparency in reporting data and samples. Accountability, as the lack of accountability of countries is the fundamental reason that we are in disarray.” The hearings continue at 8am CET on Wednesday and can be followed live. Image Credits: WHO African Region. Single Dose of HPV Vaccine is Enough to Protect Against Cervical Cancer 11/04/2022 Kerry Cullinan WHO’s Dr Kate O’Brien and SAGE chairperson Dr Alejandro Cravioto The Human Papillomavirus (HPV), which is the cause of most cervical cancer cases, can be treated with a single vaccine dose instead of the two doses currently being given, according to the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE). SAGE chairperson Dr Alejandro Cravioto told a media briefing on Monday that, after reviewing all available evidence, the group concluded that a single vaccine was effective against HPV in girls and women aged nine to 20, but that women aged 21 and over needed two doses given six months apart. As HPV is generally sexually transmitted, vaccination is also recommended for boys and men who can carry the virus and infect women – and SAGE now also recommends a single dose for younger boys and men too. Only 13% of HPV target group is vaccinated The WHO described the new recommendation as a “game-changer” for the prevention of the disease as it would enable more doses of the vaccine to reach more girls. “The HPV vaccine is highly effective for the prevention of HPV serotypes 16 and 18, which cause 70% of cervical cancer,” said Cravioto. “SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes.” Meanwhile, the WHO described cervical cancer as being “almost entirely preventable” and “a disease of inequity of access”, adding that it was concerned by the slow introduction of the HPV vaccine into immunization programs and low coverage, especially in poorer countries. In 2020, only 13% of the global target population had received two doses, with WHO citing barriers as challenges of supply, cost and delivering a two-dose regimen to older girls who are not part of childhood vaccination programs. Dr Nono Simelela, WHO Assistant Director-General for Strategic Programmatic Priorities: Cervical Cancer Elimination. WHO Assistant Director-General Dr Nono Simelela said that single-dose recommendation “has the potential to take us faster to our goal of having 90 per cent of girls vaccinated by the age of 15 by 2030”. “We need political commitment complemented with equitable pathways for the accessibility of the HPV vaccine. Failure to do so is an injustice to the generation of girls and young women who may be at risk of cervical cancer,” added Simelela. SAGE also recommended that hepatitis A could also be treated with a single vaccine. China’s CanSino Bio vaccine expected to get WHO approval SAGE also evaluated the data on the Chinese CanSino Bio (Ad5-nCOV-S) vaccine, but will only release the outcome of this discussion if the WHO grants the vaccine emergency use listing (EUL) – “hopefully in the next few weeks”, according to Cravioto. An mRNA based COVID-19 vaccine also developed by the Chinese company was cleared for clinical trials last week. Currently, there are no mRNA vaccines available in China. WHO’s Director of Immunization, Dr Kate O’Brien, expressed concern that only around 65% of healthworkers globally were vaccinated against COVID-19, and a similar number of people over the age of 60. In addition, 21 countries had vaccinated less than 10% of citizens, said O’Brien – 14 countries in the African region, four in the eastern Mediterranean region, and then one each in the Americas, the Western Pacific and the Southeast Asian region. “These are countries that are working really hard to advance their programmes now that supply is no longer the issue,” said O’Brien. SAGE admitted that there was a lack of data about the efficacy of non-mRNA vaccines’ efficacy against Omicron. As far as the spread of Omicron in Hong Kong was concerned, Cravioto said the high mortality rate in older people was related to that age group’s reluctance to be infected rather than an indictment on Chinese-produced vaccines. However, he said Nineteen More Attacks on Ukraine’s Health Facilities Since Friday: WHO 11/04/2022 Kerry Cullinan Ukraine operating theatre destroyed The World Health Organization (WHO) has verified 108 attacks on health care in Ukraine as of Monday in which 73 people have died and 51 have been injured. That is 19 more attacks on health facilities than the already deadly toll of 91 attacks that had been verified by WHO as of early Friday afternoon, and as reported at a press conference by WHO’s Regional Director Hans Kluge in Lviv. .@WHO has verified 5 additional reports of attacks on health care in #Ukraine. As of 11 April, 108 attacks on health care in Ukraine have been verified, causing 73 deaths and 51 injuries. We are outraged that attacks on health care are continuing. pic.twitter.com/8GNUQZFiK9 — WHO Ukraine (@WHOUkraine) April 11, 2022 Meanwhile, the Office of the UN High Commissioner for Human Rights (OHCHR) has recorded 1,793 civilian deaths and 2,439 injuries since the start of the Russian invasion on 24 February and Sunday. Most of the civilian casualties have been caused by “explosive weapons with a wide impact area”, including shelling from heavy artillery and rocket, missile and air strikes. https://data.humdata.org/visualization/ukraine-humanitarian-operations/ “OHCHR believes that the actual figures are considerably higher, as the receipt of information from some locations where intense hostilities have been going on has been delayed and many reports are still pending corroboration,” according to a statement from the office. “This concerns, for example, Mariupol (Donetsk region), Izium (Kharkiv region), Popasna (Luhansk region), and Borodianka (Kyiv region), where there are allegations of numerous civilian casualties. These figures are being further corroborated and are not included in the above statistics.” According to the Prosecutor General’s Office of Ukraine, 176 children had been killed and at least 336 injured as of Sunday. Image Credits: WHO. Non-Communicable Diseases: Is the ‘New Normal’ Too Much Like The Old One? 11/04/2022 Katie Dain & David Watkins The vast majority of people who died of COVID-19 had a non-communicable disease – yet investment in NCD prevention is pitiful. More than two years after the novel coronavirus erupted into a global pandemic, the world is beginning to settle into a new normal. COVID-19 changed how we live and work in ways that will continue long after the pandemic subsides. Digital and automation technologies are here to stay, work is done remotely, and shopping and entertainment have gone online. But the COVID-19 pandemic also laid bare an indisputable truth: the destructive path carved by the infectious SARS-CoV2 virus was only the tip of the iceberg. Studies have estimated that 60-90% of COVID-19 deaths have been of people living with one or more chronic conditions, like obesity, heart or kidney disease, or cardiovascular diseases. And people living with non-communicable diseases (NCDs) are still experiencing the collateral damage of the pandemic, due to severe disruptions to essential health services. The lack of investment in NCD prevention and care over the years has vastly amplified the toll of the COVID-19 pandemic. The bigger, long-term pandemic that we face Responsible for 74% of all deaths globally, NCDs are the even bigger, long-term pandemic that we face. Governments and global institutions have been learning many harsh lessons about the need to build back better, with more resilient health systems and more equitable access to quality, affordable treatment. But too often this has been a slogan without much substance behind it. We now need to see real changes taking hold. Beyond COVID, there is a strong and urgent imperative for investment in NCDs, which now cause 15 million premature deaths of people between the ages of 30 and 70 each year, 85% of them in low- and middle-income countries. This makes action and investment in NCDs a prerequisite for resilience, pandemic preparedness and health security, not to mention for meeting the most critical health challenges of the next decade in countries at all stages of development. Yet financing for NCDs has stagnated at a pitiful 1-2% of development assistance for health for two decades. If we look at development assistance that has gone towards health system strengthening which also helps people living with NCDs we can add a further 5%, but that is simply inconsequential when compared to government handouts for fossils fuels and agriculture, which climb to $1.8 trillion annually – and more importantly, when compared to the magnitude of disease and economic burden of NCDs. Still hope to see healthier populations by 2030 In 2015, all UN member countries committed to the Sustainable Development Goals (SDGs) to achieve a better and more sustainable future for all, including SDG target 3.4 to reduce NCD premature mortality by one-third by 2030. This and other NCD commitments should not lose priority because of the COVID-19 pandemic. They should actually gain priority. Although the vast majority of countries are well off-track to meet SDG 3.4, a March 2022 paper published in The Lancet shows that there is still hope. All countries – and especially low- and middle-income countries (LMICs) – can achieve or nearly achieve SDG 3.4 to reduce premature NCD mortality by one-third by 2030 by introducing a cost-effective package of NCD prevention and treatment interventions. Investment in the mitigation of NCDs boosts productivity by cutting the number of wasted lives. The paper presents an NCD investment framework that aims to support LMICs in getting back on track towards achieving SDG target 3.4 in the wake of the COVID-19 pandemic. It is centred around a package of 21 cost-effective interventions; essentially, a feasible and pragmatic roadmap to healthier populations and more resilient health systems. There are 15 clinical interventions, like screening and early detection for diabetes and cervical cancer, and cardiovascular disease prevention programmes. Many of these can be implemented at primary health care level. There are also six policy interventions, focused on taxing and regulating tobacco and alcohol, and measures to reduce intake of sodium and transfats. All of the interventions are aligned with WHO recommendations for NCD programmes, helping ensure a more coordinated NCD and pandemic response. The paper provides guidance on the types of interventions that can best accelerate progress on NCDs in 123 LMICs, and the resources required to implement these interventions. While the clinical interventions are meant to be selected according to national needs and contexts, the policy interventions are crucial for all countries, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. These actions could also generate significant revenue, which can then be reinvested in health. The bottom line for NCD investment As the paper demonstrates, implementing the most efficient package of interventions in each world region would require $140 billion in new spending over 2023–30, equivalent to $18 billion per year. This investment could avert 39 million deaths and generate an average net economic benefit of US$2.7 trillion, or US$390 per capita. This means that benefits outweigh costs by 19 to one. LMIC ministries of health would need to contribute around 20% of their budgets to the priority NCD interventions. Many countries would also need external support (bilateral, multilateral, philanthropy, private sector), particularly in light of the economic impacts of COVID-19. For the first time, we have a price tag for tackling NCDs in LMICs – and it’s peanuts alongside current NCD treatment costs and economic losses due to premature death and disability. For instance, in 2021, health expenditure for diabetes reached $966 billion; the annual cost of obesity is projected to top $1.2 trillion globally by 2025; the total economic loss due to cardiovascular disease in LMICs was estimated at $3.7 trillion between 2011 and 2015. The paper provides further evidence that underscores the urgent need to invest now in proven strategies to save lives and prevent and treat NCDs. Investments in NCDs are not only cost-effective, but they can also save money even within a short timeframe. The bottom line is that governments can reap substantial economic rewards, in both the short- and long-run, by taking bold action on NCDs and thus ensuring the security and fiscal sustainability of their health systems. This requires a view of health as an investment not a cost, and one that requires long-term thinking. Trailblazing the road to recovery Leaders must shift their priorities to achieving healthier populations, with impactful action for NCD prevention and care. Some countries are taking bold steps. India’s budget for 2021 more than doubled national healthcare and wellbeing spending from previous levels. The Philippines increased the taxation of tobacco products during the COVID-19 pandemic, with a share being earmarked to bolster capacity for universal health coverage to reach the poorest communities. Meanwhile, Latin America has made big gains for healthy diets. Recognising a high number of COVID-19 cases among overweight children and adults, the Mexican states of Oaxaca and Tabasco banned the sale of junk food and sugary drinks to people under 18 in 2020, with more states planning to follow suit. Front of package labels in Mexico A Mexican nationwide front-of-packaging warning labelling law also entered into effect in 2020, requiring black stop signs on packages of foods high in added sugar, fats, calories and sodium. Various Caribbean nations have implemented taxes on sugary beverages and made advances to control marketing of junk food in and near schools. These are just a sample of the actions being taken around the world, and are reason for optimism that real progress can be made. What we need now to accelerate this progress is strong leadership that is committed to putting health and health security first. NCD action and investment must no longer be seen as an afterthought to infectious diseases and neglected within health services, but as fundamental to resilience, security, equity, and economic stability. As Heads of State and Governments meet this week in Ghana for the International Strategic Dialogue on NCDs and the SDGs, we call on leaders to take the bold action so urgently needed. Whether NCDs and their prevention are addressed by future policy action will make or break the effectiveness of the pandemic response. Katie Dain is the Chief Executive Officer of the NCD Alliance. David Watkins, University of Washington, is the lead author of a recent Lancet NCD 2030 Countdown series article on pathways and investments to accelerate NCDs progress. Interactive map reproduced with permission from Politico Studio, based on data from WHO’s 2020 NCDs Progress Monitor. Image Credits: WHO/A. Loke, World Health Organization , World Heart Federation / WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
NCDs Finally Get Attention at Presidential Level 12/04/2022 Kerry Cullinan Diabetes protest in South Africa After years of being the neglected stepchild of global health, non-communicable diseases (NCDs) might finally be getting the urgent attention they need with Tuesday’s launch of an international NCD compact and presidential group. The measures were announced at the International Strategic Dialogue on NCDs and Sustainable Development Goals (SDGs) co-hosted by the governments of Ghana and Norway and the World Health Organization (WHO). Mike Bloomberg, the WHO Global NCD Ambassador, told the Accra meeting via video that global investment in NCDs was a “pitiful 1-2% of global health funding”. Very few countries are on track to achieve the United Nations Sustainable Development Goal (SDGs) 3.4, which commits member states to “reduce by one-third premature mortality from NCDs through prevention and treatment, and promote mental health and wellbeing by 2030”. But the NCD Alliance says that the compact and Presidential Council on NCDs (NCD Presidential Group) “could be a turning point in the fight against chronic diseases, which is responsible for 74 % of deaths annually”, finally demonstrating the political will needed to address the world’s biggest killer. Co-organized by the Governments of Ghana🇬🇭 and Norway🇳🇴, and the @WHO, the International Dialogue on #NCDs and the #SDGs taking place in #Accra, is a demonstration of our collective effort, at the leadership level, to forge ahead a common agenda to tackle the challenges of #NCDs. pic.twitter.com/wXP9JHfnP3 — UNinGhana (@UNinGhana) April 12, 2022 WHO member states and leaders will be encouraged to sign up to both the compact and the presidential group and “align strategies and operations with universal commitments made to accelerate and scale up the global collective efforts to prevent and control NCDs and achieve universal health coverage”, according to an outcome document from Tuesday’s meeting. “The NCD Compact is a living document and will be updated on a yearly basis by its current and future signatories among Heads of State and Governments to navigate in preparation of the next UN High-level meeting on NCDs in 2025 and going forward towards 2030,” the document states. “Two years into the global COVID-19 pandemic, there can no longer be any doubt about the case for investing in NCDs,” said Katie Dain, CEO of the NCD Alliance. “COVID-19 has upended health systems, drained economies and disproportionately affected people living with NCDs. This pandemic must be a wake-up call for governments and political leaders to value, prioritise and invest in healthy societies, NCD prevention and strong According to the NCD Alliance, 39 million lives could be saved before 2030 if an additional $18 billion is annually on implementing packages of cost-effective NCD interventions, tailored to local disease burden and risk factors. “This would also generate an average net economic benefit of $2.7 trillion, or $390 per capita, equal to a 19 to one return on investment,” said the alliance, referring to recent research published in The Lancet. The Accra meeting was addressed by a variety of high-profile leaders, particularly from Africa and the Caribbean, including a number of First Ladies who have an active international forum aimed at preventing NCDs. Co-host Norweigan Prime Minister Jonas Gahr Støre said that most of the premature deaths from NCDs can be avoided, and governments “must intensify our efforts to prevent and control them”. 🇳🇴Prime Minister of Norway @jonasgahrstore "Only 14 countries are on track to meet #SDG 3.4 today, we are launching the international NCD compact – a consolidated global effort to prevent people from dying. NCDs are a global problem but I am convinced it is achievable"@NorwayMFA pic.twitter.com/Nk1P7qlbVz — NCD Alliance (@ncdalliance) April 12, 2022 Barbados Prime Minister Mia Mottley lamented that only 14 countries were on track to achieving SGD 3.4, 11 years after the first UN high-level meeting on non-communicable diseases and seven years after the adoption of the SDGs. September meeting The President of Ghana will chair the first meeting of the Presidential Council on NCDs, which will take place in September during the 77th session of the UN General Assembly in New York. Meanwhile, the International NCD Compact 2022-2030 contains strategic priorities to accelerate action and encourage countries to reach SDG targets on NCDs by 2030. According to the NCD Alliance, 41 million people die every year due to an NCD and annual deaths from NCDs are projected to escalate to 52 million by 2030. “To put these figures into perspective, in 2020 annual deaths from tuberculosis, malaria and HIV/AIDS reached 1.5 million, 627,000, and 680,000 respectively. Meanwhile, deaths attributed to the COVID-19 pandemic, from its beginning in 2019 to April 2022, are nearing six million, and 60-90% of these deaths are in people living with one or more NCD. Image Credits: Kerry Cullinan. Historic Public Hearings on WHO Pandemic Instrument; Some Unhappiness with Process 12/04/2022 Kerry Cullinan The last Ebola patient leaves a treatment centre in the Democratic Republic of Congo at the end of March 2021, marking the countdown to declaring the end of that pandemic. The World Health Organization (WHO) convened public hearings for only the second time in its history on Tuesday, asking interested parties what substantive issues should be contained in its proposed international instrument on pandemic preparedness and response. The first and only other WHO hearings were held 22 years ago in the run-up to the adoption of the Framework Convention on Tobacco Control, according to WHO principal legal officer Steven Solomon. Welcoming the public hearing, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that informed opinion and active public cooperation are of the utmost importance to improve health, and it was important to learn from the COVID-19 pandemic to ensure the world is “better prepared” for the next pandemic. Tedros had been mandated by last year’s World Health Assembly Special Session to convene public hearings to inform the work of the Intergovernmental Negotiating Body (INB) which is in charge of negotiating the pandemic instrument or treaty. INB co-chair, South Africa’s Dr Precious Matsoso, described the hearings as “remarkable” and “historic”. Dr Precious Matsoso, INB co-chair Narrow responsibility However, the Civil Society Alliance for Human Rights in the Pandemic Treaty warned that the consultative process risks being “inadequate”. “While this week’s public hearings reflect the INB’s stated objective to consult the public to some extent, it has interpreted its responsibility to do so very narrowly,” according to the alliance. “The INB has allocated minimal time to engaging with the wide range of stakeholders who could inform the process and improve both the legitimacy and quality of the Treaty that emerges.” Dr Meg Davis, from the Global Health Centre at the Graduate Institute in Geneva, also said that participants had been given no indication of whether or how their submissions would be included in the negotiations and recommended policymaking models to ensure meaningful civil society engagement. A number of organisations gave two-minute speeches focusing on a wide range of issues including ‘One Health’, research and development (R&D) and intellectual property rights at the hearings, which continue on Wednesday and then reconvene in mid-June. Equity means sharing Research and Development Professor Suerie Moon, co-director of the Global Health Centre at the Graduate Institute in Geneva. All member states have committed to equity at the heart of any pandemic instrument, but Professor Suerie Moon, co-director of the Geneva Graduate Institute’s Global Health Centre, told the hearings that “equity requires collective research and development of vaccines, drugs and diagnostics”. Pointing out that COVID-19 has led to the development of technology transfer hubs in South Africa and the Republic of Korea, Moon warned that “there’s a risk that new factories will sit idle in the next emergency unless the new international instrument forges agreement on obligations to share knowledge, data and intellectual property before and during future emergencies”. “It’s unlikely, however, that countries or companies will do so out of the goodness of their hearts,” added Moon. “To make such sharing feasible, we have to tie it to commitments to jointly finance research and development to share pathogen samples and genomic sequencing data. In other words, the key idea is collective research and development for collective benefit.” Acknowledging that intellectual property was a difficult issue, Moon nonetheless said that if equitable access was to become a reality “the new instrument must include the nuts-and-bolts provisions to make sharing technology for pandemics the new normal”. To address IP, Knowledge Ecology International (KEI) recommended that governments should “agree to collectively use exceptions to intellectual property rights that are permitted in existing trade agreements and treaties”. “A model for this is the WIPO Marrakesh Treaty for the Blind, which mandates its members to use exceptions in copyrights to enhance global access to works made accessible to persons who are blind or have other disabilities,” according to KEI’s James Love. KEI also proposed “a robust chapter on transparency”, adding that “the lack of transparency in many areas for the current pandemic is an appalling and unnecessary policy failure, and one that both makes it more difficult to manage a pandemic response, and undermines the public’s trust in institutions”. Rachael Crockett from the Drugs for Neglected Diseases initiative (DNDi) stressed the need to co-ordinate R&D as a substantive element of the new instrument. DNDi wants R&D priority setting, and “globally agreed norms and binding rules that govern the R&D process, including transparency and open sharing of research, data, knowledge, technology, and equitable allocation of health tools”. Sharing pathogens IFPMA’s Grega Kumer Grega Kumer from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) said “any system should be built on what worked well during the COVID pandemic, in particular, immediate sharing of pathogens and a robust response from the IP based private sector”. The IFPMA presented eight core principles, including that the negotiation process should be “inclusive and transparent, involving the private sector and all critical contributors to pandemic preparedness efforts”. “Any system should allow for immediate access of pathogens and genetic sequence data and correct the negative effects of access and benefit-sharing legislation,” said Kumer. The IFPMA also supports more equitable access to tests, treatments and vaccines “based on medical need, thus enhancing solidarity and facilitating emergency financing to institutions procuring for developing countries”, and the protection of supply chains ”from arbitrary export restrictions and other trade barriers”. “While the public sector might play a larger role in pandemic setting, the system should build on the private sector strengths for R&D, manufacturing and distribution,” he concluded. One Health is key The need for any pandemic instrument to adopt a One Health approach also emerged as a key theme. Dame Sally Davies, speaking for the UN Global Leaders Group on Antimicrobial Resistance (AMR), said that they wanted AMR to be integrated alongside a primary focus on pandemics. “The next pandemic could be drug-resistant, or could depend on antimicrobials to mitigate it,” said Davies, saying that one health surveillance needed to be at the heart of any pandemic treaty to enable “rapid, transparent and responsive protection”. Governance principles The Panel for a Global Health Convention believes the instrument must be governed by four non-negotiable principles, according to Dame Barbara Stocking. “Solidarity, because we’re all in this together, and solidarity is in our own self-interest,” explained Stocking. “Equity: there must be equal access to vaccines and treatments, but also an equal voice in decision-making. Transparency in reporting data and samples. Accountability, as the lack of accountability of countries is the fundamental reason that we are in disarray.” The hearings continue at 8am CET on Wednesday and can be followed live. Image Credits: WHO African Region. Single Dose of HPV Vaccine is Enough to Protect Against Cervical Cancer 11/04/2022 Kerry Cullinan WHO’s Dr Kate O’Brien and SAGE chairperson Dr Alejandro Cravioto The Human Papillomavirus (HPV), which is the cause of most cervical cancer cases, can be treated with a single vaccine dose instead of the two doses currently being given, according to the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE). SAGE chairperson Dr Alejandro Cravioto told a media briefing on Monday that, after reviewing all available evidence, the group concluded that a single vaccine was effective against HPV in girls and women aged nine to 20, but that women aged 21 and over needed two doses given six months apart. As HPV is generally sexually transmitted, vaccination is also recommended for boys and men who can carry the virus and infect women – and SAGE now also recommends a single dose for younger boys and men too. Only 13% of HPV target group is vaccinated The WHO described the new recommendation as a “game-changer” for the prevention of the disease as it would enable more doses of the vaccine to reach more girls. “The HPV vaccine is highly effective for the prevention of HPV serotypes 16 and 18, which cause 70% of cervical cancer,” said Cravioto. “SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes.” Meanwhile, the WHO described cervical cancer as being “almost entirely preventable” and “a disease of inequity of access”, adding that it was concerned by the slow introduction of the HPV vaccine into immunization programs and low coverage, especially in poorer countries. In 2020, only 13% of the global target population had received two doses, with WHO citing barriers as challenges of supply, cost and delivering a two-dose regimen to older girls who are not part of childhood vaccination programs. Dr Nono Simelela, WHO Assistant Director-General for Strategic Programmatic Priorities: Cervical Cancer Elimination. WHO Assistant Director-General Dr Nono Simelela said that single-dose recommendation “has the potential to take us faster to our goal of having 90 per cent of girls vaccinated by the age of 15 by 2030”. “We need political commitment complemented with equitable pathways for the accessibility of the HPV vaccine. Failure to do so is an injustice to the generation of girls and young women who may be at risk of cervical cancer,” added Simelela. SAGE also recommended that hepatitis A could also be treated with a single vaccine. China’s CanSino Bio vaccine expected to get WHO approval SAGE also evaluated the data on the Chinese CanSino Bio (Ad5-nCOV-S) vaccine, but will only release the outcome of this discussion if the WHO grants the vaccine emergency use listing (EUL) – “hopefully in the next few weeks”, according to Cravioto. An mRNA based COVID-19 vaccine also developed by the Chinese company was cleared for clinical trials last week. Currently, there are no mRNA vaccines available in China. WHO’s Director of Immunization, Dr Kate O’Brien, expressed concern that only around 65% of healthworkers globally were vaccinated against COVID-19, and a similar number of people over the age of 60. In addition, 21 countries had vaccinated less than 10% of citizens, said O’Brien – 14 countries in the African region, four in the eastern Mediterranean region, and then one each in the Americas, the Western Pacific and the Southeast Asian region. “These are countries that are working really hard to advance their programmes now that supply is no longer the issue,” said O’Brien. SAGE admitted that there was a lack of data about the efficacy of non-mRNA vaccines’ efficacy against Omicron. As far as the spread of Omicron in Hong Kong was concerned, Cravioto said the high mortality rate in older people was related to that age group’s reluctance to be infected rather than an indictment on Chinese-produced vaccines. However, he said Nineteen More Attacks on Ukraine’s Health Facilities Since Friday: WHO 11/04/2022 Kerry Cullinan Ukraine operating theatre destroyed The World Health Organization (WHO) has verified 108 attacks on health care in Ukraine as of Monday in which 73 people have died and 51 have been injured. That is 19 more attacks on health facilities than the already deadly toll of 91 attacks that had been verified by WHO as of early Friday afternoon, and as reported at a press conference by WHO’s Regional Director Hans Kluge in Lviv. .@WHO has verified 5 additional reports of attacks on health care in #Ukraine. As of 11 April, 108 attacks on health care in Ukraine have been verified, causing 73 deaths and 51 injuries. We are outraged that attacks on health care are continuing. pic.twitter.com/8GNUQZFiK9 — WHO Ukraine (@WHOUkraine) April 11, 2022 Meanwhile, the Office of the UN High Commissioner for Human Rights (OHCHR) has recorded 1,793 civilian deaths and 2,439 injuries since the start of the Russian invasion on 24 February and Sunday. Most of the civilian casualties have been caused by “explosive weapons with a wide impact area”, including shelling from heavy artillery and rocket, missile and air strikes. https://data.humdata.org/visualization/ukraine-humanitarian-operations/ “OHCHR believes that the actual figures are considerably higher, as the receipt of information from some locations where intense hostilities have been going on has been delayed and many reports are still pending corroboration,” according to a statement from the office. “This concerns, for example, Mariupol (Donetsk region), Izium (Kharkiv region), Popasna (Luhansk region), and Borodianka (Kyiv region), where there are allegations of numerous civilian casualties. These figures are being further corroborated and are not included in the above statistics.” According to the Prosecutor General’s Office of Ukraine, 176 children had been killed and at least 336 injured as of Sunday. Image Credits: WHO. Non-Communicable Diseases: Is the ‘New Normal’ Too Much Like The Old One? 11/04/2022 Katie Dain & David Watkins The vast majority of people who died of COVID-19 had a non-communicable disease – yet investment in NCD prevention is pitiful. More than two years after the novel coronavirus erupted into a global pandemic, the world is beginning to settle into a new normal. COVID-19 changed how we live and work in ways that will continue long after the pandemic subsides. Digital and automation technologies are here to stay, work is done remotely, and shopping and entertainment have gone online. But the COVID-19 pandemic also laid bare an indisputable truth: the destructive path carved by the infectious SARS-CoV2 virus was only the tip of the iceberg. Studies have estimated that 60-90% of COVID-19 deaths have been of people living with one or more chronic conditions, like obesity, heart or kidney disease, or cardiovascular diseases. And people living with non-communicable diseases (NCDs) are still experiencing the collateral damage of the pandemic, due to severe disruptions to essential health services. The lack of investment in NCD prevention and care over the years has vastly amplified the toll of the COVID-19 pandemic. The bigger, long-term pandemic that we face Responsible for 74% of all deaths globally, NCDs are the even bigger, long-term pandemic that we face. Governments and global institutions have been learning many harsh lessons about the need to build back better, with more resilient health systems and more equitable access to quality, affordable treatment. But too often this has been a slogan without much substance behind it. We now need to see real changes taking hold. Beyond COVID, there is a strong and urgent imperative for investment in NCDs, which now cause 15 million premature deaths of people between the ages of 30 and 70 each year, 85% of them in low- and middle-income countries. This makes action and investment in NCDs a prerequisite for resilience, pandemic preparedness and health security, not to mention for meeting the most critical health challenges of the next decade in countries at all stages of development. Yet financing for NCDs has stagnated at a pitiful 1-2% of development assistance for health for two decades. If we look at development assistance that has gone towards health system strengthening which also helps people living with NCDs we can add a further 5%, but that is simply inconsequential when compared to government handouts for fossils fuels and agriculture, which climb to $1.8 trillion annually – and more importantly, when compared to the magnitude of disease and economic burden of NCDs. Still hope to see healthier populations by 2030 In 2015, all UN member countries committed to the Sustainable Development Goals (SDGs) to achieve a better and more sustainable future for all, including SDG target 3.4 to reduce NCD premature mortality by one-third by 2030. This and other NCD commitments should not lose priority because of the COVID-19 pandemic. They should actually gain priority. Although the vast majority of countries are well off-track to meet SDG 3.4, a March 2022 paper published in The Lancet shows that there is still hope. All countries – and especially low- and middle-income countries (LMICs) – can achieve or nearly achieve SDG 3.4 to reduce premature NCD mortality by one-third by 2030 by introducing a cost-effective package of NCD prevention and treatment interventions. Investment in the mitigation of NCDs boosts productivity by cutting the number of wasted lives. The paper presents an NCD investment framework that aims to support LMICs in getting back on track towards achieving SDG target 3.4 in the wake of the COVID-19 pandemic. It is centred around a package of 21 cost-effective interventions; essentially, a feasible and pragmatic roadmap to healthier populations and more resilient health systems. There are 15 clinical interventions, like screening and early detection for diabetes and cervical cancer, and cardiovascular disease prevention programmes. Many of these can be implemented at primary health care level. There are also six policy interventions, focused on taxing and regulating tobacco and alcohol, and measures to reduce intake of sodium and transfats. All of the interventions are aligned with WHO recommendations for NCD programmes, helping ensure a more coordinated NCD and pandemic response. The paper provides guidance on the types of interventions that can best accelerate progress on NCDs in 123 LMICs, and the resources required to implement these interventions. While the clinical interventions are meant to be selected according to national needs and contexts, the policy interventions are crucial for all countries, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. These actions could also generate significant revenue, which can then be reinvested in health. The bottom line for NCD investment As the paper demonstrates, implementing the most efficient package of interventions in each world region would require $140 billion in new spending over 2023–30, equivalent to $18 billion per year. This investment could avert 39 million deaths and generate an average net economic benefit of US$2.7 trillion, or US$390 per capita. This means that benefits outweigh costs by 19 to one. LMIC ministries of health would need to contribute around 20% of their budgets to the priority NCD interventions. Many countries would also need external support (bilateral, multilateral, philanthropy, private sector), particularly in light of the economic impacts of COVID-19. For the first time, we have a price tag for tackling NCDs in LMICs – and it’s peanuts alongside current NCD treatment costs and economic losses due to premature death and disability. For instance, in 2021, health expenditure for diabetes reached $966 billion; the annual cost of obesity is projected to top $1.2 trillion globally by 2025; the total economic loss due to cardiovascular disease in LMICs was estimated at $3.7 trillion between 2011 and 2015. The paper provides further evidence that underscores the urgent need to invest now in proven strategies to save lives and prevent and treat NCDs. Investments in NCDs are not only cost-effective, but they can also save money even within a short timeframe. The bottom line is that governments can reap substantial economic rewards, in both the short- and long-run, by taking bold action on NCDs and thus ensuring the security and fiscal sustainability of their health systems. This requires a view of health as an investment not a cost, and one that requires long-term thinking. Trailblazing the road to recovery Leaders must shift their priorities to achieving healthier populations, with impactful action for NCD prevention and care. Some countries are taking bold steps. India’s budget for 2021 more than doubled national healthcare and wellbeing spending from previous levels. The Philippines increased the taxation of tobacco products during the COVID-19 pandemic, with a share being earmarked to bolster capacity for universal health coverage to reach the poorest communities. Meanwhile, Latin America has made big gains for healthy diets. Recognising a high number of COVID-19 cases among overweight children and adults, the Mexican states of Oaxaca and Tabasco banned the sale of junk food and sugary drinks to people under 18 in 2020, with more states planning to follow suit. Front of package labels in Mexico A Mexican nationwide front-of-packaging warning labelling law also entered into effect in 2020, requiring black stop signs on packages of foods high in added sugar, fats, calories and sodium. Various Caribbean nations have implemented taxes on sugary beverages and made advances to control marketing of junk food in and near schools. These are just a sample of the actions being taken around the world, and are reason for optimism that real progress can be made. What we need now to accelerate this progress is strong leadership that is committed to putting health and health security first. NCD action and investment must no longer be seen as an afterthought to infectious diseases and neglected within health services, but as fundamental to resilience, security, equity, and economic stability. As Heads of State and Governments meet this week in Ghana for the International Strategic Dialogue on NCDs and the SDGs, we call on leaders to take the bold action so urgently needed. Whether NCDs and their prevention are addressed by future policy action will make or break the effectiveness of the pandemic response. Katie Dain is the Chief Executive Officer of the NCD Alliance. David Watkins, University of Washington, is the lead author of a recent Lancet NCD 2030 Countdown series article on pathways and investments to accelerate NCDs progress. Interactive map reproduced with permission from Politico Studio, based on data from WHO’s 2020 NCDs Progress Monitor. Image Credits: WHO/A. Loke, World Health Organization , World Heart Federation / WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Historic Public Hearings on WHO Pandemic Instrument; Some Unhappiness with Process 12/04/2022 Kerry Cullinan The last Ebola patient leaves a treatment centre in the Democratic Republic of Congo at the end of March 2021, marking the countdown to declaring the end of that pandemic. The World Health Organization (WHO) convened public hearings for only the second time in its history on Tuesday, asking interested parties what substantive issues should be contained in its proposed international instrument on pandemic preparedness and response. The first and only other WHO hearings were held 22 years ago in the run-up to the adoption of the Framework Convention on Tobacco Control, according to WHO principal legal officer Steven Solomon. Welcoming the public hearing, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that informed opinion and active public cooperation are of the utmost importance to improve health, and it was important to learn from the COVID-19 pandemic to ensure the world is “better prepared” for the next pandemic. Tedros had been mandated by last year’s World Health Assembly Special Session to convene public hearings to inform the work of the Intergovernmental Negotiating Body (INB) which is in charge of negotiating the pandemic instrument or treaty. INB co-chair, South Africa’s Dr Precious Matsoso, described the hearings as “remarkable” and “historic”. Dr Precious Matsoso, INB co-chair Narrow responsibility However, the Civil Society Alliance for Human Rights in the Pandemic Treaty warned that the consultative process risks being “inadequate”. “While this week’s public hearings reflect the INB’s stated objective to consult the public to some extent, it has interpreted its responsibility to do so very narrowly,” according to the alliance. “The INB has allocated minimal time to engaging with the wide range of stakeholders who could inform the process and improve both the legitimacy and quality of the Treaty that emerges.” Dr Meg Davis, from the Global Health Centre at the Graduate Institute in Geneva, also said that participants had been given no indication of whether or how their submissions would be included in the negotiations and recommended policymaking models to ensure meaningful civil society engagement. A number of organisations gave two-minute speeches focusing on a wide range of issues including ‘One Health’, research and development (R&D) and intellectual property rights at the hearings, which continue on Wednesday and then reconvene in mid-June. Equity means sharing Research and Development Professor Suerie Moon, co-director of the Global Health Centre at the Graduate Institute in Geneva. All member states have committed to equity at the heart of any pandemic instrument, but Professor Suerie Moon, co-director of the Geneva Graduate Institute’s Global Health Centre, told the hearings that “equity requires collective research and development of vaccines, drugs and diagnostics”. Pointing out that COVID-19 has led to the development of technology transfer hubs in South Africa and the Republic of Korea, Moon warned that “there’s a risk that new factories will sit idle in the next emergency unless the new international instrument forges agreement on obligations to share knowledge, data and intellectual property before and during future emergencies”. “It’s unlikely, however, that countries or companies will do so out of the goodness of their hearts,” added Moon. “To make such sharing feasible, we have to tie it to commitments to jointly finance research and development to share pathogen samples and genomic sequencing data. In other words, the key idea is collective research and development for collective benefit.” Acknowledging that intellectual property was a difficult issue, Moon nonetheless said that if equitable access was to become a reality “the new instrument must include the nuts-and-bolts provisions to make sharing technology for pandemics the new normal”. To address IP, Knowledge Ecology International (KEI) recommended that governments should “agree to collectively use exceptions to intellectual property rights that are permitted in existing trade agreements and treaties”. “A model for this is the WIPO Marrakesh Treaty for the Blind, which mandates its members to use exceptions in copyrights to enhance global access to works made accessible to persons who are blind or have other disabilities,” according to KEI’s James Love. KEI also proposed “a robust chapter on transparency”, adding that “the lack of transparency in many areas for the current pandemic is an appalling and unnecessary policy failure, and one that both makes it more difficult to manage a pandemic response, and undermines the public’s trust in institutions”. Rachael Crockett from the Drugs for Neglected Diseases initiative (DNDi) stressed the need to co-ordinate R&D as a substantive element of the new instrument. DNDi wants R&D priority setting, and “globally agreed norms and binding rules that govern the R&D process, including transparency and open sharing of research, data, knowledge, technology, and equitable allocation of health tools”. Sharing pathogens IFPMA’s Grega Kumer Grega Kumer from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) said “any system should be built on what worked well during the COVID pandemic, in particular, immediate sharing of pathogens and a robust response from the IP based private sector”. The IFPMA presented eight core principles, including that the negotiation process should be “inclusive and transparent, involving the private sector and all critical contributors to pandemic preparedness efforts”. “Any system should allow for immediate access of pathogens and genetic sequence data and correct the negative effects of access and benefit-sharing legislation,” said Kumer. The IFPMA also supports more equitable access to tests, treatments and vaccines “based on medical need, thus enhancing solidarity and facilitating emergency financing to institutions procuring for developing countries”, and the protection of supply chains ”from arbitrary export restrictions and other trade barriers”. “While the public sector might play a larger role in pandemic setting, the system should build on the private sector strengths for R&D, manufacturing and distribution,” he concluded. One Health is key The need for any pandemic instrument to adopt a One Health approach also emerged as a key theme. Dame Sally Davies, speaking for the UN Global Leaders Group on Antimicrobial Resistance (AMR), said that they wanted AMR to be integrated alongside a primary focus on pandemics. “The next pandemic could be drug-resistant, or could depend on antimicrobials to mitigate it,” said Davies, saying that one health surveillance needed to be at the heart of any pandemic treaty to enable “rapid, transparent and responsive protection”. Governance principles The Panel for a Global Health Convention believes the instrument must be governed by four non-negotiable principles, according to Dame Barbara Stocking. “Solidarity, because we’re all in this together, and solidarity is in our own self-interest,” explained Stocking. “Equity: there must be equal access to vaccines and treatments, but also an equal voice in decision-making. Transparency in reporting data and samples. Accountability, as the lack of accountability of countries is the fundamental reason that we are in disarray.” The hearings continue at 8am CET on Wednesday and can be followed live. Image Credits: WHO African Region. Single Dose of HPV Vaccine is Enough to Protect Against Cervical Cancer 11/04/2022 Kerry Cullinan WHO’s Dr Kate O’Brien and SAGE chairperson Dr Alejandro Cravioto The Human Papillomavirus (HPV), which is the cause of most cervical cancer cases, can be treated with a single vaccine dose instead of the two doses currently being given, according to the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE). SAGE chairperson Dr Alejandro Cravioto told a media briefing on Monday that, after reviewing all available evidence, the group concluded that a single vaccine was effective against HPV in girls and women aged nine to 20, but that women aged 21 and over needed two doses given six months apart. As HPV is generally sexually transmitted, vaccination is also recommended for boys and men who can carry the virus and infect women – and SAGE now also recommends a single dose for younger boys and men too. Only 13% of HPV target group is vaccinated The WHO described the new recommendation as a “game-changer” for the prevention of the disease as it would enable more doses of the vaccine to reach more girls. “The HPV vaccine is highly effective for the prevention of HPV serotypes 16 and 18, which cause 70% of cervical cancer,” said Cravioto. “SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes.” Meanwhile, the WHO described cervical cancer as being “almost entirely preventable” and “a disease of inequity of access”, adding that it was concerned by the slow introduction of the HPV vaccine into immunization programs and low coverage, especially in poorer countries. In 2020, only 13% of the global target population had received two doses, with WHO citing barriers as challenges of supply, cost and delivering a two-dose regimen to older girls who are not part of childhood vaccination programs. Dr Nono Simelela, WHO Assistant Director-General for Strategic Programmatic Priorities: Cervical Cancer Elimination. WHO Assistant Director-General Dr Nono Simelela said that single-dose recommendation “has the potential to take us faster to our goal of having 90 per cent of girls vaccinated by the age of 15 by 2030”. “We need political commitment complemented with equitable pathways for the accessibility of the HPV vaccine. Failure to do so is an injustice to the generation of girls and young women who may be at risk of cervical cancer,” added Simelela. SAGE also recommended that hepatitis A could also be treated with a single vaccine. China’s CanSino Bio vaccine expected to get WHO approval SAGE also evaluated the data on the Chinese CanSino Bio (Ad5-nCOV-S) vaccine, but will only release the outcome of this discussion if the WHO grants the vaccine emergency use listing (EUL) – “hopefully in the next few weeks”, according to Cravioto. An mRNA based COVID-19 vaccine also developed by the Chinese company was cleared for clinical trials last week. Currently, there are no mRNA vaccines available in China. WHO’s Director of Immunization, Dr Kate O’Brien, expressed concern that only around 65% of healthworkers globally were vaccinated against COVID-19, and a similar number of people over the age of 60. In addition, 21 countries had vaccinated less than 10% of citizens, said O’Brien – 14 countries in the African region, four in the eastern Mediterranean region, and then one each in the Americas, the Western Pacific and the Southeast Asian region. “These are countries that are working really hard to advance their programmes now that supply is no longer the issue,” said O’Brien. SAGE admitted that there was a lack of data about the efficacy of non-mRNA vaccines’ efficacy against Omicron. As far as the spread of Omicron in Hong Kong was concerned, Cravioto said the high mortality rate in older people was related to that age group’s reluctance to be infected rather than an indictment on Chinese-produced vaccines. However, he said Nineteen More Attacks on Ukraine’s Health Facilities Since Friday: WHO 11/04/2022 Kerry Cullinan Ukraine operating theatre destroyed The World Health Organization (WHO) has verified 108 attacks on health care in Ukraine as of Monday in which 73 people have died and 51 have been injured. That is 19 more attacks on health facilities than the already deadly toll of 91 attacks that had been verified by WHO as of early Friday afternoon, and as reported at a press conference by WHO’s Regional Director Hans Kluge in Lviv. .@WHO has verified 5 additional reports of attacks on health care in #Ukraine. As of 11 April, 108 attacks on health care in Ukraine have been verified, causing 73 deaths and 51 injuries. We are outraged that attacks on health care are continuing. pic.twitter.com/8GNUQZFiK9 — WHO Ukraine (@WHOUkraine) April 11, 2022 Meanwhile, the Office of the UN High Commissioner for Human Rights (OHCHR) has recorded 1,793 civilian deaths and 2,439 injuries since the start of the Russian invasion on 24 February and Sunday. Most of the civilian casualties have been caused by “explosive weapons with a wide impact area”, including shelling from heavy artillery and rocket, missile and air strikes. https://data.humdata.org/visualization/ukraine-humanitarian-operations/ “OHCHR believes that the actual figures are considerably higher, as the receipt of information from some locations where intense hostilities have been going on has been delayed and many reports are still pending corroboration,” according to a statement from the office. “This concerns, for example, Mariupol (Donetsk region), Izium (Kharkiv region), Popasna (Luhansk region), and Borodianka (Kyiv region), where there are allegations of numerous civilian casualties. These figures are being further corroborated and are not included in the above statistics.” According to the Prosecutor General’s Office of Ukraine, 176 children had been killed and at least 336 injured as of Sunday. Image Credits: WHO. Non-Communicable Diseases: Is the ‘New Normal’ Too Much Like The Old One? 11/04/2022 Katie Dain & David Watkins The vast majority of people who died of COVID-19 had a non-communicable disease – yet investment in NCD prevention is pitiful. More than two years after the novel coronavirus erupted into a global pandemic, the world is beginning to settle into a new normal. COVID-19 changed how we live and work in ways that will continue long after the pandemic subsides. Digital and automation technologies are here to stay, work is done remotely, and shopping and entertainment have gone online. But the COVID-19 pandemic also laid bare an indisputable truth: the destructive path carved by the infectious SARS-CoV2 virus was only the tip of the iceberg. Studies have estimated that 60-90% of COVID-19 deaths have been of people living with one or more chronic conditions, like obesity, heart or kidney disease, or cardiovascular diseases. And people living with non-communicable diseases (NCDs) are still experiencing the collateral damage of the pandemic, due to severe disruptions to essential health services. The lack of investment in NCD prevention and care over the years has vastly amplified the toll of the COVID-19 pandemic. The bigger, long-term pandemic that we face Responsible for 74% of all deaths globally, NCDs are the even bigger, long-term pandemic that we face. Governments and global institutions have been learning many harsh lessons about the need to build back better, with more resilient health systems and more equitable access to quality, affordable treatment. But too often this has been a slogan without much substance behind it. We now need to see real changes taking hold. Beyond COVID, there is a strong and urgent imperative for investment in NCDs, which now cause 15 million premature deaths of people between the ages of 30 and 70 each year, 85% of them in low- and middle-income countries. This makes action and investment in NCDs a prerequisite for resilience, pandemic preparedness and health security, not to mention for meeting the most critical health challenges of the next decade in countries at all stages of development. Yet financing for NCDs has stagnated at a pitiful 1-2% of development assistance for health for two decades. If we look at development assistance that has gone towards health system strengthening which also helps people living with NCDs we can add a further 5%, but that is simply inconsequential when compared to government handouts for fossils fuels and agriculture, which climb to $1.8 trillion annually – and more importantly, when compared to the magnitude of disease and economic burden of NCDs. Still hope to see healthier populations by 2030 In 2015, all UN member countries committed to the Sustainable Development Goals (SDGs) to achieve a better and more sustainable future for all, including SDG target 3.4 to reduce NCD premature mortality by one-third by 2030. This and other NCD commitments should not lose priority because of the COVID-19 pandemic. They should actually gain priority. Although the vast majority of countries are well off-track to meet SDG 3.4, a March 2022 paper published in The Lancet shows that there is still hope. All countries – and especially low- and middle-income countries (LMICs) – can achieve or nearly achieve SDG 3.4 to reduce premature NCD mortality by one-third by 2030 by introducing a cost-effective package of NCD prevention and treatment interventions. Investment in the mitigation of NCDs boosts productivity by cutting the number of wasted lives. The paper presents an NCD investment framework that aims to support LMICs in getting back on track towards achieving SDG target 3.4 in the wake of the COVID-19 pandemic. It is centred around a package of 21 cost-effective interventions; essentially, a feasible and pragmatic roadmap to healthier populations and more resilient health systems. There are 15 clinical interventions, like screening and early detection for diabetes and cervical cancer, and cardiovascular disease prevention programmes. Many of these can be implemented at primary health care level. There are also six policy interventions, focused on taxing and regulating tobacco and alcohol, and measures to reduce intake of sodium and transfats. All of the interventions are aligned with WHO recommendations for NCD programmes, helping ensure a more coordinated NCD and pandemic response. The paper provides guidance on the types of interventions that can best accelerate progress on NCDs in 123 LMICs, and the resources required to implement these interventions. While the clinical interventions are meant to be selected according to national needs and contexts, the policy interventions are crucial for all countries, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. These actions could also generate significant revenue, which can then be reinvested in health. The bottom line for NCD investment As the paper demonstrates, implementing the most efficient package of interventions in each world region would require $140 billion in new spending over 2023–30, equivalent to $18 billion per year. This investment could avert 39 million deaths and generate an average net economic benefit of US$2.7 trillion, or US$390 per capita. This means that benefits outweigh costs by 19 to one. LMIC ministries of health would need to contribute around 20% of their budgets to the priority NCD interventions. Many countries would also need external support (bilateral, multilateral, philanthropy, private sector), particularly in light of the economic impacts of COVID-19. For the first time, we have a price tag for tackling NCDs in LMICs – and it’s peanuts alongside current NCD treatment costs and economic losses due to premature death and disability. For instance, in 2021, health expenditure for diabetes reached $966 billion; the annual cost of obesity is projected to top $1.2 trillion globally by 2025; the total economic loss due to cardiovascular disease in LMICs was estimated at $3.7 trillion between 2011 and 2015. The paper provides further evidence that underscores the urgent need to invest now in proven strategies to save lives and prevent and treat NCDs. Investments in NCDs are not only cost-effective, but they can also save money even within a short timeframe. The bottom line is that governments can reap substantial economic rewards, in both the short- and long-run, by taking bold action on NCDs and thus ensuring the security and fiscal sustainability of their health systems. This requires a view of health as an investment not a cost, and one that requires long-term thinking. Trailblazing the road to recovery Leaders must shift their priorities to achieving healthier populations, with impactful action for NCD prevention and care. Some countries are taking bold steps. India’s budget for 2021 more than doubled national healthcare and wellbeing spending from previous levels. The Philippines increased the taxation of tobacco products during the COVID-19 pandemic, with a share being earmarked to bolster capacity for universal health coverage to reach the poorest communities. Meanwhile, Latin America has made big gains for healthy diets. Recognising a high number of COVID-19 cases among overweight children and adults, the Mexican states of Oaxaca and Tabasco banned the sale of junk food and sugary drinks to people under 18 in 2020, with more states planning to follow suit. Front of package labels in Mexico A Mexican nationwide front-of-packaging warning labelling law also entered into effect in 2020, requiring black stop signs on packages of foods high in added sugar, fats, calories and sodium. Various Caribbean nations have implemented taxes on sugary beverages and made advances to control marketing of junk food in and near schools. These are just a sample of the actions being taken around the world, and are reason for optimism that real progress can be made. What we need now to accelerate this progress is strong leadership that is committed to putting health and health security first. NCD action and investment must no longer be seen as an afterthought to infectious diseases and neglected within health services, but as fundamental to resilience, security, equity, and economic stability. As Heads of State and Governments meet this week in Ghana for the International Strategic Dialogue on NCDs and the SDGs, we call on leaders to take the bold action so urgently needed. Whether NCDs and their prevention are addressed by future policy action will make or break the effectiveness of the pandemic response. Katie Dain is the Chief Executive Officer of the NCD Alliance. David Watkins, University of Washington, is the lead author of a recent Lancet NCD 2030 Countdown series article on pathways and investments to accelerate NCDs progress. Interactive map reproduced with permission from Politico Studio, based on data from WHO’s 2020 NCDs Progress Monitor. Image Credits: WHO/A. Loke, World Health Organization , World Heart Federation / WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Single Dose of HPV Vaccine is Enough to Protect Against Cervical Cancer 11/04/2022 Kerry Cullinan WHO’s Dr Kate O’Brien and SAGE chairperson Dr Alejandro Cravioto The Human Papillomavirus (HPV), which is the cause of most cervical cancer cases, can be treated with a single vaccine dose instead of the two doses currently being given, according to the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE). SAGE chairperson Dr Alejandro Cravioto told a media briefing on Monday that, after reviewing all available evidence, the group concluded that a single vaccine was effective against HPV in girls and women aged nine to 20, but that women aged 21 and over needed two doses given six months apart. As HPV is generally sexually transmitted, vaccination is also recommended for boys and men who can carry the virus and infect women – and SAGE now also recommends a single dose for younger boys and men too. Only 13% of HPV target group is vaccinated The WHO described the new recommendation as a “game-changer” for the prevention of the disease as it would enable more doses of the vaccine to reach more girls. “The HPV vaccine is highly effective for the prevention of HPV serotypes 16 and 18, which cause 70% of cervical cancer,” said Cravioto. “SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes.” Meanwhile, the WHO described cervical cancer as being “almost entirely preventable” and “a disease of inequity of access”, adding that it was concerned by the slow introduction of the HPV vaccine into immunization programs and low coverage, especially in poorer countries. In 2020, only 13% of the global target population had received two doses, with WHO citing barriers as challenges of supply, cost and delivering a two-dose regimen to older girls who are not part of childhood vaccination programs. Dr Nono Simelela, WHO Assistant Director-General for Strategic Programmatic Priorities: Cervical Cancer Elimination. WHO Assistant Director-General Dr Nono Simelela said that single-dose recommendation “has the potential to take us faster to our goal of having 90 per cent of girls vaccinated by the age of 15 by 2030”. “We need political commitment complemented with equitable pathways for the accessibility of the HPV vaccine. Failure to do so is an injustice to the generation of girls and young women who may be at risk of cervical cancer,” added Simelela. SAGE also recommended that hepatitis A could also be treated with a single vaccine. China’s CanSino Bio vaccine expected to get WHO approval SAGE also evaluated the data on the Chinese CanSino Bio (Ad5-nCOV-S) vaccine, but will only release the outcome of this discussion if the WHO grants the vaccine emergency use listing (EUL) – “hopefully in the next few weeks”, according to Cravioto. An mRNA based COVID-19 vaccine also developed by the Chinese company was cleared for clinical trials last week. Currently, there are no mRNA vaccines available in China. WHO’s Director of Immunization, Dr Kate O’Brien, expressed concern that only around 65% of healthworkers globally were vaccinated against COVID-19, and a similar number of people over the age of 60. In addition, 21 countries had vaccinated less than 10% of citizens, said O’Brien – 14 countries in the African region, four in the eastern Mediterranean region, and then one each in the Americas, the Western Pacific and the Southeast Asian region. “These are countries that are working really hard to advance their programmes now that supply is no longer the issue,” said O’Brien. SAGE admitted that there was a lack of data about the efficacy of non-mRNA vaccines’ efficacy against Omicron. As far as the spread of Omicron in Hong Kong was concerned, Cravioto said the high mortality rate in older people was related to that age group’s reluctance to be infected rather than an indictment on Chinese-produced vaccines. However, he said Nineteen More Attacks on Ukraine’s Health Facilities Since Friday: WHO 11/04/2022 Kerry Cullinan Ukraine operating theatre destroyed The World Health Organization (WHO) has verified 108 attacks on health care in Ukraine as of Monday in which 73 people have died and 51 have been injured. That is 19 more attacks on health facilities than the already deadly toll of 91 attacks that had been verified by WHO as of early Friday afternoon, and as reported at a press conference by WHO’s Regional Director Hans Kluge in Lviv. .@WHO has verified 5 additional reports of attacks on health care in #Ukraine. As of 11 April, 108 attacks on health care in Ukraine have been verified, causing 73 deaths and 51 injuries. We are outraged that attacks on health care are continuing. pic.twitter.com/8GNUQZFiK9 — WHO Ukraine (@WHOUkraine) April 11, 2022 Meanwhile, the Office of the UN High Commissioner for Human Rights (OHCHR) has recorded 1,793 civilian deaths and 2,439 injuries since the start of the Russian invasion on 24 February and Sunday. Most of the civilian casualties have been caused by “explosive weapons with a wide impact area”, including shelling from heavy artillery and rocket, missile and air strikes. https://data.humdata.org/visualization/ukraine-humanitarian-operations/ “OHCHR believes that the actual figures are considerably higher, as the receipt of information from some locations where intense hostilities have been going on has been delayed and many reports are still pending corroboration,” according to a statement from the office. “This concerns, for example, Mariupol (Donetsk region), Izium (Kharkiv region), Popasna (Luhansk region), and Borodianka (Kyiv region), where there are allegations of numerous civilian casualties. These figures are being further corroborated and are not included in the above statistics.” According to the Prosecutor General’s Office of Ukraine, 176 children had been killed and at least 336 injured as of Sunday. Image Credits: WHO. Non-Communicable Diseases: Is the ‘New Normal’ Too Much Like The Old One? 11/04/2022 Katie Dain & David Watkins The vast majority of people who died of COVID-19 had a non-communicable disease – yet investment in NCD prevention is pitiful. More than two years after the novel coronavirus erupted into a global pandemic, the world is beginning to settle into a new normal. COVID-19 changed how we live and work in ways that will continue long after the pandemic subsides. Digital and automation technologies are here to stay, work is done remotely, and shopping and entertainment have gone online. But the COVID-19 pandemic also laid bare an indisputable truth: the destructive path carved by the infectious SARS-CoV2 virus was only the tip of the iceberg. Studies have estimated that 60-90% of COVID-19 deaths have been of people living with one or more chronic conditions, like obesity, heart or kidney disease, or cardiovascular diseases. And people living with non-communicable diseases (NCDs) are still experiencing the collateral damage of the pandemic, due to severe disruptions to essential health services. The lack of investment in NCD prevention and care over the years has vastly amplified the toll of the COVID-19 pandemic. The bigger, long-term pandemic that we face Responsible for 74% of all deaths globally, NCDs are the even bigger, long-term pandemic that we face. Governments and global institutions have been learning many harsh lessons about the need to build back better, with more resilient health systems and more equitable access to quality, affordable treatment. But too often this has been a slogan without much substance behind it. We now need to see real changes taking hold. Beyond COVID, there is a strong and urgent imperative for investment in NCDs, which now cause 15 million premature deaths of people between the ages of 30 and 70 each year, 85% of them in low- and middle-income countries. This makes action and investment in NCDs a prerequisite for resilience, pandemic preparedness and health security, not to mention for meeting the most critical health challenges of the next decade in countries at all stages of development. Yet financing for NCDs has stagnated at a pitiful 1-2% of development assistance for health for two decades. If we look at development assistance that has gone towards health system strengthening which also helps people living with NCDs we can add a further 5%, but that is simply inconsequential when compared to government handouts for fossils fuels and agriculture, which climb to $1.8 trillion annually – and more importantly, when compared to the magnitude of disease and economic burden of NCDs. Still hope to see healthier populations by 2030 In 2015, all UN member countries committed to the Sustainable Development Goals (SDGs) to achieve a better and more sustainable future for all, including SDG target 3.4 to reduce NCD premature mortality by one-third by 2030. This and other NCD commitments should not lose priority because of the COVID-19 pandemic. They should actually gain priority. Although the vast majority of countries are well off-track to meet SDG 3.4, a March 2022 paper published in The Lancet shows that there is still hope. All countries – and especially low- and middle-income countries (LMICs) – can achieve or nearly achieve SDG 3.4 to reduce premature NCD mortality by one-third by 2030 by introducing a cost-effective package of NCD prevention and treatment interventions. Investment in the mitigation of NCDs boosts productivity by cutting the number of wasted lives. The paper presents an NCD investment framework that aims to support LMICs in getting back on track towards achieving SDG target 3.4 in the wake of the COVID-19 pandemic. It is centred around a package of 21 cost-effective interventions; essentially, a feasible and pragmatic roadmap to healthier populations and more resilient health systems. There are 15 clinical interventions, like screening and early detection for diabetes and cervical cancer, and cardiovascular disease prevention programmes. Many of these can be implemented at primary health care level. There are also six policy interventions, focused on taxing and regulating tobacco and alcohol, and measures to reduce intake of sodium and transfats. All of the interventions are aligned with WHO recommendations for NCD programmes, helping ensure a more coordinated NCD and pandemic response. The paper provides guidance on the types of interventions that can best accelerate progress on NCDs in 123 LMICs, and the resources required to implement these interventions. While the clinical interventions are meant to be selected according to national needs and contexts, the policy interventions are crucial for all countries, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. These actions could also generate significant revenue, which can then be reinvested in health. The bottom line for NCD investment As the paper demonstrates, implementing the most efficient package of interventions in each world region would require $140 billion in new spending over 2023–30, equivalent to $18 billion per year. This investment could avert 39 million deaths and generate an average net economic benefit of US$2.7 trillion, or US$390 per capita. This means that benefits outweigh costs by 19 to one. LMIC ministries of health would need to contribute around 20% of their budgets to the priority NCD interventions. Many countries would also need external support (bilateral, multilateral, philanthropy, private sector), particularly in light of the economic impacts of COVID-19. For the first time, we have a price tag for tackling NCDs in LMICs – and it’s peanuts alongside current NCD treatment costs and economic losses due to premature death and disability. For instance, in 2021, health expenditure for diabetes reached $966 billion; the annual cost of obesity is projected to top $1.2 trillion globally by 2025; the total economic loss due to cardiovascular disease in LMICs was estimated at $3.7 trillion between 2011 and 2015. The paper provides further evidence that underscores the urgent need to invest now in proven strategies to save lives and prevent and treat NCDs. Investments in NCDs are not only cost-effective, but they can also save money even within a short timeframe. The bottom line is that governments can reap substantial economic rewards, in both the short- and long-run, by taking bold action on NCDs and thus ensuring the security and fiscal sustainability of their health systems. This requires a view of health as an investment not a cost, and one that requires long-term thinking. Trailblazing the road to recovery Leaders must shift their priorities to achieving healthier populations, with impactful action for NCD prevention and care. Some countries are taking bold steps. India’s budget for 2021 more than doubled national healthcare and wellbeing spending from previous levels. The Philippines increased the taxation of tobacco products during the COVID-19 pandemic, with a share being earmarked to bolster capacity for universal health coverage to reach the poorest communities. Meanwhile, Latin America has made big gains for healthy diets. Recognising a high number of COVID-19 cases among overweight children and adults, the Mexican states of Oaxaca and Tabasco banned the sale of junk food and sugary drinks to people under 18 in 2020, with more states planning to follow suit. Front of package labels in Mexico A Mexican nationwide front-of-packaging warning labelling law also entered into effect in 2020, requiring black stop signs on packages of foods high in added sugar, fats, calories and sodium. Various Caribbean nations have implemented taxes on sugary beverages and made advances to control marketing of junk food in and near schools. These are just a sample of the actions being taken around the world, and are reason for optimism that real progress can be made. What we need now to accelerate this progress is strong leadership that is committed to putting health and health security first. NCD action and investment must no longer be seen as an afterthought to infectious diseases and neglected within health services, but as fundamental to resilience, security, equity, and economic stability. As Heads of State and Governments meet this week in Ghana for the International Strategic Dialogue on NCDs and the SDGs, we call on leaders to take the bold action so urgently needed. Whether NCDs and their prevention are addressed by future policy action will make or break the effectiveness of the pandemic response. Katie Dain is the Chief Executive Officer of the NCD Alliance. David Watkins, University of Washington, is the lead author of a recent Lancet NCD 2030 Countdown series article on pathways and investments to accelerate NCDs progress. Interactive map reproduced with permission from Politico Studio, based on data from WHO’s 2020 NCDs Progress Monitor. Image Credits: WHO/A. Loke, World Health Organization , World Heart Federation / WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Nineteen More Attacks on Ukraine’s Health Facilities Since Friday: WHO 11/04/2022 Kerry Cullinan Ukraine operating theatre destroyed The World Health Organization (WHO) has verified 108 attacks on health care in Ukraine as of Monday in which 73 people have died and 51 have been injured. That is 19 more attacks on health facilities than the already deadly toll of 91 attacks that had been verified by WHO as of early Friday afternoon, and as reported at a press conference by WHO’s Regional Director Hans Kluge in Lviv. .@WHO has verified 5 additional reports of attacks on health care in #Ukraine. As of 11 April, 108 attacks on health care in Ukraine have been verified, causing 73 deaths and 51 injuries. We are outraged that attacks on health care are continuing. pic.twitter.com/8GNUQZFiK9 — WHO Ukraine (@WHOUkraine) April 11, 2022 Meanwhile, the Office of the UN High Commissioner for Human Rights (OHCHR) has recorded 1,793 civilian deaths and 2,439 injuries since the start of the Russian invasion on 24 February and Sunday. Most of the civilian casualties have been caused by “explosive weapons with a wide impact area”, including shelling from heavy artillery and rocket, missile and air strikes. https://data.humdata.org/visualization/ukraine-humanitarian-operations/ “OHCHR believes that the actual figures are considerably higher, as the receipt of information from some locations where intense hostilities have been going on has been delayed and many reports are still pending corroboration,” according to a statement from the office. “This concerns, for example, Mariupol (Donetsk region), Izium (Kharkiv region), Popasna (Luhansk region), and Borodianka (Kyiv region), where there are allegations of numerous civilian casualties. These figures are being further corroborated and are not included in the above statistics.” According to the Prosecutor General’s Office of Ukraine, 176 children had been killed and at least 336 injured as of Sunday. Image Credits: WHO. Non-Communicable Diseases: Is the ‘New Normal’ Too Much Like The Old One? 11/04/2022 Katie Dain & David Watkins The vast majority of people who died of COVID-19 had a non-communicable disease – yet investment in NCD prevention is pitiful. More than two years after the novel coronavirus erupted into a global pandemic, the world is beginning to settle into a new normal. COVID-19 changed how we live and work in ways that will continue long after the pandemic subsides. Digital and automation technologies are here to stay, work is done remotely, and shopping and entertainment have gone online. But the COVID-19 pandemic also laid bare an indisputable truth: the destructive path carved by the infectious SARS-CoV2 virus was only the tip of the iceberg. Studies have estimated that 60-90% of COVID-19 deaths have been of people living with one or more chronic conditions, like obesity, heart or kidney disease, or cardiovascular diseases. And people living with non-communicable diseases (NCDs) are still experiencing the collateral damage of the pandemic, due to severe disruptions to essential health services. The lack of investment in NCD prevention and care over the years has vastly amplified the toll of the COVID-19 pandemic. The bigger, long-term pandemic that we face Responsible for 74% of all deaths globally, NCDs are the even bigger, long-term pandemic that we face. Governments and global institutions have been learning many harsh lessons about the need to build back better, with more resilient health systems and more equitable access to quality, affordable treatment. But too often this has been a slogan without much substance behind it. We now need to see real changes taking hold. Beyond COVID, there is a strong and urgent imperative for investment in NCDs, which now cause 15 million premature deaths of people between the ages of 30 and 70 each year, 85% of them in low- and middle-income countries. This makes action and investment in NCDs a prerequisite for resilience, pandemic preparedness and health security, not to mention for meeting the most critical health challenges of the next decade in countries at all stages of development. Yet financing for NCDs has stagnated at a pitiful 1-2% of development assistance for health for two decades. If we look at development assistance that has gone towards health system strengthening which also helps people living with NCDs we can add a further 5%, but that is simply inconsequential when compared to government handouts for fossils fuels and agriculture, which climb to $1.8 trillion annually – and more importantly, when compared to the magnitude of disease and economic burden of NCDs. Still hope to see healthier populations by 2030 In 2015, all UN member countries committed to the Sustainable Development Goals (SDGs) to achieve a better and more sustainable future for all, including SDG target 3.4 to reduce NCD premature mortality by one-third by 2030. This and other NCD commitments should not lose priority because of the COVID-19 pandemic. They should actually gain priority. Although the vast majority of countries are well off-track to meet SDG 3.4, a March 2022 paper published in The Lancet shows that there is still hope. All countries – and especially low- and middle-income countries (LMICs) – can achieve or nearly achieve SDG 3.4 to reduce premature NCD mortality by one-third by 2030 by introducing a cost-effective package of NCD prevention and treatment interventions. Investment in the mitigation of NCDs boosts productivity by cutting the number of wasted lives. The paper presents an NCD investment framework that aims to support LMICs in getting back on track towards achieving SDG target 3.4 in the wake of the COVID-19 pandemic. It is centred around a package of 21 cost-effective interventions; essentially, a feasible and pragmatic roadmap to healthier populations and more resilient health systems. There are 15 clinical interventions, like screening and early detection for diabetes and cervical cancer, and cardiovascular disease prevention programmes. Many of these can be implemented at primary health care level. There are also six policy interventions, focused on taxing and regulating tobacco and alcohol, and measures to reduce intake of sodium and transfats. All of the interventions are aligned with WHO recommendations for NCD programmes, helping ensure a more coordinated NCD and pandemic response. The paper provides guidance on the types of interventions that can best accelerate progress on NCDs in 123 LMICs, and the resources required to implement these interventions. While the clinical interventions are meant to be selected according to national needs and contexts, the policy interventions are crucial for all countries, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. These actions could also generate significant revenue, which can then be reinvested in health. The bottom line for NCD investment As the paper demonstrates, implementing the most efficient package of interventions in each world region would require $140 billion in new spending over 2023–30, equivalent to $18 billion per year. This investment could avert 39 million deaths and generate an average net economic benefit of US$2.7 trillion, or US$390 per capita. This means that benefits outweigh costs by 19 to one. LMIC ministries of health would need to contribute around 20% of their budgets to the priority NCD interventions. Many countries would also need external support (bilateral, multilateral, philanthropy, private sector), particularly in light of the economic impacts of COVID-19. For the first time, we have a price tag for tackling NCDs in LMICs – and it’s peanuts alongside current NCD treatment costs and economic losses due to premature death and disability. For instance, in 2021, health expenditure for diabetes reached $966 billion; the annual cost of obesity is projected to top $1.2 trillion globally by 2025; the total economic loss due to cardiovascular disease in LMICs was estimated at $3.7 trillion between 2011 and 2015. The paper provides further evidence that underscores the urgent need to invest now in proven strategies to save lives and prevent and treat NCDs. Investments in NCDs are not only cost-effective, but they can also save money even within a short timeframe. The bottom line is that governments can reap substantial economic rewards, in both the short- and long-run, by taking bold action on NCDs and thus ensuring the security and fiscal sustainability of their health systems. This requires a view of health as an investment not a cost, and one that requires long-term thinking. Trailblazing the road to recovery Leaders must shift their priorities to achieving healthier populations, with impactful action for NCD prevention and care. Some countries are taking bold steps. India’s budget for 2021 more than doubled national healthcare and wellbeing spending from previous levels. The Philippines increased the taxation of tobacco products during the COVID-19 pandemic, with a share being earmarked to bolster capacity for universal health coverage to reach the poorest communities. Meanwhile, Latin America has made big gains for healthy diets. Recognising a high number of COVID-19 cases among overweight children and adults, the Mexican states of Oaxaca and Tabasco banned the sale of junk food and sugary drinks to people under 18 in 2020, with more states planning to follow suit. Front of package labels in Mexico A Mexican nationwide front-of-packaging warning labelling law also entered into effect in 2020, requiring black stop signs on packages of foods high in added sugar, fats, calories and sodium. Various Caribbean nations have implemented taxes on sugary beverages and made advances to control marketing of junk food in and near schools. These are just a sample of the actions being taken around the world, and are reason for optimism that real progress can be made. What we need now to accelerate this progress is strong leadership that is committed to putting health and health security first. NCD action and investment must no longer be seen as an afterthought to infectious diseases and neglected within health services, but as fundamental to resilience, security, equity, and economic stability. As Heads of State and Governments meet this week in Ghana for the International Strategic Dialogue on NCDs and the SDGs, we call on leaders to take the bold action so urgently needed. Whether NCDs and their prevention are addressed by future policy action will make or break the effectiveness of the pandemic response. Katie Dain is the Chief Executive Officer of the NCD Alliance. David Watkins, University of Washington, is the lead author of a recent Lancet NCD 2030 Countdown series article on pathways and investments to accelerate NCDs progress. Interactive map reproduced with permission from Politico Studio, based on data from WHO’s 2020 NCDs Progress Monitor. Image Credits: WHO/A. Loke, World Health Organization , World Heart Federation / WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Non-Communicable Diseases: Is the ‘New Normal’ Too Much Like The Old One? 11/04/2022 Katie Dain & David Watkins The vast majority of people who died of COVID-19 had a non-communicable disease – yet investment in NCD prevention is pitiful. More than two years after the novel coronavirus erupted into a global pandemic, the world is beginning to settle into a new normal. COVID-19 changed how we live and work in ways that will continue long after the pandemic subsides. Digital and automation technologies are here to stay, work is done remotely, and shopping and entertainment have gone online. But the COVID-19 pandemic also laid bare an indisputable truth: the destructive path carved by the infectious SARS-CoV2 virus was only the tip of the iceberg. Studies have estimated that 60-90% of COVID-19 deaths have been of people living with one or more chronic conditions, like obesity, heart or kidney disease, or cardiovascular diseases. And people living with non-communicable diseases (NCDs) are still experiencing the collateral damage of the pandemic, due to severe disruptions to essential health services. The lack of investment in NCD prevention and care over the years has vastly amplified the toll of the COVID-19 pandemic. The bigger, long-term pandemic that we face Responsible for 74% of all deaths globally, NCDs are the even bigger, long-term pandemic that we face. Governments and global institutions have been learning many harsh lessons about the need to build back better, with more resilient health systems and more equitable access to quality, affordable treatment. But too often this has been a slogan without much substance behind it. We now need to see real changes taking hold. Beyond COVID, there is a strong and urgent imperative for investment in NCDs, which now cause 15 million premature deaths of people between the ages of 30 and 70 each year, 85% of them in low- and middle-income countries. This makes action and investment in NCDs a prerequisite for resilience, pandemic preparedness and health security, not to mention for meeting the most critical health challenges of the next decade in countries at all stages of development. Yet financing for NCDs has stagnated at a pitiful 1-2% of development assistance for health for two decades. If we look at development assistance that has gone towards health system strengthening which also helps people living with NCDs we can add a further 5%, but that is simply inconsequential when compared to government handouts for fossils fuels and agriculture, which climb to $1.8 trillion annually – and more importantly, when compared to the magnitude of disease and economic burden of NCDs. Still hope to see healthier populations by 2030 In 2015, all UN member countries committed to the Sustainable Development Goals (SDGs) to achieve a better and more sustainable future for all, including SDG target 3.4 to reduce NCD premature mortality by one-third by 2030. This and other NCD commitments should not lose priority because of the COVID-19 pandemic. They should actually gain priority. Although the vast majority of countries are well off-track to meet SDG 3.4, a March 2022 paper published in The Lancet shows that there is still hope. All countries – and especially low- and middle-income countries (LMICs) – can achieve or nearly achieve SDG 3.4 to reduce premature NCD mortality by one-third by 2030 by introducing a cost-effective package of NCD prevention and treatment interventions. Investment in the mitigation of NCDs boosts productivity by cutting the number of wasted lives. The paper presents an NCD investment framework that aims to support LMICs in getting back on track towards achieving SDG target 3.4 in the wake of the COVID-19 pandemic. It is centred around a package of 21 cost-effective interventions; essentially, a feasible and pragmatic roadmap to healthier populations and more resilient health systems. There are 15 clinical interventions, like screening and early detection for diabetes and cervical cancer, and cardiovascular disease prevention programmes. Many of these can be implemented at primary health care level. There are also six policy interventions, focused on taxing and regulating tobacco and alcohol, and measures to reduce intake of sodium and transfats. All of the interventions are aligned with WHO recommendations for NCD programmes, helping ensure a more coordinated NCD and pandemic response. The paper provides guidance on the types of interventions that can best accelerate progress on NCDs in 123 LMICs, and the resources required to implement these interventions. While the clinical interventions are meant to be selected according to national needs and contexts, the policy interventions are crucial for all countries, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. These actions could also generate significant revenue, which can then be reinvested in health. The bottom line for NCD investment As the paper demonstrates, implementing the most efficient package of interventions in each world region would require $140 billion in new spending over 2023–30, equivalent to $18 billion per year. This investment could avert 39 million deaths and generate an average net economic benefit of US$2.7 trillion, or US$390 per capita. This means that benefits outweigh costs by 19 to one. LMIC ministries of health would need to contribute around 20% of their budgets to the priority NCD interventions. Many countries would also need external support (bilateral, multilateral, philanthropy, private sector), particularly in light of the economic impacts of COVID-19. For the first time, we have a price tag for tackling NCDs in LMICs – and it’s peanuts alongside current NCD treatment costs and economic losses due to premature death and disability. For instance, in 2021, health expenditure for diabetes reached $966 billion; the annual cost of obesity is projected to top $1.2 trillion globally by 2025; the total economic loss due to cardiovascular disease in LMICs was estimated at $3.7 trillion between 2011 and 2015. The paper provides further evidence that underscores the urgent need to invest now in proven strategies to save lives and prevent and treat NCDs. Investments in NCDs are not only cost-effective, but they can also save money even within a short timeframe. The bottom line is that governments can reap substantial economic rewards, in both the short- and long-run, by taking bold action on NCDs and thus ensuring the security and fiscal sustainability of their health systems. This requires a view of health as an investment not a cost, and one that requires long-term thinking. Trailblazing the road to recovery Leaders must shift their priorities to achieving healthier populations, with impactful action for NCD prevention and care. Some countries are taking bold steps. India’s budget for 2021 more than doubled national healthcare and wellbeing spending from previous levels. The Philippines increased the taxation of tobacco products during the COVID-19 pandemic, with a share being earmarked to bolster capacity for universal health coverage to reach the poorest communities. Meanwhile, Latin America has made big gains for healthy diets. Recognising a high number of COVID-19 cases among overweight children and adults, the Mexican states of Oaxaca and Tabasco banned the sale of junk food and sugary drinks to people under 18 in 2020, with more states planning to follow suit. Front of package labels in Mexico A Mexican nationwide front-of-packaging warning labelling law also entered into effect in 2020, requiring black stop signs on packages of foods high in added sugar, fats, calories and sodium. Various Caribbean nations have implemented taxes on sugary beverages and made advances to control marketing of junk food in and near schools. These are just a sample of the actions being taken around the world, and are reason for optimism that real progress can be made. What we need now to accelerate this progress is strong leadership that is committed to putting health and health security first. NCD action and investment must no longer be seen as an afterthought to infectious diseases and neglected within health services, but as fundamental to resilience, security, equity, and economic stability. As Heads of State and Governments meet this week in Ghana for the International Strategic Dialogue on NCDs and the SDGs, we call on leaders to take the bold action so urgently needed. Whether NCDs and their prevention are addressed by future policy action will make or break the effectiveness of the pandemic response. Katie Dain is the Chief Executive Officer of the NCD Alliance. David Watkins, University of Washington, is the lead author of a recent Lancet NCD 2030 Countdown series article on pathways and investments to accelerate NCDs progress. Interactive map reproduced with permission from Politico Studio, based on data from WHO’s 2020 NCDs Progress Monitor. Image Credits: WHO/A. Loke, World Health Organization , World Heart Federation / WHO. Posts navigation Older postsNewer posts